#FORMAT=WebAnno TSV 3.3
#T_SP=webanno.custom.ConceptLayer|identifier


#Text=A preliminary study of longitudinal neuroadaptation associated with recovery from addiction
#Text=Background
#Text=Few studies have explored longitudinal change in event-related brain responses during early recovery from addiction.
1-1	0-1	A	_	
1-2	2-13	preliminary	_	
1-3	14-19	study	_	
1-4	20-22	of	_	
1-5	23-35	longitudinal	_	
1-6	36-51	neuroadaptation	_	
1-7	52-62	associated	_	
1-8	63-67	with	_	
1-9	68-76	recovery	_	
1-10	77-81	from	_	
1-11	82-91	addiction	_	
1-12	92-102	Background	_	
1-13	103-106	Few	_	
1-14	107-114	studies	_	
1-15	115-119	have	_	
1-16	120-128	explored	_	
1-17	129-141	longitudinal	_	
1-18	142-148	change	_	
1-19	149-151	in	_	
1-20	152-165	event-related	_	
1-21	166-171	brain	_	
1-22	172-181	responses	_	
1-23	182-188	during	_	
1-24	189-194	early	_	
1-25	195-203	recovery	_	
1-26	204-208	from	_	
1-27	209-218	addiction	_	
1-28	218-219	.	_	

#Text=Moreover, existing findings yield evidence of both increased and decreased signaling within reward and control centers over time.
2-1	220-228	Moreover	_	
2-2	228-229	,	_	
2-3	230-238	existing	_	
2-4	239-247	findings	_	
2-5	248-253	yield	_	
2-6	254-262	evidence	_	
2-7	263-265	of	_	
2-8	266-270	both	_	
2-9	271-280	increased	_	
2-10	281-284	and	_	
2-11	285-294	decreased	_	
2-12	295-304	signaling	_	
2-13	305-311	within	_	
2-14	312-318	reward	_	
2-15	319-322	and	_	
2-16	323-330	control	_	
2-17	331-338	centers	_	
2-18	339-343	over	_	
2-19	344-348	time	_	
2-20	348-349	.	_	

#Text=The current study explored reward- and control-related signals in a risky decision-making task and specifically investigated parametric modulations of the BOLD signal, rather than signal magnitude alone.
3-1	350-353	The	_	
3-2	354-361	current	_	
3-3	362-367	study	_	
3-4	368-376	explored	_	
3-5	377-383	reward	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImaging[1]	
3-6	383-384	-	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImaging[1]	
3-7	385-388	and	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImaging[1]	
3-8	389-404	control-related	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImaging[1]	
3-9	405-412	signals	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImaging[1]	
3-10	413-415	in	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImaging[1]	
3-11	416-417	a	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImaging[1]	
3-12	418-423	risky	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImaging[1]	
3-13	424-439	decision-making	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImaging[1]	
3-14	440-444	task	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImaging[1]	
3-15	445-448	and	_	
3-16	449-461	specifically	_	
3-17	462-474	investigated	_	
3-18	475-485	parametric	_	
3-19	486-497	modulations	_	
3-20	498-500	of	_	
3-21	501-504	the	_	
3-22	505-509	BOLD	_	
3-23	510-516	signal	_	
3-24	516-517	,	_	
3-25	518-524	rather	_	
3-26	525-529	than	_	
3-27	530-536	signal	_	
3-28	537-546	magnitude	_	
3-29	547-552	alone	_	
3-30	552-553	.	_	

#Text=It was hypothesized that risk-related signals during decision-making and outcome evaluation would reflect recovery and that change in specific signals would correspond with improved treatment outcomes.
4-1	554-556	It	_	
4-2	557-560	was	_	
4-3	561-573	hypothesized	_	
4-4	574-578	that	_	
4-5	579-591	risk-related	_	
4-6	592-599	signals	_	
4-7	600-606	during	_	
4-8	607-622	decision-making	_	
4-9	623-626	and	_	
4-10	627-634	outcome	_	
4-11	635-645	evaluation	_	
4-12	646-651	would	_	
4-13	652-659	reflect	_	
4-14	660-668	recovery	_	
4-15	669-672	and	_	
4-16	673-677	that	_	
4-17	678-684	change	_	
4-18	685-687	in	_	
4-19	688-696	specific	_	
4-20	697-704	signals	_	
4-21	705-710	would	_	
4-22	711-721	correspond	_	
4-23	722-726	with	_	
4-24	727-735	improved	_	
4-25	736-745	treatment	_	
4-26	746-754	outcomes	_	
4-27	754-755	.	_	

#Text=Methods
#Text=Twenty-one substance dependent individuals were recruited upon enrollment in community-based substance use treatment programs, wherein they received treatment-as-usual.
5-1	756-763	Methods	_	
5-2	764-774	Twenty-one	_	
5-3	775-784	substance	http://maven.renci.org/NeuroBridge/neurobridge#SubstanceDisorder[2]	
5-4	785-794	dependent	http://maven.renci.org/NeuroBridge/neurobridge#SubstanceDisorder[2]	
5-5	795-806	individuals	http://maven.renci.org/NeuroBridge/neurobridge#SubstanceDisorder[2]	
5-6	807-811	were	_	
5-7	812-821	recruited	_	
5-8	822-826	upon	_	
5-9	827-837	enrollment	_	
5-10	838-840	in	_	
5-11	841-856	community-based	_	
5-12	857-866	substance	_	
5-13	867-870	use	_	
5-14	871-880	treatment	_	
5-15	881-889	programs	_	
5-16	889-890	,	_	
5-17	891-898	wherein	_	
5-18	899-903	they	_	
5-19	904-912	received	_	
5-20	913-931	treatment-as-usual	_	
5-21	931-932	.	_	

#Text=Participants completed functional neuroimaging assessments at baseline and 3-month follow-up while performing the Balloon Analogue Risk Task (BART).
6-1	933-945	Participants	_	
6-2	946-955	completed	_	
6-3	956-966	functional	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalImagingProtocol[3]	
6-4	967-979	neuroimaging	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalImagingProtocol[3]	
6-5	980-991	assessments	_	
6-6	992-994	at	_	
6-7	995-1003	baseline	_	
6-8	1004-1007	and	_	
6-9	1008-1009	3	_	
6-10	1009-1010	-	_	
6-11	1010-1015	month	_	
6-12	1016-1025	follow-up	_	
6-13	1026-1031	while	_	
6-14	1032-1042	performing	_	
6-15	1043-1046	the	_	
6-16	1047-1054	Balloon	http://maven.renci.org/NeuroBridge/neurobridge#BalloonAnalogueRiskTask[4]|http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImaging[5]	
6-17	1055-1063	Analogue	http://maven.renci.org/NeuroBridge/neurobridge#BalloonAnalogueRiskTask[4]|http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImaging[5]	
6-18	1064-1068	Risk	http://maven.renci.org/NeuroBridge/neurobridge#BalloonAnalogueRiskTask[4]|http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImaging[5]	
6-19	1069-1073	Task	http://maven.renci.org/NeuroBridge/neurobridge#BalloonAnalogueRiskTask[4]|http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImaging[5]	
6-20	1074-1075	(	http://maven.renci.org/NeuroBridge/neurobridge#BalloonAnalogueRiskTask[4]|http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImaging[5]	
6-21	1075-1079	BART	http://maven.renci.org/NeuroBridge/neurobridge#BalloonAnalogueRiskTask[4]|http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImaging[5]	
6-22	1079-1080	)	http://maven.renci.org/NeuroBridge/neurobridge#BalloonAnalogueRiskTask[4]|http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImaging[5]	
6-23	1080-1081	.	_	

#Text=Risk- and reward-sensitive signals were identified using parametric modulators.
7-1	1082-1086	Risk	_	
7-2	1086-1087	-	_	
7-3	1088-1091	and	_	
7-4	1092-1108	reward-sensitive	_	
7-5	1109-1116	signals	_	
7-6	1117-1121	were	_	
7-7	1122-1132	identified	_	
7-8	1133-1138	using	_	
7-9	1139-1149	parametric	_	
7-10	1150-1160	modulators	_	
7-11	1160-1161	.	_	

#Text=Substance use was tracked throughout the 3-month study interval using the timeline follow-back procedure.
8-1	1162-1171	Substance	http://maven.renci.org/NeuroBridge/neurobridge#SubstanceDisorder[6]	
8-2	1172-1175	use	http://maven.renci.org/NeuroBridge/neurobridge#SubstanceDisorder[6]	
8-3	1176-1179	was	_	
8-4	1180-1187	tracked	_	
8-5	1188-1198	throughout	_	
8-6	1199-1202	the	_	
8-7	1203-1204	3	_	
8-8	1204-1205	-	_	
8-9	1205-1210	month	_	
8-10	1211-1216	study	_	
8-11	1217-1225	interval	_	
8-12	1226-1231	using	_	
8-13	1232-1235	the	_	
8-14	1236-1244	timeline	http://maven.renci.org/NeuroBridge/neurobridge#SubstanceUseScale[7]	
8-15	1245-1256	follow-back	http://maven.renci.org/NeuroBridge/neurobridge#SubstanceUseScale[7]	
8-16	1257-1266	procedure	http://maven.renci.org/NeuroBridge/neurobridge#SubstanceUseScale[7]	
8-17	1266-1267	.	_	

#Text=Results
#Text=Longitudinal contrasts of parametric modulators suggested improved formation of risk-informed outcome expectations at follow-up.
9-1	1268-1275	Results	_	
9-2	1276-1288	Longitudinal	_	
9-3	1289-1298	contrasts	_	
9-4	1299-1301	of	_	
9-5	1302-1312	parametric	_	
9-6	1313-1323	modulators	_	
9-7	1324-1333	suggested	_	
9-8	1334-1342	improved	_	
9-9	1343-1352	formation	_	
9-10	1353-1355	of	_	
9-11	1356-1369	risk-informed	_	
9-12	1370-1377	outcome	_	
9-13	1378-1390	expectations	_	
9-14	1391-1393	at	_	
9-15	1394-1403	follow-up	_	
9-16	1403-1404	.	_	

#Text=Specifically, a greater response to high risk (low-likelihood) positive feedback was identified in caudal anterior cingulate cortex (ACC) and a greater response to low risk (low-likelihood) negative feedback was identified in caudal ACC and inferior frontal gyrus.
10-1	1405-1417	Specifically	_	
10-2	1417-1418	,	_	
10-3	1419-1420	a	_	
10-4	1421-1428	greater	_	
10-5	1429-1437	response	_	
10-6	1438-1440	to	_	
10-7	1441-1445	high	_	
10-8	1446-1450	risk	_	
10-9	1451-1452	(	_	
10-10	1452-1466	low-likelihood	_	
10-11	1466-1467	)	_	
10-12	1468-1476	positive	_	
10-13	1477-1485	feedback	_	
10-14	1486-1489	was	_	
10-15	1490-1500	identified	_	
10-16	1501-1503	in	_	
10-17	1504-1510	caudal	_	
10-18	1511-1519	anterior	_	
10-19	1520-1529	cingulate	_	
10-20	1530-1536	cortex	_	
10-21	1537-1538	(	_	
10-22	1538-1541	ACC	_	
10-23	1541-1542	)	_	
10-24	1543-1546	and	_	
10-25	1547-1548	a	_	
10-26	1549-1556	greater	_	
10-27	1557-1565	response	_	
10-28	1566-1568	to	_	
10-29	1569-1572	low	_	
10-30	1573-1577	risk	_	
10-31	1578-1579	(	_	
10-32	1579-1593	low-likelihood	_	
10-33	1593-1594	)	_	
10-34	1595-1603	negative	_	
10-35	1604-1612	feedback	_	
10-36	1613-1616	was	_	
10-37	1617-1627	identified	_	
10-38	1628-1630	in	_	
10-39	1631-1637	caudal	_	
10-40	1638-1641	ACC	_	
10-41	1642-1645	and	_	
10-42	1646-1654	inferior	_	
10-43	1655-1662	frontal	_	
10-44	1663-1668	gyrus	_	
10-45	1668-1669	.	_	

#Text=In addition, attenuation of a ventromedial prefrontal cortex (vmPFC) “reward-seeking” signal (i.e., increasing response with greater reward) during risky decisions at follow-up was associated with less substance use during the study interval.
11-1	1670-1672	In	_	
11-2	1673-1681	addition	_	
11-3	1681-1682	,	_	
11-4	1683-1694	attenuation	_	
11-5	1695-1697	of	_	
11-6	1698-1699	a	_	
11-7	1700-1712	ventromedial	_	
11-8	1713-1723	prefrontal	_	
11-9	1724-1730	cortex	_	
11-10	1731-1732	(	_	
11-11	1732-1737	vmPFC	_	
11-12	1737-1738	)	_	
11-13	1739-1740	“	_	
11-14	1740-1754	reward-seeking	_	
11-15	1754-1755	”	_	
11-16	1756-1762	signal	_	
11-17	1763-1764	(	_	
11-18	1764-1767	i.e	_	
11-19	1767-1768	.	_	
11-20	1768-1769	,	_	
11-21	1770-1780	increasing	_	
11-22	1781-1789	response	_	
11-23	1790-1794	with	_	
11-24	1795-1802	greater	_	
11-25	1803-1809	reward	_	
11-26	1809-1810	)	_	
11-27	1811-1817	during	_	
11-28	1818-1823	risky	_	
11-29	1824-1833	decisions	_	
11-30	1834-1836	at	_	
11-31	1837-1846	follow-up	_	
11-32	1847-1850	was	_	
11-33	1851-1861	associated	_	
11-34	1862-1866	with	_	
11-35	1867-1871	less	_	
11-36	1872-1881	substance	http://maven.renci.org/NeuroBridge/neurobridge#SubstanceDisorder[8]	
11-37	1882-1885	use	http://maven.renci.org/NeuroBridge/neurobridge#SubstanceDisorder[8]	
11-38	1886-1892	during	_	
11-39	1893-1896	the	_	
11-40	1897-1902	study	_	
11-41	1903-1911	interval	_	
11-42	1911-1912	.	_	

#Text=Conclusions
#Text=Changes in risk- and reward-related signaling in ACC/vmPFC appear to reflect recovery and may support sobriety.
#Text=1.
12-1	1913-1924	Conclusions	_	
12-2	1925-1932	Changes	_	
12-3	1933-1935	in	_	
12-4	1936-1940	risk	_	
12-5	1940-1941	-	_	
12-6	1942-1945	and	_	
12-7	1946-1960	reward-related	_	
12-8	1961-1970	signaling	_	
12-9	1971-1973	in	_	
12-10	1974-1977	ACC	_	
12-11	1977-1978	/	_	
12-12	1978-1983	vmPFC	_	
12-13	1984-1990	appear	_	
12-14	1991-1993	to	_	
12-15	1994-2001	reflect	_	
12-16	2002-2010	recovery	_	
12-17	2011-2014	and	_	
12-18	2015-2018	may	_	
12-19	2019-2026	support	_	
12-20	2027-2035	sobriety	_	
12-21	2035-2036	.	_	
12-22	2037-2038	1	_	
12-23	2038-2039	.	_	

#Text=Introduction
#Text=Changes within primary reward circuitry and prefrontal control networks underlie the neurobiological instantiation of substance use disorders (SUDs), resulting in a disturbance of salience attribution and response inhibition that drives compulsive use.
13-1	2040-2052	Introduction	_	
13-2	2053-2060	Changes	_	
13-3	2061-2067	within	_	
13-4	2068-2075	primary	_	
13-5	2076-2082	reward	_	
13-6	2083-2092	circuitry	_	
13-7	2093-2096	and	_	
13-8	2097-2107	prefrontal	_	
13-9	2108-2115	control	_	
13-10	2116-2124	networks	_	
13-11	2125-2133	underlie	_	
13-12	2134-2137	the	_	
13-13	2138-2153	neurobiological	_	
13-14	2154-2167	instantiation	_	
13-15	2168-2170	of	_	
13-16	2171-2180	substance	_	
13-17	2181-2184	use	_	
13-18	2185-2194	disorders	_	
13-19	2195-2196	(	_	
13-20	2196-2200	SUDs	_	
13-21	2200-2201	)	_	
13-22	2201-2202	,	_	
13-23	2203-2212	resulting	_	
13-24	2213-2215	in	_	
13-25	2216-2217	a	_	
13-26	2218-2229	disturbance	_	
13-27	2230-2232	of	_	
13-28	2233-2241	salience	_	
13-29	2242-2253	attribution	_	
13-30	2254-2257	and	_	
13-31	2258-2266	response	_	
13-32	2267-2277	inhibition	_	
13-33	2278-2282	that	_	
13-34	2283-2289	drives	_	
13-35	2290-2300	compulsive	_	
13-36	2301-2304	use	_	
13-37	2304-2305	.	_	

#Text=Interventions for SUDs should restore functioning within these neural systems, but few studies explore longitudinal neuroadaptation during early recovery.
14-1	2306-2319	Interventions	_	
14-2	2320-2323	for	_	
14-3	2324-2328	SUDs	_	
14-4	2329-2335	should	_	
14-5	2336-2343	restore	_	
14-6	2344-2355	functioning	_	
14-7	2356-2362	within	_	
14-8	2363-2368	these	_	
14-9	2369-2375	neural	_	
14-10	2376-2383	systems	_	
14-11	2383-2384	,	_	
14-12	2385-2388	but	_	
14-13	2389-2392	few	_	
14-14	2393-2400	studies	_	
14-15	2401-2408	explore	_	
14-16	2409-2421	longitudinal	_	
14-17	2422-2437	neuroadaptation	_	
14-18	2438-2444	during	_	
14-19	2445-2450	early	_	
14-20	2451-2459	recovery	_	
14-21	2459-2460	.	_	

#Text=In a recent meta-analysis, both pharmacologic and cognitive-behavioral interventions affected the ventral striatum, orbitofrontal cortex, and inferior frontal gyrus (IFG) – regions associated with reward-learning, reward-seeking, and response inhibition, respectively.
15-1	2461-2463	In	_	
15-2	2464-2465	a	_	
15-3	2466-2472	recent	_	
15-4	2473-2486	meta-analysis	_	
15-5	2486-2487	,	_	
15-6	2488-2492	both	_	
15-7	2493-2506	pharmacologic	_	
15-8	2507-2510	and	_	
15-9	2511-2531	cognitive-behavioral	_	
15-10	2532-2545	interventions	_	
15-11	2546-2554	affected	_	
15-12	2555-2558	the	_	
15-13	2559-2566	ventral	_	
15-14	2567-2575	striatum	_	
15-15	2575-2576	,	_	
15-16	2577-2590	orbitofrontal	_	
15-17	2591-2597	cortex	_	
15-18	2597-2598	,	_	
15-19	2599-2602	and	_	
15-20	2603-2611	inferior	_	
15-21	2612-2619	frontal	_	
15-22	2620-2625	gyrus	_	
15-23	2626-2627	(	_	
15-24	2627-2630	IFG	_	
15-25	2630-2631	)	_	
15-26	2632-2633	–	_	
15-27	2634-2641	regions	_	
15-28	2642-2652	associated	_	
15-29	2653-2657	with	_	
15-30	2658-2673	reward-learning	_	
15-31	2673-2674	,	_	
15-32	2675-2689	reward-seeking	_	
15-33	2689-2690	,	_	
15-34	2691-2694	and	_	
15-35	2695-2703	response	_	
15-36	2704-2714	inhibition	_	
15-37	2714-2715	,	_	
15-38	2716-2728	respectively	_	
15-39	2728-2729	.	_	

#Text=Cognitive-behavioral interventions also recruited control-related brain areas (e.g., anterior cingulate cortex (ACC), posterior cingulate cortex (PCC), and middle frontal gyrus) – suggesting an added benefit of these approaches.
16-1	2730-2750	Cognitive-behavioral	_	
16-2	2751-2764	interventions	_	
16-3	2765-2769	also	_	
16-4	2770-2779	recruited	_	
16-5	2780-2795	control-related	_	
16-6	2796-2801	brain	_	
16-7	2802-2807	areas	_	
16-8	2808-2809	(	_	
16-9	2809-2812	e.g	_	
16-10	2812-2813	.	_	
16-11	2813-2814	,	_	
16-12	2815-2823	anterior	_	
16-13	2824-2833	cingulate	_	
16-14	2834-2840	cortex	_	
16-15	2841-2842	(	_	
16-16	2842-2845	ACC	_	
16-17	2845-2846	)	_	
16-18	2846-2847	,	_	
16-19	2848-2857	posterior	_	
16-20	2858-2867	cingulate	_	
16-21	2868-2874	cortex	_	
16-22	2875-2876	(	_	
16-23	2876-2879	PCC	_	
16-24	2879-2880	)	_	
16-25	2880-2881	,	_	
16-26	2882-2885	and	_	
16-27	2886-2892	middle	_	
16-28	2893-2900	frontal	_	
16-29	2901-2906	gyrus	_	
16-30	2906-2907	)	_	
16-31	2908-2909	–	_	
16-32	2910-2920	suggesting	_	
16-33	2921-2923	an	_	
16-34	2924-2929	added	_	
16-35	2930-2937	benefit	_	
16-36	2938-2940	of	_	
16-37	2941-2946	these	_	
16-38	2947-2957	approaches	_	
16-39	2957-2958	.	_	

#Text=Konova et al. primarily considered acute treatment effects and were unable to target neuroadaptive change over the longer term because few longitudinal neuroimaging studies have been conducted.
17-1	2959-2965	Konova	_	
17-2	2966-2968	et	_	
17-3	2969-2971	al	_	
17-4	2971-2972	.	_	
17-5	2973-2982	primarily	_	
17-6	2983-2993	considered	_	
17-7	2994-2999	acute	_	
17-8	3000-3009	treatment	_	
17-9	3010-3017	effects	_	
17-10	3018-3021	and	_	
17-11	3022-3026	were	_	
17-12	3027-3033	unable	_	
17-13	3034-3036	to	_	
17-14	3037-3043	target	_	
17-15	3044-3057	neuroadaptive	_	
17-16	3058-3064	change	_	
17-17	3065-3069	over	_	
17-18	3070-3073	the	_	
17-19	3074-3080	longer	_	
17-20	3081-3085	term	_	
17-21	3086-3093	because	_	
17-22	3094-3097	few	_	
17-23	3098-3110	longitudinal	_	
17-24	3111-3123	neuroimaging	_	
17-25	3124-3131	studies	_	
17-26	3132-3136	have	_	
17-27	3137-3141	been	_	
17-28	3142-3151	conducted	_	
17-29	3151-3152	.	_	

#Text=A few studies have explored longitudinal change in brain function during recovery from SUDs. studied a mixed sample of substance dependent individuals (SDIs) receiving treatment-as-usual (with or without adjunctive cognitive-behavioral therapy) and found improved Stroop performance and reduced control-related activation in regions including ACC, IFG, and midbrain following 8 weeks of treatment – consistent with enhanced processing efficiency in these regions.
18-1	3153-3154	A	_	
18-2	3155-3158	few	_	
18-3	3159-3166	studies	_	
18-4	3167-3171	have	_	
18-5	3172-3180	explored	_	
18-6	3181-3193	longitudinal	_	
18-7	3194-3200	change	_	
18-8	3201-3203	in	_	
18-9	3204-3209	brain	_	
18-10	3210-3218	function	_	
18-11	3219-3225	during	_	
18-12	3226-3234	recovery	_	
18-13	3235-3239	from	_	
18-14	3240-3244	SUDs	_	
18-15	3244-3245	.	_	
18-16	3246-3253	studied	_	
18-17	3254-3255	a	_	
18-18	3256-3261	mixed	_	
18-19	3262-3268	sample	_	
18-20	3269-3271	of	_	
18-21	3272-3281	substance	_	
18-22	3282-3291	dependent	_	
18-23	3292-3303	individuals	_	
18-24	3304-3305	(	_	
18-25	3305-3309	SDIs	_	
18-26	3309-3310	)	_	
18-27	3311-3320	receiving	_	
18-28	3321-3339	treatment-as-usual	_	
18-29	3340-3341	(	_	
18-30	3341-3345	with	_	
18-31	3346-3348	or	_	
18-32	3349-3356	without	_	
18-33	3357-3367	adjunctive	_	
18-34	3368-3388	cognitive-behavioral	_	
18-35	3389-3396	therapy	_	
18-36	3396-3397	)	_	
18-37	3398-3401	and	_	
18-38	3402-3407	found	_	
18-39	3408-3416	improved	_	
18-40	3417-3423	Stroop	_	
18-41	3424-3435	performance	_	
18-42	3436-3439	and	_	
18-43	3440-3447	reduced	_	
18-44	3448-3463	control-related	_	
18-45	3464-3474	activation	_	
18-46	3475-3477	in	_	
18-47	3478-3485	regions	_	
18-48	3486-3495	including	_	
18-49	3496-3499	ACC	_	
18-50	3499-3500	,	_	
18-51	3501-3504	IFG	_	
18-52	3504-3505	,	_	
18-53	3506-3509	and	_	
18-54	3510-3518	midbrain	_	
18-55	3519-3528	following	_	
18-56	3529-3530	8	_	
18-57	3531-3536	weeks	_	
18-58	3537-3539	of	_	
18-59	3540-3549	treatment	_	
18-60	3550-3551	–	_	
18-61	3552-3562	consistent	_	
18-62	3563-3567	with	_	
18-63	3568-3576	enhanced	_	
18-64	3577-3587	processing	_	
18-65	3588-3598	efficiency	_	
18-66	3599-3601	in	_	
18-67	3602-3607	these	_	
18-68	3608-3615	regions	_	
18-69	3615-3616	.	_	

#Text=Increased activation has also been reported following treatment for cocaine dependence in midbrain and thalamus – both in response to neutral and drug Stroop stimuli and during reward anticipation in a monetary incentive delay task.
19-1	3617-3626	Increased	_	
19-2	3627-3637	activation	_	
19-3	3638-3641	has	_	
19-4	3642-3646	also	_	
19-5	3647-3651	been	_	
19-6	3652-3660	reported	_	
19-7	3661-3670	following	_	
19-8	3671-3680	treatment	_	
19-9	3681-3684	for	_	
19-10	3685-3692	cocaine	_	
19-11	3693-3703	dependence	_	
19-12	3704-3706	in	_	
19-13	3707-3715	midbrain	_	
19-14	3716-3719	and	_	
19-15	3720-3728	thalamus	_	
19-16	3729-3730	–	_	
19-17	3731-3735	both	_	
19-18	3736-3738	in	_	
19-19	3739-3747	response	_	
19-20	3748-3750	to	_	
19-21	3751-3758	neutral	_	
19-22	3759-3762	and	_	
19-23	3763-3767	drug	_	
19-24	3768-3774	Stroop	_	
19-25	3775-3782	stimuli	_	
19-26	3783-3786	and	_	
19-27	3787-3793	during	_	
19-28	3794-3800	reward	_	
19-29	3801-3813	anticipation	_	
19-30	3814-3816	in	_	
19-31	3817-3818	a	_	
19-32	3819-3827	monetary	_	
19-33	3828-3837	incentive	_	
19-34	3838-3843	delay	_	
19-35	3844-3848	task	_	
19-36	3848-3849	.	_	

#Text=Moeller et al. also identified a trend toward increased ACC activation to drug words, specifically.
20-1	3850-3857	Moeller	_	
20-2	3858-3860	et	_	
20-3	3861-3863	al	_	
20-4	3863-3864	.	_	
20-5	3865-3869	also	_	
20-6	3870-3880	identified	_	
20-7	3881-3882	a	_	
20-8	3883-3888	trend	_	
20-9	3889-3895	toward	_	
20-10	3896-3905	increased	_	
20-11	3906-3909	ACC	_	
20-12	3910-3920	activation	_	
20-13	3921-3923	to	_	
20-14	3924-3928	drug	_	
20-15	3929-3934	words	_	
20-16	3934-3935	,	_	
20-17	3936-3948	specifically	_	
20-18	3948-3949	.	_	

#Text=Taken together, these results suggest restoration of dopaminergic neurotransmission within the midbrain and improved recruitment and/or efficiency of dopaminergically-innervated regions associated with cognitive control and motivational salience.
21-1	3950-3955	Taken	_	
21-2	3956-3964	together	_	
21-3	3964-3965	,	_	
21-4	3966-3971	these	_	
21-5	3972-3979	results	_	
21-6	3980-3987	suggest	_	
21-7	3988-3999	restoration	_	
21-8	4000-4002	of	_	
21-9	4003-4015	dopaminergic	_	
21-10	4016-4033	neurotransmission	_	
21-11	4034-4040	within	_	
21-12	4041-4044	the	_	
21-13	4045-4053	midbrain	_	
21-14	4054-4057	and	_	
21-15	4058-4066	improved	_	
21-16	4067-4078	recruitment	_	
21-17	4079-4082	and	_	
21-18	4082-4083	/	_	
21-19	4083-4085	or	_	
21-20	4086-4096	efficiency	_	
21-21	4097-4099	of	_	
21-22	4100-4127	dopaminergically-innervated	_	
21-23	4128-4135	regions	_	
21-24	4136-4146	associated	_	
21-25	4147-4151	with	_	
21-26	4152-4161	cognitive	_	
21-27	4162-4169	control	_	
21-28	4170-4173	and	_	
21-29	4174-4186	motivational	_	
21-30	4187-4195	salience	_	
21-31	4195-4196	.	_	

#Text=also report a relationship between increased midbrain activity at follow-up, reduced drug-seeking in a simulated cocaine choice paradigm, and fewer days of use during recovery – while increased dorsolateral prefrontal cortex activity was associated with less spending on cocaine during treatment. also found that an increased midbrain response at follow-up was associated with reduced use, while a greater ventral striatum response during loss anticipation was associated with fewer negative urine drug screens.
22-1	4198-4202	also	_	
22-2	4203-4209	report	_	
22-3	4210-4211	a	_	
22-4	4212-4224	relationship	_	
22-5	4225-4232	between	_	
22-6	4233-4242	increased	_	
22-7	4243-4251	midbrain	_	
22-8	4252-4260	activity	_	
22-9	4261-4263	at	_	
22-10	4264-4273	follow-up	_	
22-11	4273-4274	,	_	
22-12	4275-4282	reduced	_	
22-13	4283-4295	drug-seeking	_	
22-14	4296-4298	in	_	
22-15	4299-4300	a	_	
22-16	4301-4310	simulated	_	
22-17	4311-4318	cocaine	_	
22-18	4319-4325	choice	_	
22-19	4326-4334	paradigm	_	
22-20	4334-4335	,	_	
22-21	4336-4339	and	_	
22-22	4340-4345	fewer	_	
22-23	4346-4350	days	_	
22-24	4351-4353	of	_	
22-25	4354-4357	use	_	
22-26	4358-4364	during	_	
22-27	4365-4373	recovery	_	
22-28	4374-4375	–	_	
22-29	4376-4381	while	_	
22-30	4382-4391	increased	_	
22-31	4392-4404	dorsolateral	_	
22-32	4405-4415	prefrontal	_	
22-33	4416-4422	cortex	_	
22-34	4423-4431	activity	_	
22-35	4432-4435	was	_	
22-36	4436-4446	associated	_	
22-37	4447-4451	with	_	
22-38	4452-4456	less	_	
22-39	4457-4465	spending	_	
22-40	4466-4468	on	_	
22-41	4469-4476	cocaine	_	
22-42	4477-4483	during	_	
22-43	4484-4493	treatment	_	
22-44	4493-4494	.	_	
22-45	4495-4499	also	_	
22-46	4500-4505	found	_	
22-47	4506-4510	that	_	
22-48	4511-4513	an	_	
22-49	4514-4523	increased	_	
22-50	4524-4532	midbrain	_	
22-51	4533-4541	response	_	
22-52	4542-4544	at	_	
22-53	4545-4554	follow-up	_	
22-54	4555-4558	was	_	
22-55	4559-4569	associated	_	
22-56	4570-4574	with	_	
22-57	4575-4582	reduced	_	
22-58	4583-4586	use	_	
22-59	4586-4587	,	_	
22-60	4588-4593	while	_	
22-61	4594-4595	a	_	
22-62	4596-4603	greater	_	
22-63	4604-4611	ventral	_	
22-64	4612-4620	striatum	_	
22-65	4621-4629	response	_	
22-66	4630-4636	during	_	
22-67	4637-4641	loss	_	
22-68	4642-4654	anticipation	_	
22-69	4655-4658	was	_	
22-70	4659-4669	associated	_	
22-71	4670-4674	with	_	
22-72	4675-4680	fewer	_	
22-73	4681-4689	negative	_	
22-74	4690-4695	urine	_	
22-75	4696-4700	drug	_	
22-76	4701-4708	screens	_	
22-77	4708-4709	.	_	

#Text=Correlations with treatment outcome were also explored by but no significant effects were identified.
23-1	4710-4722	Correlations	_	
23-2	4723-4727	with	_	
23-3	4728-4737	treatment	_	
23-4	4738-4745	outcome	_	
23-5	4746-4750	were	_	
23-6	4751-4755	also	_	
23-7	4756-4764	explored	_	
23-8	4765-4767	by	_	
23-9	4768-4771	but	_	
23-10	4772-4774	no	_	
23-11	4775-4786	significant	_	
23-12	4787-4794	effects	_	
23-13	4795-4799	were	_	
23-14	4800-4810	identified	_	
23-15	4810-4811	.	_	

#Text=Despite the apparent importance of decision-making in substance use recovery, no previous work has addressed change in reward- and control-related signaling in this context.
24-1	4812-4819	Despite	_	
24-2	4820-4823	the	_	
24-3	4824-4832	apparent	_	
24-4	4833-4843	importance	_	
24-5	4844-4846	of	_	
24-6	4847-4862	decision-making	_	
24-7	4863-4865	in	_	
24-8	4866-4875	substance	_	
24-9	4876-4879	use	_	
24-10	4880-4888	recovery	_	
24-11	4888-4889	,	_	
24-12	4890-4892	no	_	
24-13	4893-4901	previous	_	
24-14	4902-4906	work	_	
24-15	4907-4910	has	_	
24-16	4911-4920	addressed	_	
24-17	4921-4927	change	_	
24-18	4928-4930	in	_	
24-19	4931-4937	reward	_	
24-20	4937-4938	-	_	
24-21	4939-4942	and	_	
24-22	4943-4958	control-related	_	
24-23	4959-4968	signaling	_	
24-24	4969-4971	in	_	
24-25	4972-4976	this	_	
24-26	4977-4984	context	_	
24-27	4984-4985	.	_	

#Text=The current study specifically targeted recovery-related change in neural activation during risky decision-making in a mixed sample of SDIs during the three months following treatment engagement.
25-1	4986-4989	The	_	
25-2	4990-4997	current	_	
25-3	4998-5003	study	_	
25-4	5004-5016	specifically	_	
25-5	5017-5025	targeted	_	
25-6	5026-5042	recovery-related	_	
25-7	5043-5049	change	_	
25-8	5050-5052	in	_	
25-9	5053-5059	neural	_	
25-10	5060-5070	activation	_	
25-11	5071-5077	during	_	
25-12	5078-5083	risky	_	
25-13	5084-5099	decision-making	_	
25-14	5100-5102	in	_	
25-15	5103-5104	a	_	
25-16	5105-5110	mixed	_	
25-17	5111-5117	sample	_	
25-18	5118-5120	of	_	
25-19	5121-5125	SDIs	_	
25-20	5126-5132	during	_	
25-21	5133-5136	the	_	
25-22	5137-5142	three	_	
25-23	5143-5149	months	_	
25-24	5150-5159	following	_	
25-25	5160-5169	treatment	_	
25-26	5170-5180	engagement	_	
25-27	5180-5181	.	_	

#Text=Specifically, the Balloon Analogue Risk Task (BART) was selected due to its good test-retest reliability, external validity with respect to real-life risky behavior (including substance use), and existing framework for disentangling reward-seeking, loss aversion, and infrequency effects, previously developed by our lab (please see; for details).
26-1	5182-5194	Specifically	_	
26-2	5194-5195	,	_	
26-3	5196-5199	the	_	
26-4	5200-5207	Balloon	_	
26-5	5208-5216	Analogue	_	
26-6	5217-5221	Risk	_	
26-7	5222-5226	Task	_	
26-8	5227-5228	(	_	
26-9	5228-5232	BART	_	
26-10	5232-5233	)	_	
26-11	5234-5237	was	_	
26-12	5238-5246	selected	_	
26-13	5247-5250	due	_	
26-14	5251-5253	to	_	
26-15	5254-5257	its	_	
26-16	5258-5262	good	_	
26-17	5263-5274	test-retest	_	
26-18	5275-5286	reliability	_	
26-19	5286-5287	,	_	
26-20	5288-5296	external	_	
26-21	5297-5305	validity	_	
26-22	5306-5310	with	_	
26-23	5311-5318	respect	_	
26-24	5319-5321	to	_	
26-25	5322-5331	real-life	_	
26-26	5332-5337	risky	_	
26-27	5338-5346	behavior	_	
26-28	5347-5348	(	_	
26-29	5348-5357	including	_	
26-30	5358-5367	substance	_	
26-31	5368-5371	use	_	
26-32	5371-5372	)	_	
26-33	5372-5373	,	_	
26-34	5374-5377	and	_	
26-35	5378-5386	existing	_	
26-36	5387-5396	framework	_	
26-37	5397-5400	for	_	
26-38	5401-5414	disentangling	_	
26-39	5415-5429	reward-seeking	_	
26-40	5429-5430	,	_	
26-41	5431-5435	loss	_	
26-42	5436-5444	aversion	_	
26-43	5444-5445	,	_	
26-44	5446-5449	and	_	
26-45	5450-5461	infrequency	_	
26-46	5462-5469	effects	_	
26-47	5469-5470	,	_	
26-48	5471-5481	previously	_	
26-49	5482-5491	developed	_	
26-50	5492-5494	by	_	
26-51	5495-5498	our	_	
26-52	5499-5502	lab	_	
26-53	5503-5504	(	_	
26-54	5504-5510	please	_	
26-55	5511-5514	see	_	
26-56	5514-5515	;	_	
26-57	5516-5519	for	_	
26-58	5520-5527	details	_	
26-59	5527-5528	)	_	
26-60	5528-5529	.	_	

#Text=Our previous work identified BART-related activation in mPFC/ACC that was associated with uncontrolled substance use and substance abuse risk factors in alcohol-using undergraduates.
27-1	5530-5533	Our	_	
27-2	5534-5542	previous	_	
27-3	5543-5547	work	_	
27-4	5548-5558	identified	_	
27-5	5559-5571	BART-related	_	
27-6	5572-5582	activation	_	
27-7	5583-5585	in	_	
27-8	5586-5590	mPFC	_	
27-9	5590-5591	/	_	
27-10	5591-5594	ACC	_	
27-11	5595-5599	that	_	
27-12	5600-5603	was	_	
27-13	5604-5614	associated	_	
27-14	5615-5619	with	_	
27-15	5620-5632	uncontrolled	_	
27-16	5633-5642	substance	_	
27-17	5643-5646	use	_	
27-18	5647-5650	and	_	
27-19	5651-5660	substance	_	
27-20	5661-5666	abuse	_	
27-21	5667-5671	risk	_	
27-22	5672-5679	factors	_	
27-23	5680-5682	in	_	
27-24	5683-5696	alcohol-using	_	
27-25	5697-5711	undergraduates	_	
27-26	5711-5712	.	_	

#Text=Specifically, high-risk substance use was associated with reduced mPFC/ACC signal in relation to increasingly risky decision-making and increased mPFC/ACC signal in relation to unexpected, high-risk reward.
28-1	5713-5725	Specifically	_	
28-2	5725-5726	,	_	
28-3	5727-5736	high-risk	_	
28-4	5737-5746	substance	_	
28-5	5747-5750	use	_	
28-6	5751-5754	was	_	
28-7	5755-5765	associated	_	
28-8	5766-5770	with	_	
28-9	5771-5778	reduced	_	
28-10	5779-5783	mPFC	_	
28-11	5783-5784	/	_	
28-12	5784-5787	ACC	_	
28-13	5788-5794	signal	_	
28-14	5795-5797	in	_	
28-15	5798-5806	relation	_	
28-16	5807-5809	to	_	
28-17	5810-5822	increasingly	_	
28-18	5823-5828	risky	_	
28-19	5829-5844	decision-making	_	
28-20	5845-5848	and	_	
28-21	5849-5858	increased	_	
28-22	5859-5863	mPFC	_	
28-23	5863-5864	/	_	
28-24	5864-5867	ACC	_	
28-25	5868-5874	signal	_	
28-26	5875-5877	in	_	
28-27	5878-5886	relation	_	
28-28	5887-5889	to	_	
28-29	5890-5900	unexpected	_	
28-30	5900-5901	,	_	
28-31	5902-5911	high-risk	_	
28-32	5912-5918	reward	_	
28-33	5918-5919	.	_	

#Text=This is consistent with the notion that control-related mPFC/ACC activity biases decisions away from riskier options and signals predictions errors based on risk appraisal.
29-1	5920-5924	This	_	
29-2	5925-5927	is	_	
29-3	5928-5938	consistent	_	
29-4	5939-5943	with	_	
29-5	5944-5947	the	_	
29-6	5948-5954	notion	_	
29-7	5955-5959	that	_	
29-8	5960-5975	control-related	_	
29-9	5976-5980	mPFC	_	
29-10	5980-5981	/	_	
29-11	5981-5984	ACC	_	
29-12	5985-5993	activity	_	
29-13	5994-6000	biases	_	
29-14	6001-6010	decisions	_	
29-15	6011-6015	away	_	
29-16	6016-6020	from	_	
29-17	6021-6028	riskier	_	
29-18	6029-6036	options	_	
29-19	6037-6040	and	_	
29-20	6041-6048	signals	_	
29-21	6049-6060	predictions	_	
29-22	6061-6067	errors	_	
29-23	6068-6073	based	_	
29-24	6074-6076	on	_	
29-25	6077-6081	risk	_	
29-26	6082-6091	appraisal	_	
29-27	6091-6092	.	_	

#Text=We specifically hypothesized that individuals with improved recovery outcomes would exhibit remediation of these event-related signals over time (i.e., increased mPFC/ACC activity during risky decision-making and reduced signal to high-risk reward).
30-1	6093-6095	We	_	
30-2	6096-6108	specifically	_	
30-3	6109-6121	hypothesized	_	
30-4	6122-6126	that	_	
30-5	6127-6138	individuals	_	
30-6	6139-6143	with	_	
30-7	6144-6152	improved	_	
30-8	6153-6161	recovery	_	
30-9	6162-6170	outcomes	_	
30-10	6171-6176	would	_	
30-11	6177-6184	exhibit	_	
30-12	6185-6196	remediation	_	
30-13	6197-6199	of	_	
30-14	6200-6205	these	_	
30-15	6206-6219	event-related	_	
30-16	6220-6227	signals	_	
30-17	6228-6232	over	_	
30-18	6233-6237	time	_	
30-19	6238-6239	(	_	
30-20	6239-6242	i.e	_	
30-21	6242-6243	.	_	
30-22	6243-6244	,	_	
30-23	6245-6254	increased	_	
30-24	6255-6259	mPFC	_	
30-25	6259-6260	/	_	
30-26	6260-6263	ACC	_	
30-27	6264-6272	activity	_	
30-28	6273-6279	during	_	
30-29	6280-6285	risky	_	
30-30	6286-6301	decision-making	_	
30-31	6302-6305	and	_	
30-32	6306-6313	reduced	_	
30-33	6314-6320	signal	_	
30-34	6321-6323	to	_	
30-35	6324-6333	high-risk	_	
30-36	6334-6340	reward	_	
30-37	6340-6341	)	_	
30-38	6341-6342	.	_	

#Text=Further, unlike previous longitudinal imaging studies of recovery, the current study investigated parametric modulations of the BOLD response that reflect dynamic sensitivity to task context (specifically, trial-to-trial variation in risk and reward).
31-1	6343-6350	Further	_	
31-2	6350-6351	,	_	
31-3	6352-6358	unlike	_	
31-4	6359-6367	previous	_	
31-5	6368-6380	longitudinal	_	
31-6	6381-6388	imaging	_	
31-7	6389-6396	studies	_	
31-8	6397-6399	of	_	
31-9	6400-6408	recovery	_	
31-10	6408-6409	,	_	
31-11	6410-6413	the	_	
31-12	6414-6421	current	_	
31-13	6422-6427	study	_	
31-14	6428-6440	investigated	_	
31-15	6441-6451	parametric	_	
31-16	6452-6463	modulations	_	
31-17	6464-6466	of	_	
31-18	6467-6470	the	_	
31-19	6471-6475	BOLD	_	
31-20	6476-6484	response	_	
31-21	6485-6489	that	_	
31-22	6490-6497	reflect	_	
31-23	6498-6505	dynamic	_	
31-24	6506-6517	sensitivity	_	
31-25	6518-6520	to	_	
31-26	6521-6525	task	_	
31-27	6526-6533	context	_	
31-28	6534-6535	(	_	
31-29	6535-6547	specifically	_	
31-30	6547-6548	,	_	
31-31	6549-6563	trial-to-trial	_	
31-32	6564-6573	variation	_	
31-33	6574-6576	in	_	
31-34	6577-6581	risk	_	
31-35	6582-6585	and	_	
31-36	6586-6592	reward	_	
31-37	6592-6593	)	_	
31-38	6593-6594	.	_	

#Text=Such signals provide unique insight into the neural representation of relapse-relevant constructs (e.g., reward sensitivity, loss aversion) and may be robust to changes in processing efficiency that complicate interpretation of findings from main effect contrasts.
#Text=2.
32-1	6595-6599	Such	_	
32-2	6600-6607	signals	_	
32-3	6608-6615	provide	_	
32-4	6616-6622	unique	_	
32-5	6623-6630	insight	_	
32-6	6631-6635	into	_	
32-7	6636-6639	the	_	
32-8	6640-6646	neural	_	
32-9	6647-6661	representation	_	
32-10	6662-6664	of	_	
32-11	6665-6681	relapse-relevant	_	
32-12	6682-6692	constructs	_	
32-13	6693-6694	(	_	
32-14	6694-6697	e.g	_	
32-15	6697-6698	.	_	
32-16	6698-6699	,	_	
32-17	6700-6706	reward	_	
32-18	6707-6718	sensitivity	_	
32-19	6718-6719	,	_	
32-20	6720-6724	loss	_	
32-21	6725-6733	aversion	_	
32-22	6733-6734	)	_	
32-23	6735-6738	and	_	
32-24	6739-6742	may	_	
32-25	6743-6745	be	_	
32-26	6746-6752	robust	_	
32-27	6753-6755	to	_	
32-28	6756-6763	changes	_	
32-29	6764-6766	in	_	
32-30	6767-6777	processing	_	
32-31	6778-6788	efficiency	_	
32-32	6789-6793	that	_	
32-33	6794-6804	complicate	_	
32-34	6805-6819	interpretation	_	
32-35	6820-6822	of	_	
32-36	6823-6831	findings	_	
32-37	6832-6836	from	_	
32-38	6837-6841	main	_	
32-39	6842-6848	effect	_	
32-40	6849-6858	contrasts	_	
32-41	6858-6859	.	_	
32-42	6860-6861	2	_	
32-43	6861-6862	.	_	

#Text=Methods
#Text=2.1.
33-1	6863-6870	Methods	http://www.case.edu/ProvCaRe/provcare#StudyMethod	
33-2	6871-6874	2.1	_	
33-3	6874-6875	.	_	

#Text=Participants and design
#Text=Twenty-six SDIs were enrolled upon treatment engagement at one of two community-based clinics; 21 completed baseline and follow-up assessments and are included in the current sample (6 female; see Table 1 for demographic and recruitment data).
34-1	6876-6888	Participants	_	
34-2	6889-6892	and	_	
34-3	6893-6899	design	_	
34-4	6900-6910	Twenty-six	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[9]	
34-5	6911-6915	SDIs	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[9]|http://maven.renci.org/NeuroBridge/neurobridge#SubstanceDisorder[10]	
34-6	6916-6920	were	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[9]	
34-7	6921-6929	enrolled	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[9]	
34-8	6930-6934	upon	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[9]	
34-9	6935-6944	treatment	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[9]	
34-10	6945-6955	engagement	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[9]	
34-11	6956-6958	at	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[9]	
34-12	6959-6962	one	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[9]	
34-13	6963-6965	of	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[9]	
34-14	6966-6969	two	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[9]	
34-15	6970-6985	community-based	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[9]	
34-16	6986-6993	clinics	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[9]	
34-17	6993-6994	;	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[9]	
34-18	6995-6997	21	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[9]	
34-19	6998-7007	completed	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[9]	
34-20	7008-7016	baseline	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[9]	
34-21	7017-7020	and	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[9]	
34-22	7021-7030	follow-up	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[9]	
34-23	7031-7042	assessments	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[9]	
34-24	7043-7046	and	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[9]	
34-25	7047-7050	are	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[9]	
34-26	7051-7059	included	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[9]	
34-27	7060-7062	in	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[9]	
34-28	7063-7066	the	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[9]	
34-29	7067-7074	current	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[9]	
34-30	7075-7081	sample	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[9]	
34-31	7082-7083	(	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[9]	
34-32	7083-7084	6	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[9]	
34-33	7085-7091	female	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[9]	
34-34	7091-7092	;	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[9]	
34-35	7093-7096	see	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[9]	
34-36	7097-7102	Table	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[9]	
34-37	7103-7104	1	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[9]	
34-38	7105-7108	for	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[9]	
34-39	7109-7120	demographic	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[9]	
34-40	7121-7124	and	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[9]	
34-41	7125-7136	recruitment	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[9]	
34-42	7137-7141	data	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[9]	
34-43	7141-7142	)	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[9]	
34-44	7142-7143	.	_	

#Text=Participants were (1) diagnosed with alcohol, drug, or polysubstance dependence using DSM-IV criteria, (2) 18–50 years of age, (3) 1–4 weeks abstinent at time of baseline assessment, and (4) actively participating in substance use treatment.
35-1	7144-7156	Participants	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]	
35-2	7157-7161	were	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]	
35-3	7162-7163	(	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]	
35-4	7163-7164	1	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]	
35-5	7164-7165	)	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]	
35-6	7166-7175	diagnosed	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]	
35-7	7176-7180	with	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]	
35-8	7181-7188	alcohol	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]|http://maven.renci.org/NeuroBridge/neurobridge#AlcoholAbuse[12]	
35-9	7188-7189	,	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]	
35-10	7190-7194	drug	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]|http://maven.renci.org/NeuroBridge/neurobridge#DrugDependence[13]	
35-11	7194-7195	,	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]	
35-12	7196-7198	or	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]	
35-13	7199-7212	polysubstance	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]|http://maven.renci.org/NeuroBridge/neurobridge#PolysubstanceDependence[14]	
35-14	7213-7223	dependence	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]|http://maven.renci.org/NeuroBridge/neurobridge#PolysubstanceDependence[14]	
35-15	7224-7229	using	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]	
35-16	7230-7236	DSM-IV	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]	
35-17	7237-7245	criteria	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]	
35-18	7245-7246	,	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]	
35-19	7247-7248	(	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]	
35-20	7248-7249	2	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]	
35-21	7249-7250	)	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]	
35-22	7251-7253	18	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]	
35-23	7253-7254	–	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]	
35-24	7254-7256	50	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]	
35-25	7257-7262	years	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]	
35-26	7263-7265	of	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]	
35-27	7266-7269	age	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]	
35-28	7269-7270	,	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]	
35-29	7271-7272	(	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]	
35-30	7272-7273	3	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]	
35-31	7273-7274	)	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]	
35-32	7275-7276	1	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]	
35-33	7276-7277	–	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]	
35-34	7277-7278	4	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]	
35-35	7279-7284	weeks	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]	
35-36	7285-7294	abstinent	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]	
35-37	7295-7297	at	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]	
35-38	7298-7302	time	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]	
35-39	7303-7305	of	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]	
35-40	7306-7314	baseline	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]	
35-41	7315-7325	assessment	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]	
35-42	7325-7326	,	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]	
35-43	7327-7330	and	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]	
35-44	7331-7332	(	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]	
35-45	7332-7333	4	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]	
35-46	7333-7334	)	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]	
35-47	7335-7343	actively	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]	
35-48	7344-7357	participating	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]	
35-49	7358-7360	in	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]	
35-50	7361-7370	substance	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]|http://maven.renci.org/NeuroBridge/neurobridge#SubstanceDisorder[15]	
35-51	7371-7374	use	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]|http://maven.renci.org/NeuroBridge/neurobridge#SubstanceDisorder[15]	
35-52	7375-7384	treatment	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]	
35-53	7384-7385	.	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]	

#Text=Individuals receiving replacement pharmacotherapy and those reporting contraindications to magnetic resonance imaging or a history of traumatic brain injury, other neurocognitive disorders, Bipolar disorder, or psychotic illness were excluded.
36-1	7386-7397	Individuals	_	
36-2	7398-7407	receiving	_	
36-3	7408-7419	replacement	_	
36-4	7420-7435	pharmacotherapy	_	
36-5	7436-7439	and	_	
36-6	7440-7445	those	_	
36-7	7446-7455	reporting	_	
36-8	7456-7473	contraindications	_	
36-9	7474-7476	to	_	
36-10	7477-7485	magnetic	_	
36-11	7486-7495	resonance	_	
36-12	7496-7503	imaging	_	
36-13	7504-7506	or	_	
36-14	7507-7508	a	_	
36-15	7509-7516	history	_	
36-16	7517-7519	of	_	
36-17	7520-7529	traumatic	_	
36-18	7530-7535	brain	_	
36-19	7536-7542	injury	_	
36-20	7542-7543	,	_	
36-21	7544-7549	other	_	
36-22	7550-7564	neurocognitive	_	
36-23	7565-7574	disorders	_	
36-24	7574-7575	,	_	
36-25	7576-7583	Bipolar	_	
36-26	7584-7592	disorder	_	
36-27	7592-7593	,	_	
36-28	7594-7596	or	_	
36-29	7597-7606	psychotic	_	
36-30	7607-7614	illness	_	
36-31	7615-7619	were	_	
36-32	7620-7628	excluded	_	
36-33	7628-7629	.	_	

#Text=Participants received treatment-as-usual in an intensive outpatient or residential treatment program.
37-1	7630-7642	Participants	_	
37-2	7643-7651	received	_	
37-3	7652-7670	treatment-as-usual	_	
37-4	7671-7673	in	_	
37-5	7674-7676	an	_	
37-6	7677-7686	intensive	_	
37-7	7687-7697	outpatient	_	
37-8	7698-7700	or	_	
37-9	7701-7712	residential	_	
37-10	7713-7722	treatment	_	
37-11	7723-7730	program	_	
37-12	7730-7731	.	_	

#Text=Both programs were abstinence-oriented and utilized a twelve-step facilitation approach, as well as routine urinalysis (see Supplementary materials for additional details).
38-1	7732-7736	Both	_	
38-2	7737-7745	programs	_	
38-3	7746-7750	were	_	
38-4	7751-7770	abstinence-oriented	_	
38-5	7771-7774	and	_	
38-6	7775-7783	utilized	_	
38-7	7784-7785	a	_	
38-8	7786-7797	twelve-step	_	
38-9	7798-7810	facilitation	_	
38-10	7811-7819	approach	_	
38-11	7819-7820	,	_	
38-12	7821-7823	as	_	
38-13	7824-7828	well	_	
38-14	7829-7831	as	_	
38-15	7832-7839	routine	_	
38-16	7840-7850	urinalysis	_	
38-17	7851-7852	(	_	
38-18	7852-7855	see	_	
38-19	7856-7869	Supplementary	_	
38-20	7870-7879	materials	_	
38-21	7880-7883	for	_	
38-22	7884-7894	additional	_	
38-23	7895-7902	details	_	
38-24	7902-7903	)	_	
38-25	7903-7904	.	_	

#Text=Participants completed a baseline assessment and follow-up fMRI assessment at 3-months.
39-1	7905-7917	Participants	_	
39-2	7918-7927	completed	_	
39-3	7928-7929	a	_	
39-4	7930-7938	baseline	_	
39-5	7939-7949	assessment	_	
39-6	7950-7953	and	_	
39-7	7954-7963	follow-up	_	
39-8	7964-7968	fMRI	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalMagneticResonanceImaging	
39-9	7969-7979	assessment	_	
39-10	7980-7982	at	_	
39-11	7983-7984	3	_	
39-12	7984-7985	-	_	
39-13	7985-7991	months	_	
39-14	7991-7992	.	_	

#Text=The timeline follow-back procedure was conducted at monthly intervals to track drug and alcohol use during the 3-month period and additional narrative details (e.g., subjective intoxication) were also collected (see Supplementary materials for additional information).
40-1	7993-7996	The	_	
40-2	7997-8005	timeline	http://maven.renci.org/NeuroBridge/neurobridge#SubstanceUseScale[16]	
40-3	8006-8017	follow-back	http://maven.renci.org/NeuroBridge/neurobridge#SubstanceUseScale[16]	
40-4	8018-8027	procedure	http://maven.renci.org/NeuroBridge/neurobridge#SubstanceUseScale[16]	
40-5	8028-8031	was	_	
40-6	8032-8041	conducted	_	
40-7	8042-8044	at	_	
40-8	8045-8052	monthly	_	
40-9	8053-8062	intervals	_	
40-10	8063-8065	to	_	
40-11	8066-8071	track	_	
40-12	8072-8076	drug	http://maven.renci.org/NeuroBridge/neurobridge#DrugAbuse	
40-13	8077-8080	and	_	
40-14	8081-8088	alcohol	http://maven.renci.org/NeuroBridge/neurobridge#AlcoholAbuse[17]	
40-15	8089-8092	use	http://maven.renci.org/NeuroBridge/neurobridge#AlcoholAbuse[17]	
40-16	8093-8099	during	_	
40-17	8100-8103	the	_	
40-18	8104-8105	3	_	
40-19	8105-8106	-	_	
40-20	8106-8111	month	_	
40-21	8112-8118	period	_	
40-22	8119-8122	and	_	
40-23	8123-8133	additional	_	
40-24	8134-8143	narrative	_	
40-25	8144-8151	details	_	
40-26	8152-8153	(	_	
40-27	8153-8156	e.g	_	
40-28	8156-8157	.	_	
40-29	8157-8158	,	_	
40-30	8159-8169	subjective	_	
40-31	8170-8182	intoxication	_	
40-32	8182-8183	)	_	
40-33	8184-8188	were	_	
40-34	8189-8193	also	_	
40-35	8194-8203	collected	_	
40-36	8204-8205	(	_	
40-37	8205-8208	see	_	
40-38	8209-8222	Supplementary	_	
40-39	8223-8232	materials	_	
40-40	8233-8236	for	_	
40-41	8237-8247	additional	_	
40-42	8248-8259	information	_	
40-43	8259-8260	)	_	
40-44	8260-8261	.	_	

#Text=A breathalyzer test (AlcoSensor IV, Intoximeters, Inc., St.
41-1	8262-8263	A	_	
41-2	8264-8276	breathalyzer	_	
41-3	8277-8281	test	_	
41-4	8282-8283	(	_	
41-5	8283-8293	AlcoSensor	_	
41-6	8294-8296	IV	_	
41-7	8296-8297	,	_	
41-8	8298-8310	Intoximeters	_	
41-9	8310-8311	,	_	
41-10	8312-8315	Inc	_	
41-11	8315-8316	.	_	
41-12	8316-8317	,	_	
41-13	8318-8320	St	_	
41-14	8320-8321	.	_	

#Text=Louis, MO) and 6-panel urine drug screen (Alere Toxicology, Portsmouth, VA) were conducted prior to baseline and 3-month assessments.
42-1	8322-8327	Louis	_	
42-2	8327-8328	,	_	
42-3	8329-8331	MO	_	
42-4	8331-8332	)	_	
42-5	8333-8336	and	_	
42-6	8337-8338	6	_	
42-7	8338-8339	-	_	
42-8	8339-8344	panel	_	
42-9	8345-8350	urine	_	
42-10	8351-8355	drug	_	
42-11	8356-8362	screen	_	
42-12	8363-8364	(	_	
42-13	8364-8369	Alere	_	
42-14	8370-8380	Toxicology	_	
42-15	8380-8381	,	_	
42-16	8382-8392	Portsmouth	_	
42-17	8392-8393	,	_	
42-18	8394-8396	VA	_	
42-19	8396-8397	)	_	
42-20	8398-8402	were	_	
42-21	8403-8412	conducted	_	
42-22	8413-8418	prior	_	
42-23	8419-8421	to	_	
42-24	8422-8430	baseline	_	
42-25	8431-8434	and	_	
42-26	8435-8436	3	_	
42-27	8436-8437	-	_	
42-28	8437-8442	month	_	
42-29	8443-8454	assessments	_	
42-30	8454-8455	.	_	

#Text=Participants who resumed use during the study were required to maintain abstinence for 48 h prior to testing and were evaluated for signs of intoxication.
43-1	8456-8468	Participants	_	
43-2	8469-8472	who	_	
43-3	8473-8480	resumed	_	
43-4	8481-8484	use	_	
43-5	8485-8491	during	_	
43-6	8492-8495	the	_	
43-7	8496-8501	study	_	
43-8	8502-8506	were	_	
43-9	8507-8515	required	_	
43-10	8516-8518	to	_	
43-11	8519-8527	maintain	_	
43-12	8528-8538	abstinence	_	
43-13	8539-8542	for	_	
43-14	8543-8545	48	_	
43-15	8546-8547	h	_	
43-16	8548-8553	prior	_	
43-17	8554-8556	to	_	
43-18	8557-8564	testing	_	
43-19	8565-8568	and	_	
43-20	8569-8573	were	_	
43-21	8574-8583	evaluated	_	
43-22	8584-8587	for	_	
43-23	8588-8593	signs	_	
43-24	8594-8596	of	_	
43-25	8597-8609	intoxication	_	
43-26	8609-8610	.	_	

#Text=Study assessments were not conducted if urinalysis results were positive for recent substance use or blood alcohol content was greater than 0.000 percent by volume.
44-1	8611-8616	Study	_	
44-2	8617-8628	assessments	_	
44-3	8629-8633	were	_	
44-4	8634-8637	not	_	
44-5	8638-8647	conducted	_	
44-6	8648-8650	if	_	
44-7	8651-8661	urinalysis	_	
44-8	8662-8669	results	_	
44-9	8670-8674	were	_	
44-10	8675-8683	positive	_	
44-11	8684-8687	for	_	
44-12	8688-8694	recent	_	
44-13	8695-8704	substance	http://maven.renci.org/NeuroBridge/neurobridge#SubstanceDisorder[18]	
44-14	8705-8708	use	http://maven.renci.org/NeuroBridge/neurobridge#SubstanceDisorder[18]	
44-15	8709-8711	or	_	
44-16	8712-8717	blood	_	
44-17	8718-8725	alcohol	_	
44-18	8726-8733	content	_	
44-19	8734-8737	was	_	
44-20	8738-8745	greater	_	
44-21	8746-8750	than	_	
44-22	8751-8756	0.000	_	
44-23	8757-8764	percent	_	
44-24	8765-8767	by	_	
44-25	8768-8774	volume	_	
44-26	8774-8775	.	_	

#Text=Two participants screened positive for use at 3-month follow-up; both were rescheduled and completed this assessment after providing negative urine specimen and breathalyzer results.
45-1	8776-8779	Two	_	
45-2	8780-8792	participants	_	
45-3	8793-8801	screened	_	
45-4	8802-8810	positive	_	
45-5	8811-8814	for	_	
45-6	8815-8818	use	_	
45-7	8819-8821	at	_	
45-8	8822-8823	3	_	
45-9	8823-8824	-	_	
45-10	8824-8829	month	_	
45-11	8830-8839	follow-up	_	
45-12	8839-8840	;	_	
45-13	8841-8845	both	_	
45-14	8846-8850	were	_	
45-15	8851-8862	rescheduled	_	
45-16	8863-8866	and	_	
45-17	8867-8876	completed	_	
45-18	8877-8881	this	_	
45-19	8882-8892	assessment	_	
45-20	8893-8898	after	_	
45-21	8899-8908	providing	_	
45-22	8909-8917	negative	_	
45-23	8918-8923	urine	_	
45-24	8924-8932	specimen	_	
45-25	8933-8936	and	_	
45-26	8937-8949	breathalyzer	_	
45-27	8950-8957	results	_	
45-28	8957-8958	.	_	

#Text=Lifetime problems with alcohol and other substances were assessed at baseline using the Semi-structured Assessment for the Genetics of Alcoholism.
46-1	8959-8967	Lifetime	_	
46-2	8968-8976	problems	_	
46-3	8977-8981	with	_	
46-4	8982-8989	alcohol	http://maven.renci.org/NeuroBridge/neurobridge#AlcoholAbuse	
46-5	8990-8993	and	_	
46-6	8994-8999	other	_	
46-7	9000-9010	substances	_	
46-8	9011-9015	were	_	
46-9	9016-9024	assessed	_	
46-10	9025-9027	at	_	
46-11	9028-9036	baseline	_	
46-12	9037-9042	using	_	
46-13	9043-9046	the	_	
46-14	9047-9062	Semi-structured	http://maven.renci.org/NeuroBridge/neurobridge#Semi-StructuredAssessmentfortheGeneticsofAlcoholism[19]	
46-15	9063-9073	Assessment	http://maven.renci.org/NeuroBridge/neurobridge#Semi-StructuredAssessmentfortheGeneticsofAlcoholism[19]	
46-16	9074-9077	for	http://maven.renci.org/NeuroBridge/neurobridge#Semi-StructuredAssessmentfortheGeneticsofAlcoholism[19]	
46-17	9078-9081	the	http://maven.renci.org/NeuroBridge/neurobridge#Semi-StructuredAssessmentfortheGeneticsofAlcoholism[19]	
46-18	9082-9090	Genetics	http://maven.renci.org/NeuroBridge/neurobridge#Semi-StructuredAssessmentfortheGeneticsofAlcoholism[19]	
46-19	9091-9093	of	http://maven.renci.org/NeuroBridge/neurobridge#Semi-StructuredAssessmentfortheGeneticsofAlcoholism[19]	
46-20	9094-9104	Alcoholism	http://maven.renci.org/NeuroBridge/neurobridge#Semi-StructuredAssessmentfortheGeneticsofAlcoholism[19]	
46-21	9104-9105	.	_	

#Text=Data from the timeline follow-back were used to compute a substance use metric (SUM),1 summarizing days of use (with and without intoxication) for each participant; values were arcsine-transformed to better approximate the normal distribution.
47-1	9106-9110	Data	_	
47-2	9111-9115	from	_	
47-3	9116-9119	the	_	
47-4	9120-9128	timeline	http://maven.renci.org/NeuroBridge/neurobridge#SubstanceUseScale[20]	
47-5	9129-9140	follow-back	http://maven.renci.org/NeuroBridge/neurobridge#SubstanceUseScale[20]	
47-6	9141-9145	were	_	
47-7	9146-9150	used	_	
47-8	9151-9153	to	_	
47-9	9154-9161	compute	_	
47-10	9162-9163	a	_	
47-11	9164-9173	substance	http://maven.renci.org/NeuroBridge/neurobridge#SubstanceUseScale[21]	
47-12	9174-9177	use	http://maven.renci.org/NeuroBridge/neurobridge#SubstanceUseScale[21]	
47-13	9178-9184	metric	http://maven.renci.org/NeuroBridge/neurobridge#SubstanceUseScale[21]	
47-14	9185-9186	(	http://maven.renci.org/NeuroBridge/neurobridge#SubstanceUseScale[21]	
47-15	9186-9189	SUM	http://maven.renci.org/NeuroBridge/neurobridge#SubstanceUseScale[21]	
47-16	9189-9190	)	http://maven.renci.org/NeuroBridge/neurobridge#SubstanceUseScale[21]	
47-17	9190-9191	,	_	
47-18	9191-9192	1	_	
47-19	9193-9204	summarizing	_	
47-20	9205-9209	days	_	
47-21	9210-9212	of	_	
47-22	9213-9216	use	_	
47-23	9217-9218	(	_	
47-24	9218-9222	with	_	
47-25	9223-9226	and	_	
47-26	9227-9234	without	_	
47-27	9235-9247	intoxication	_	
47-28	9247-9248	)	_	
47-29	9249-9252	for	_	
47-30	9253-9257	each	_	
47-31	9258-9269	participant	_	
47-32	9269-9270	;	_	
47-33	9271-9277	values	_	
47-34	9278-9282	were	_	
47-35	9283-9302	arcsine-transformed	_	
47-36	9303-9305	to	_	
47-37	9306-9312	better	_	
47-38	9313-9324	approximate	_	
47-39	9325-9328	the	_	
47-40	9329-9335	normal	_	
47-41	9336-9348	distribution	_	
47-42	9348-9349	.	_	

#Text=Additional self-report (including measures of social investment, craving, anxiety, depression, and coping) and cognitive-behavioral (i.e., Go/No-Go, Delay Discounting, and Brown-Peterson tasks) measures of recovery are described in Supplementary materials and Supplementary Table 1.
#Text=2.2. fMRI procedure
#Text=Imaging datasets were acquired at baseline and 3-month follow-up using a Siemens Magnetom Trio 3-T MRI scanner and 32-channel head coil.
48-1	9350-9360	Additional	_	
48-2	9361-9372	self-report	http://www.case.edu/ProvCaRe/provcare#Questionnaire	
48-3	9373-9374	(	_	
48-4	9374-9383	including	_	
48-5	9384-9392	measures	_	
48-6	9393-9395	of	_	
48-7	9396-9402	social	_	
48-8	9403-9413	investment	_	
48-9	9413-9414	,	_	
48-10	9415-9422	craving	http://maven.renci.org/NeuroBridge/neurobridge#SubstanceCravingScale	
48-11	9422-9423	,	_	
48-12	9424-9431	anxiety	_	
48-13	9431-9432	,	_	
48-14	9433-9443	depression	http://maven.renci.org/NeuroBridge/neurobridge#DepressionRatingScale	
48-15	9443-9444	,	_	
48-16	9445-9448	and	_	
48-17	9449-9455	coping	_	
48-18	9455-9456	)	_	
48-19	9457-9460	and	_	
48-20	9461-9481	cognitive-behavioral	http://www.case.edu/ProvCaRe/provcare#NeurocognitiveTest	
48-21	9482-9483	(	_	
48-22	9483-9486	i.e	_	
48-23	9486-9487	.	_	
48-24	9487-9488	,	_	
48-25	9489-9491	Go	http://maven.renci.org/NeuroBridge/neurobridge#GoNoGoTask[22]	
48-26	9491-9492	/	http://maven.renci.org/NeuroBridge/neurobridge#GoNoGoTask[22]	
48-27	9492-9497	No-Go	http://maven.renci.org/NeuroBridge/neurobridge#GoNoGoTask[22]	
48-28	9497-9498	,	_	
48-29	9499-9504	Delay	_	
48-30	9505-9516	Discounting	_	
48-31	9516-9517	,	_	
48-32	9518-9521	and	_	
48-33	9522-9536	Brown-Peterson	_	
48-34	9537-9542	tasks	_	
48-35	9542-9543	)	_	
48-36	9544-9552	measures	_	
48-37	9553-9555	of	_	
48-38	9556-9564	recovery	_	
48-39	9565-9568	are	_	
48-40	9569-9578	described	_	
48-41	9579-9581	in	_	
48-42	9582-9595	Supplementary	_	
48-43	9596-9605	materials	_	
48-44	9606-9609	and	_	
48-45	9610-9623	Supplementary	_	
48-46	9624-9629	Table	_	
48-47	9630-9631	1	_	
48-48	9631-9632	.	_	
48-49	9633-9636	2.2	_	
48-50	9636-9637	.	_	
48-51	9638-9642	fMRI	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalMagneticResonanceImaging	
48-52	9643-9652	procedure	_	
48-53	9653-9660	Imaging	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalImagingProtocol[23]	
48-54	9661-9669	datasets	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalImagingProtocol[23]	
48-55	9670-9674	were	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalImagingProtocol[23]	
48-56	9675-9683	acquired	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalImagingProtocol[23]	
48-57	9684-9686	at	_	
48-58	9687-9695	baseline	_	
48-59	9696-9699	and	_	
48-60	9700-9701	3	_	
48-61	9701-9702	-	_	
48-62	9702-9707	month	_	
48-63	9708-9717	follow-up	_	
48-64	9718-9723	using	_	
48-65	9724-9725	a	_	
48-66	9726-9733	Siemens	http://maven.renci.org/NeuroBridge/neurobridge#MagneticResonanceImaging[24]	
48-67	9734-9742	Magnetom	http://maven.renci.org/NeuroBridge/neurobridge#MagneticResonanceImaging[24]	
48-68	9743-9747	Trio	http://maven.renci.org/NeuroBridge/neurobridge#MagneticResonanceImaging[24]	
48-69	9748-9749	3	http://maven.renci.org/NeuroBridge/neurobridge#MagneticResonanceImaging[24]	
48-70	9749-9750	-	http://maven.renci.org/NeuroBridge/neurobridge#MagneticResonanceImaging[24]	
48-71	9750-9751	T	http://maven.renci.org/NeuroBridge/neurobridge#MagneticResonanceImaging[24]	
48-72	9752-9755	MRI	http://maven.renci.org/NeuroBridge/neurobridge#MagneticResonanceImaging[24]	
48-73	9756-9763	scanner	http://maven.renci.org/NeuroBridge/neurobridge#MagneticResonanceImaging[24]	
48-74	9764-9767	and	_	
48-75	9768-9770	32	_	
48-76	9770-9771	-	_	
48-77	9771-9778	channel	_	
48-78	9779-9783	head	_	
48-79	9784-9788	coil	_	
48-80	9788-9789	.	_	

#Text=We used a version of the BART (see Fig. 1), previously validated in neuroimaging studies of healthy individuals, substance users, and at-risk youth, developed from the original implementation of the BART for fMRI and utilizing a similar analytic approach.
49-1	9790-9792	We	_	
49-2	9793-9797	used	_	
49-3	9798-9799	a	_	
49-4	9800-9807	version	_	
49-5	9808-9810	of	_	
49-6	9811-9814	the	_	
49-7	9815-9819	BART	http://maven.renci.org/NeuroBridge/neurobridge#BalloonAnalogueRiskTask	
49-8	9820-9821	(	_	
49-9	9821-9824	see	_	
49-10	9825-9828	Fig	_	
49-11	9828-9829	.	_	
49-12	9830-9831	1	_	
49-13	9831-9832	)	_	
49-14	9832-9833	,	_	
49-15	9834-9844	previously	_	
49-16	9845-9854	validated	_	
49-17	9855-9857	in	_	
49-18	9858-9870	neuroimaging	_	
49-19	9871-9878	studies	_	
49-20	9879-9881	of	_	
49-21	9882-9889	healthy	http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder[25]	
49-22	9890-9901	individuals	http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder[25]	
49-23	9901-9902	,	_	
49-24	9903-9912	substance	http://maven.renci.org/NeuroBridge/neurobridge#SubstanceDisorder[26]	
49-25	9913-9918	users	http://maven.renci.org/NeuroBridge/neurobridge#SubstanceDisorder[26]	
49-26	9918-9919	,	_	
49-27	9920-9923	and	_	
49-28	9924-9931	at-risk	_	
49-29	9932-9937	youth	_	
49-30	9937-9938	,	_	
49-31	9939-9948	developed	_	
49-32	9949-9953	from	_	
49-33	9954-9957	the	_	
49-34	9958-9966	original	_	
49-35	9967-9981	implementation	_	
49-36	9982-9984	of	_	
49-37	9985-9988	the	_	
49-38	9989-9993	BART	http://maven.renci.org/NeuroBridge/neurobridge#BalloonAnalogueRiskTask	
49-39	9994-9997	for	_	
49-40	9998-10002	fMRI	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalMagneticResonanceImaging	
49-41	10003-10006	and	_	
49-42	10007-10016	utilizing	_	
49-43	10017-10018	a	_	
49-44	10019-10026	similar	_	
49-45	10027-10035	analytic	_	
49-46	10036-10044	approach	_	
49-47	10044-10045	.	_	

#Text=Acquisition parameters were identical to those used in and are reported in Supplementary materials.
50-1	10046-10057	Acquisition	_	
50-2	10058-10068	parameters	_	
50-3	10069-10073	were	_	
50-4	10074-10083	identical	_	
50-5	10084-10086	to	_	
50-6	10087-10092	those	_	
50-7	10093-10097	used	_	
50-8	10098-10100	in	_	
50-9	10101-10104	and	_	
50-10	10105-10108	are	_	
50-11	10109-10117	reported	_	
50-12	10118-10120	in	_	
50-13	10121-10134	Supplementary	_	
50-14	10135-10144	materials	_	
50-15	10144-10145	.	_	

#Text=Stimuli were presented using E-Prime (Psychology Software Tools, Pittsburgh, PA) and a projector to display images within the scanner bore.
51-1	10146-10153	Stimuli	_	
51-2	10154-10158	were	_	
51-3	10159-10168	presented	_	
51-4	10169-10174	using	_	
51-5	10175-10182	E-Prime	_	
51-6	10183-10184	(	_	
51-7	10184-10194	Psychology	_	
51-8	10195-10203	Software	_	
51-9	10204-10209	Tools	_	
51-10	10209-10210	,	_	
51-11	10211-10221	Pittsburgh	_	
51-12	10221-10222	,	_	
51-13	10223-10225	PA	_	
51-14	10225-10226	)	_	
51-15	10227-10230	and	_	
51-16	10231-10232	a	_	
51-17	10233-10242	projector	_	
51-18	10243-10245	to	_	
51-19	10246-10253	display	_	
51-20	10254-10260	images	_	
51-21	10261-10267	within	_	
51-22	10268-10271	the	_	
51-23	10272-10279	scanner	_	
51-24	10280-10284	bore	_	
51-25	10284-10285	.	_	

#Text=Each inflation sequence began with a small balloon, valued at $0.00, in the center of the screen.
52-1	10286-10290	Each	_	
52-2	10291-10300	inflation	_	
52-3	10301-10309	sequence	_	
52-4	10310-10315	began	_	
52-5	10316-10320	with	_	
52-6	10321-10322	a	_	
52-7	10323-10328	small	_	
52-8	10329-10336	balloon	_	
52-9	10336-10337	,	_	
52-10	10338-10344	valued	_	
52-11	10345-10347	at	_	
52-12	10348-10353	$0.00	_	
52-13	10353-10354	,	_	
52-14	10355-10357	in	_	
52-15	10358-10361	the	_	
52-16	10362-10368	center	_	
52-17	10369-10371	of	_	
52-18	10372-10375	the	_	
52-19	10376-10382	screen	_	
52-20	10382-10383	.	_	

#Text=Participants could 'Inflate' the balloon, increasing its value in the next trial, or 'Redeem' the balloon for its current value by responding with left and right index fingers (assignment counterbalanced across participants).
53-1	10384-10396	Participants	_	
53-2	10397-10402	could	_	
53-3	10403-10404	'	_	
53-4	10404-10411	Inflate	_	
53-5	10411-10412	'	_	
53-6	10413-10416	the	_	
53-7	10417-10424	balloon	_	
53-8	10424-10425	,	_	
53-9	10426-10436	increasing	_	
53-10	10437-10440	its	_	
53-11	10441-10446	value	_	
53-12	10447-10449	in	_	
53-13	10450-10453	the	_	
53-14	10454-10458	next	_	
53-15	10459-10464	trial	_	
53-16	10464-10465	,	_	
53-17	10466-10468	or	_	
53-18	10469-10470	'	_	
53-19	10470-10476	Redeem	_	
53-20	10476-10477	'	_	
53-21	10478-10481	the	_	
53-22	10482-10489	balloon	_	
53-23	10490-10493	for	_	
53-24	10494-10497	its	_	
53-25	10498-10505	current	_	
53-26	10506-10511	value	_	
53-27	10512-10514	by	_	
53-28	10515-10525	responding	_	
53-29	10526-10530	with	_	
53-30	10531-10535	left	_	
53-31	10536-10539	and	_	
53-32	10540-10545	right	_	
53-33	10546-10551	index	_	
53-34	10552-10559	fingers	_	
53-35	10560-10561	(	_	
53-36	10561-10571	assignment	_	
53-37	10572-10587	counterbalanced	_	
53-38	10588-10594	across	_	
53-39	10595-10607	participants	_	
53-40	10607-10608	)	_	
53-41	10608-10609	.	_	

#Text=Each decision was preceded by a red rectangle, presented below the balloon for a pseudo-randomly-determined delay of 1.5, 2, or 2.5 s, signaling participants to withhold responses.
54-1	10610-10614	Each	_	
54-2	10615-10623	decision	_	
54-3	10624-10627	was	_	
54-4	10628-10636	preceded	_	
54-5	10637-10639	by	_	
54-6	10640-10641	a	_	
54-7	10642-10645	red	_	
54-8	10646-10655	rectangle	_	
54-9	10655-10656	,	_	
54-10	10657-10666	presented	_	
54-11	10667-10672	below	_	
54-12	10673-10676	the	_	
54-13	10677-10684	balloon	_	
54-14	10685-10688	for	_	
54-15	10689-10690	a	_	
54-16	10691-10717	pseudo-randomly-determined	_	
54-17	10718-10723	delay	_	
54-18	10724-10726	of	_	
54-19	10727-10730	1.5	_	
54-20	10730-10731	,	_	
54-21	10732-10733	2	_	
54-22	10733-10734	,	_	
54-23	10735-10737	or	_	
54-24	10738-10741	2.5	_	
54-25	10742-10743	s	_	
54-26	10743-10744	,	_	
54-27	10745-10754	signaling	_	
54-28	10755-10767	participants	_	
54-29	10768-10770	to	_	
54-30	10771-10779	withhold	_	
54-31	10780-10789	responses	_	
54-32	10789-10790	.	_	

#Text=The rectangle then turned green, indicating participants could respond when ready.
55-1	10791-10794	The	_	
55-2	10795-10804	rectangle	_	
55-3	10805-10809	then	_	
55-4	10810-10816	turned	_	
55-5	10817-10822	green	_	
55-6	10822-10823	,	_	
55-7	10824-10834	indicating	_	
55-8	10835-10847	participants	_	
55-9	10848-10853	could	_	
55-10	10854-10861	respond	_	
55-11	10862-10866	when	_	
55-12	10867-10872	ready	_	
55-13	10872-10873	.	_	

#Text=Following response production, a jittered delay of 0–6 s preceded feedback such that decision and outcome intervals could be estimated separately in the general linear model (GLM).
56-1	10874-10883	Following	_	
56-2	10884-10892	response	_	
56-3	10893-10903	production	_	
56-4	10903-10904	,	_	
56-5	10905-10906	a	_	
56-6	10907-10915	jittered	_	
56-7	10916-10921	delay	_	
56-8	10922-10924	of	_	
56-9	10925-10926	0	_	
56-10	10926-10927	–	_	
56-11	10927-10928	6	_	
56-12	10929-10930	s	_	
56-13	10931-10939	preceded	_	
56-14	10940-10948	feedback	_	
56-15	10949-10953	such	_	
56-16	10954-10958	that	_	
56-17	10959-10967	decision	_	
56-18	10968-10971	and	_	
56-19	10972-10979	outcome	_	
56-20	10980-10989	intervals	_	
56-21	10990-10995	could	_	
56-22	10996-10998	be	_	
56-23	10999-11008	estimated	_	
56-24	11009-11019	separately	_	
56-25	11020-11022	in	_	
56-26	11023-11026	the	_	
56-27	11027-11034	general	_	
56-28	11035-11041	linear	_	
56-29	11042-11047	model	_	
56-30	11048-11049	(	_	
56-31	11049-11052	GLM	_	
56-32	11052-11053	)	_	
56-33	11053-11054	.	_	

#Text=After 'Redeem' responses, the words, “You Win!”
57-1	11055-11060	After	_	
57-2	11061-11062	'	_	
57-3	11062-11068	Redeem	_	
57-4	11068-11069	'	_	
57-5	11070-11079	responses	_	
57-6	11079-11080	,	_	
57-7	11081-11084	the	_	
57-8	11085-11090	words	_	
57-9	11090-11091	,	_	
57-10	11092-11093	“	_	
57-11	11093-11096	You	_	
57-12	11097-11100	Win	_	
57-13	11100-11101	!	_	
57-14	11101-11102	”	_	

#Text=were presented for 1 s ('Win') and the wager value was added to block winnings (visible at bottom of screen).
58-1	11103-11107	were	_	
58-2	11108-11117	presented	_	
58-3	11118-11121	for	_	
58-4	11122-11123	1	_	
58-5	11124-11125	s	_	
58-6	11126-11127	(	_	
58-7	11127-11128	'	_	
58-8	11128-11131	Win	_	
58-9	11131-11132	'	_	
58-10	11132-11133	)	_	
58-11	11134-11137	and	_	
58-12	11138-11141	the	_	
58-13	11142-11147	wager	_	
58-14	11148-11153	value	_	
58-15	11154-11157	was	_	
58-16	11158-11163	added	_	
58-17	11164-11166	to	_	
58-18	11167-11172	block	_	
58-19	11173-11181	winnings	_	
58-20	11182-11183	(	_	
58-21	11183-11190	visible	_	
58-22	11191-11193	at	_	
58-23	11194-11200	bottom	_	
58-24	11201-11203	of	_	
58-25	11204-11210	screen	_	
58-26	11210-11211	)	_	
58-27	11211-11212	.	_	

#Text=After 'Inflate' responses, 'Success' was signaled by an increased wager value and balloon size, cueing the start of the next decision trial.
59-1	11213-11218	After	_	
59-2	11219-11220	'	_	
59-3	11220-11227	Inflate	_	
59-4	11227-11228	'	_	
59-5	11229-11238	responses	_	
59-6	11238-11239	,	_	
59-7	11240-11241	'	_	
59-8	11241-11248	Success	_	
59-9	11248-11249	'	_	
59-10	11250-11253	was	_	
59-11	11254-11262	signaled	_	
59-12	11263-11265	by	_	
59-13	11266-11268	an	_	
59-14	11269-11278	increased	_	
59-15	11279-11284	wager	_	
59-16	11285-11290	value	_	
59-17	11291-11294	and	_	
59-18	11295-11302	balloon	_	
59-19	11303-11307	size	_	
59-20	11307-11308	,	_	
59-21	11309-11315	cueing	_	
59-22	11316-11319	the	_	
59-23	11320-11325	start	_	
59-24	11326-11328	of	_	
59-25	11329-11332	the	_	
59-26	11333-11337	next	_	
59-27	11338-11346	decision	_	
59-28	11347-11352	trial	_	
59-29	11352-11353	.	_	

#Text=Alternatively, an 'Explode' outcome (resulting in loss of the current wager) was signaled by presentation of an exploding balloon for 500 ms and the words, “You Lose!”
60-1	11354-11367	Alternatively	_	
60-2	11367-11368	,	_	
60-3	11369-11371	an	_	
60-4	11372-11373	'	_	
60-5	11373-11380	Explode	_	
60-6	11380-11381	'	_	
60-7	11382-11389	outcome	_	
60-8	11390-11391	(	_	
60-9	11391-11400	resulting	_	
60-10	11401-11403	in	_	
60-11	11404-11408	loss	_	
60-12	11409-11411	of	_	
60-13	11412-11415	the	_	
60-14	11416-11423	current	_	
60-15	11424-11429	wager	_	
60-16	11429-11430	)	_	
60-17	11431-11434	was	_	
60-18	11435-11443	signaled	_	
60-19	11444-11446	by	_	
60-20	11447-11459	presentation	_	
60-21	11460-11462	of	_	
60-22	11463-11465	an	_	
60-23	11466-11475	exploding	_	
60-24	11476-11483	balloon	_	
60-25	11484-11487	for	_	
60-26	11488-11491	500	_	
60-27	11492-11494	ms	_	
60-28	11495-11498	and	_	
60-29	11499-11502	the	_	
60-30	11503-11508	words	_	
60-31	11508-11509	,	_	
60-32	11510-11511	“	_	
60-33	11511-11514	You	_	
60-34	11515-11519	Lose	_	
60-35	11519-11520	!	_	
60-36	11520-11521	”	_	

#Text=for 1 s.
61-1	11522-11525	for	_	
61-2	11526-11527	1	_	
61-3	11528-11529	s	_	
61-4	11529-11530	.	_	

#Text=An equiprobable delay of 2, 4, or 6 s preceded new inflation sequences, signaled by presentation of a new $0.00 balloon after 'Win' and 'Explode' events.
62-1	11531-11533	An	_	
62-2	11534-11546	equiprobable	_	
62-3	11547-11552	delay	_	
62-4	11553-11555	of	_	
62-5	11556-11557	2	_	
62-6	11557-11558	,	_	
62-7	11559-11560	4	_	
62-8	11560-11561	,	_	
62-9	11562-11564	or	_	
62-10	11565-11566	6	_	
62-11	11567-11568	s	_	
62-12	11569-11577	preceded	_	
62-13	11578-11581	new	_	
62-14	11582-11591	inflation	_	
62-15	11592-11601	sequences	_	
62-16	11601-11602	,	_	
62-17	11603-11611	signaled	_	
62-18	11612-11614	by	_	
62-19	11615-11627	presentation	_	
62-20	11628-11630	of	_	
62-21	11631-11632	a	_	
62-22	11633-11636	new	_	
62-23	11637-11642	$0.00	_	
62-24	11643-11650	balloon	_	
62-25	11651-11656	after	_	
62-26	11657-11658	'	_	
62-27	11658-11661	Win	_	
62-28	11661-11662	'	_	
62-29	11663-11666	and	_	
62-30	11667-11668	'	_	
62-31	11668-11675	Explode	_	
62-32	11675-11676	'	_	
62-33	11677-11683	events	_	
62-34	11683-11684	.	_	

#Text=Explosion probability and reward increased in parallel with each inflation, in accordance with values specified in Table 2.
63-1	11685-11694	Explosion	_	
63-2	11695-11706	probability	_	
63-3	11707-11710	and	_	
63-4	11711-11717	reward	_	
63-5	11718-11727	increased	_	
63-6	11728-11730	in	_	
63-7	11731-11739	parallel	_	
63-8	11740-11744	with	_	
63-9	11745-11749	each	_	
63-10	11750-11759	inflation	_	
63-11	11759-11760	,	_	
63-12	11761-11763	in	_	
63-13	11764-11774	accordance	_	
63-14	11775-11779	with	_	
63-15	11780-11786	values	_	
63-16	11787-11796	specified	_	
63-17	11797-11799	in	_	
63-18	11800-11805	Table	_	
63-19	11806-11807	2	_	
63-20	11807-11808	.	_	

#Text=Participants were informed that both wager value and explosion probability increased with consecutive inflations; the rate of increase was not described.
64-1	11809-11821	Participants	_	
64-2	11822-11826	were	_	
64-3	11827-11835	informed	_	
64-4	11836-11840	that	_	
64-5	11841-11845	both	_	
64-6	11846-11851	wager	_	
64-7	11852-11857	value	_	
64-8	11858-11861	and	_	
64-9	11862-11871	explosion	_	
64-10	11872-11883	probability	_	
64-11	11884-11893	increased	_	
64-12	11894-11898	with	_	
64-13	11899-11910	consecutive	_	
64-14	11911-11921	inflations	_	
64-15	11921-11922	;	_	
64-16	11923-11926	the	_	
64-17	11927-11931	rate	_	
64-18	11932-11934	of	_	
64-19	11935-11943	increase	_	
64-20	11944-11947	was	_	
64-21	11948-11951	not	_	
64-22	11952-11961	described	_	
64-23	11961-11962	.	_	

#Text=Participants completed two 8-min blocks per timepoint, each with an average of 17 inflation sequences (SD = 2) and 96 decisions (SD = 9) per block; participants were unaware that the number of balloons per block was unlimited.
65-1	11963-11975	Participants	_	
65-2	11976-11985	completed	_	
65-3	11986-11989	two	_	
65-4	11990-11991	8	_	
65-5	11991-11992	-	_	
65-6	11992-11995	min	_	
65-7	11996-12002	blocks	_	
65-8	12003-12006	per	_	
65-9	12007-12016	timepoint	_	
65-10	12016-12017	,	_	
65-11	12018-12022	each	_	
65-12	12023-12027	with	_	
65-13	12028-12030	an	_	
65-14	12031-12038	average	_	
65-15	12039-12041	of	_	
65-16	12042-12044	17	_	
65-17	12045-12054	inflation	_	
65-18	12055-12064	sequences	_	
65-19	12065-12066	(	_	
65-20	12066-12068	SD	_	
65-21	12069-12070	=	_	
65-22	12071-12072	2	_	
65-23	12072-12073	)	_	
65-24	12074-12077	and	_	
65-25	12078-12080	96	_	
65-26	12081-12090	decisions	_	
65-27	12091-12092	(	_	
65-28	12092-12094	SD	_	
65-29	12095-12096	=	_	
65-30	12097-12098	9	_	
65-31	12098-12099	)	_	
65-32	12100-12103	per	_	
65-33	12104-12109	block	_	
65-34	12109-12110	;	_	
65-35	12111-12123	participants	_	
65-36	12124-12128	were	_	
65-37	12129-12136	unaware	_	
65-38	12137-12141	that	_	
65-39	12142-12145	the	_	
65-40	12146-12152	number	_	
65-41	12153-12155	of	_	
65-42	12156-12164	balloons	_	
65-43	12165-12168	per	_	
65-44	12169-12174	block	_	
65-45	12175-12178	was	_	
65-46	12179-12188	unlimited	_	
65-47	12188-12189	.	_	

#Text=Winnings were reset at the beginning of each block; participants received a monetary bonus equal to 25% of total earnings at each timepoint.
66-1	12190-12198	Winnings	_	
66-2	12199-12203	were	_	
66-3	12204-12209	reset	_	
66-4	12210-12212	at	_	
66-5	12213-12216	the	_	
66-6	12217-12226	beginning	_	
66-7	12227-12229	of	_	
66-8	12230-12234	each	_	
66-9	12235-12240	block	_	
66-10	12240-12241	;	_	
66-11	12242-12254	participants	_	
66-12	12255-12263	received	_	
66-13	12264-12265	a	_	
66-14	12266-12274	monetary	_	
66-15	12275-12280	bonus	_	
66-16	12281-12286	equal	_	
66-17	12287-12289	to	_	
66-18	12290-12293	25%	_	
66-19	12294-12296	of	_	
66-20	12297-12302	total	_	
66-21	12303-12311	earnings	_	
66-22	12312-12314	at	_	
66-23	12315-12319	each	_	
66-24	12320-12329	timepoint	_	
66-25	12329-12330	.	_	

#Text=While it was possible for participants to produce a different number of events for entry into the first-level GLM at each timepoint, participants generated a similar number of events of each type (see Supplementary Table 2).
#Text=2.3.
67-1	12331-12336	While	_	
67-2	12337-12339	it	_	
67-3	12340-12343	was	_	
67-4	12344-12352	possible	_	
67-5	12353-12356	for	_	
67-6	12357-12369	participants	_	
67-7	12370-12372	to	_	
67-8	12373-12380	produce	_	
67-9	12381-12382	a	_	
67-10	12383-12392	different	_	
67-11	12393-12399	number	_	
67-12	12400-12402	of	_	
67-13	12403-12409	events	_	
67-14	12410-12413	for	_	
67-15	12414-12419	entry	_	
67-16	12420-12424	into	_	
67-17	12425-12428	the	_	
67-18	12429-12440	first-level	_	
67-19	12441-12444	GLM	_	
67-20	12445-12447	at	_	
67-21	12448-12452	each	_	
67-22	12453-12462	timepoint	_	
67-23	12462-12463	,	_	
67-24	12464-12476	participants	_	
67-25	12477-12486	generated	_	
67-26	12487-12488	a	_	
67-27	12489-12496	similar	_	
67-28	12497-12503	number	_	
67-29	12504-12506	of	_	
67-30	12507-12513	events	_	
67-31	12514-12516	of	_	
67-32	12517-12521	each	_	
67-33	12522-12526	type	_	
67-34	12527-12528	(	_	
67-35	12528-12531	see	_	
67-36	12532-12545	Supplementary	_	
67-37	12546-12551	Table	_	
67-38	12552-12553	2	_	
67-39	12553-12554	)	_	
67-40	12554-12555	.	_	
67-41	12556-12559	2.3	_	
67-42	12559-12560	.	_	

#Text=Preprocessing and analysis of neuroimaging data
#Text=Preprocessing steps were identical to those reported by and are described in Supplementary materials.
68-1	12561-12574	Preprocessing	_	
68-2	12575-12578	and	_	
68-3	12579-12587	analysis	_	
68-4	12588-12590	of	_	
68-5	12591-12603	neuroimaging	_	
68-6	12604-12608	data	_	
68-7	12609-12622	Preprocessing	_	
68-8	12623-12628	steps	_	
68-9	12629-12633	were	_	
68-10	12634-12643	identical	_	
68-11	12644-12646	to	_	
68-12	12647-12652	those	_	
68-13	12653-12661	reported	_	
68-14	12662-12664	by	_	
68-15	12665-12668	and	_	
68-16	12669-12672	are	_	
68-17	12673-12682	described	_	
68-18	12683-12685	in	_	
68-19	12686-12699	Supplementary	_	
68-20	12700-12709	materials	_	
68-21	12709-12710	.	_	

#Text=Functional images from both timepoints were coregistered to the high resolution structural from baseline.
69-1	12711-12721	Functional	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalImagingProtocol[27]	
69-2	12722-12728	images	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalImagingProtocol[27]	
69-3	12729-12733	from	_	
69-4	12734-12738	both	_	
69-5	12739-12749	timepoints	_	
69-6	12750-12754	were	_	
69-7	12755-12767	coregistered	_	
69-8	12768-12770	to	_	
69-9	12771-12774	the	_	
69-10	12775-12779	high	_	
69-11	12780-12790	resolution	_	
69-12	12791-12801	structural	_	
69-13	12802-12806	from	_	
69-14	12807-12815	baseline	_	
69-15	12815-12816	.	_	

#Text=First- and second-level statistical analyses were conducted in SPM5.
70-1	12817-12822	First	_	
70-2	12822-12823	-	_	
70-3	12824-12827	and	_	
70-4	12828-12840	second-level	_	
70-5	12841-12852	statistical	_	
70-6	12853-12861	analyses	_	
70-7	12862-12866	were	_	
70-8	12867-12876	conducted	_	
70-9	12877-12879	in	_	
70-10	12880-12884	SPM5	_	
70-11	12884-12885	.	_	

#Text=Event-related BOLD responses during the BART were estimated using a GLM with a global constant and 20 regressors for each timepoint (baseline vs. follow-up): six motion regressors, two constant terms, five basic (i.e., main effect) event regressors (i.e., 'Redeem', 'Inflate', 'Explode', 'Success', and 'Win'), five parametric modulators representing explosion probability for each event, and 2 parametric modulators representing response time (RT) for 'Redeem' and 'Inflate' events.
71-1	12886-12899	Event-related	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImagingProtocol[28]	
71-2	12900-12904	BOLD	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImagingProtocol[28]	
71-3	12905-12914	responses	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImagingProtocol[28]	
71-4	12915-12921	during	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImagingProtocol[28]	
71-5	12922-12925	the	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImagingProtocol[28]	
71-6	12926-12930	BART	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImagingProtocol[28]|http://maven.renci.org/NeuroBridge/neurobridge#BalloonAnalogueRiskTask[29]	
71-7	12931-12935	were	_	
71-8	12936-12945	estimated	_	
71-9	12946-12951	using	_	
71-10	12952-12953	a	_	
71-11	12954-12957	GLM	_	
71-12	12958-12962	with	_	
71-13	12963-12964	a	_	
71-14	12965-12971	global	_	
71-15	12972-12980	constant	_	
71-16	12981-12984	and	_	
71-17	12985-12987	20	_	
71-18	12988-12998	regressors	_	
71-19	12999-13002	for	_	
71-20	13003-13007	each	_	
71-21	13008-13017	timepoint	_	
71-22	13018-13019	(	_	
71-23	13019-13027	baseline	_	
71-24	13028-13030	vs	_	
71-25	13030-13031	.	_	
71-26	13032-13041	follow-up	_	
71-27	13041-13042	)	_	
71-28	13042-13043	:	_	
71-29	13044-13047	six	_	
71-30	13048-13054	motion	_	
71-31	13055-13065	regressors	_	
71-32	13065-13066	,	_	
71-33	13067-13070	two	_	
71-34	13071-13079	constant	_	
71-35	13080-13085	terms	_	
71-36	13085-13086	,	_	
71-37	13087-13091	five	_	
71-38	13092-13097	basic	_	
71-39	13098-13099	(	_	
71-40	13099-13102	i.e	_	
71-41	13102-13103	.	_	
71-42	13103-13104	,	_	
71-43	13105-13109	main	_	
71-44	13110-13116	effect	_	
71-45	13116-13117	)	_	
71-46	13118-13123	event	_	
71-47	13124-13134	regressors	_	
71-48	13135-13136	(	_	
71-49	13136-13139	i.e	_	
71-50	13139-13140	.	_	
71-51	13140-13141	,	_	
71-52	13142-13143	'	_	
71-53	13143-13149	Redeem	_	
71-54	13149-13150	'	_	
71-55	13150-13151	,	_	
71-56	13152-13153	'	_	
71-57	13153-13160	Inflate	_	
71-58	13160-13161	'	_	
71-59	13161-13162	,	_	
71-60	13163-13164	'	_	
71-61	13164-13171	Explode	_	
71-62	13171-13172	'	_	
71-63	13172-13173	,	_	
71-64	13174-13175	'	_	
71-65	13175-13182	Success	_	
71-66	13182-13183	'	_	
71-67	13183-13184	,	_	
71-68	13185-13188	and	_	
71-69	13189-13190	'	_	
71-70	13190-13193	Win	_	
71-71	13193-13194	'	_	
71-72	13194-13195	)	_	
71-73	13195-13196	,	_	
71-74	13197-13201	five	_	
71-75	13202-13212	parametric	_	
71-76	13213-13223	modulators	_	
71-77	13224-13236	representing	_	
71-78	13237-13246	explosion	_	
71-79	13247-13258	probability	_	
71-80	13259-13262	for	_	
71-81	13263-13267	each	_	
71-82	13268-13273	event	_	
71-83	13273-13274	,	_	
71-84	13275-13278	and	_	
71-85	13279-13280	2	_	
71-86	13281-13291	parametric	_	
71-87	13292-13302	modulators	_	
71-88	13303-13315	representing	_	
71-89	13316-13324	response	_	
71-90	13325-13329	time	_	
71-91	13330-13331	(	_	
71-92	13331-13333	RT	_	
71-93	13333-13334	)	_	
71-94	13335-13338	for	_	
71-95	13339-13340	'	_	
71-96	13340-13346	Redeem	_	
71-97	13346-13347	'	_	
71-98	13348-13351	and	_	
71-99	13352-13353	'	_	
71-100	13353-13360	Inflate	_	
71-101	13360-13361	'	_	
71-102	13362-13368	events	_	
71-103	13368-13369	.	_	

#Text=A canonical hemodynamic response function was used to model BOLD response, with decision-related regressors time-locked to RT and outcome-related regressors time-locked to feedback latency.
72-1	13370-13371	A	_	
72-2	13372-13381	canonical	_	
72-3	13382-13393	hemodynamic	_	
72-4	13394-13402	response	_	
72-5	13403-13411	function	_	
72-6	13412-13415	was	_	
72-7	13416-13420	used	_	
72-8	13421-13423	to	_	
72-9	13424-13429	model	_	
72-10	13430-13434	BOLD	_	
72-11	13435-13443	response	_	
72-12	13443-13444	,	_	
72-13	13445-13449	with	_	
72-14	13450-13466	decision-related	_	
72-15	13467-13477	regressors	_	
72-16	13478-13489	time-locked	_	
72-17	13490-13492	to	_	
72-18	13493-13495	RT	_	
72-19	13496-13499	and	_	
72-20	13500-13515	outcome-related	_	
72-21	13516-13526	regressors	_	
72-22	13527-13538	time-locked	_	
72-23	13539-13541	to	_	
72-24	13542-13550	feedback	_	
72-25	13551-13558	latency	_	
72-26	13558-13559	.	_	

#Text=Due to the relationship between risk and reward in the task, parametric modulators specified with reference to explosion probability also tracked trial-to-trial variation in reward magnitude.
73-1	13560-13563	Due	_	
73-2	13564-13566	to	_	
73-3	13567-13570	the	_	
73-4	13571-13583	relationship	_	
73-5	13584-13591	between	_	
73-6	13592-13596	risk	_	
73-7	13597-13600	and	_	
73-8	13601-13607	reward	_	
73-9	13608-13610	in	_	
73-10	13611-13614	the	_	
73-11	13615-13619	task	_	
73-12	13619-13620	,	_	
73-13	13621-13631	parametric	_	
73-14	13632-13642	modulators	_	
73-15	13643-13652	specified	_	
73-16	13653-13657	with	_	
73-17	13658-13667	reference	_	
73-18	13668-13670	to	_	
73-19	13671-13680	explosion	_	
73-20	13681-13692	probability	_	
73-21	13693-13697	also	_	
73-22	13698-13705	tracked	_	
73-23	13706-13720	trial-to-trial	_	
73-24	13721-13730	variation	_	
73-25	13731-13733	in	_	
73-26	13734-13740	reward	_	
73-27	13741-13750	magnitude	_	
73-28	13750-13751	.	_	

#Text=These parametrically-modulated regressors were identical to the five basic event regressors, except that the magnitude of each modeled event was multiplied by that event's explosion probability.
74-1	13752-13757	These	_	
74-2	13758-13782	parametrically-modulated	_	
74-3	13783-13793	regressors	_	
74-4	13794-13798	were	_	
74-5	13799-13808	identical	_	
74-6	13809-13811	to	_	
74-7	13812-13815	the	_	
74-8	13816-13820	five	_	
74-9	13821-13826	basic	_	
74-10	13827-13832	event	_	
74-11	13833-13843	regressors	_	
74-12	13843-13844	,	_	
74-13	13845-13851	except	_	
74-14	13852-13856	that	_	
74-15	13857-13860	the	_	
74-16	13861-13870	magnitude	_	
74-17	13871-13873	of	_	
74-18	13874-13878	each	_	
74-19	13879-13886	modeled	_	
74-20	13887-13892	event	_	
74-21	13893-13896	was	_	
74-22	13897-13907	multiplied	_	
74-23	13908-13910	by	_	
74-24	13911-13915	that	_	
74-25	13916-13923	event's	_	
74-26	13924-13933	explosion	_	
74-27	13934-13945	probability	_	
74-28	13945-13946	.	_	

#Text=Each parametrically-modulated regressor was mean-centered, so that the sum of regressor values across all time points was zero.
75-1	13947-13951	Each	_	
75-2	13952-13976	parametrically-modulated	_	
75-3	13977-13986	regressor	_	
75-4	13987-13990	was	_	
75-5	13991-14004	mean-centered	_	
75-6	14004-14005	,	_	
75-7	14006-14008	so	_	
75-8	14009-14013	that	_	
75-9	14014-14017	the	_	
75-10	14018-14021	sum	_	
75-11	14022-14024	of	_	
75-12	14025-14034	regressor	_	
75-13	14035-14041	values	_	
75-14	14042-14048	across	_	
75-15	14049-14052	all	_	
75-16	14053-14057	time	_	
75-17	14058-14064	points	_	
75-18	14065-14068	was	_	
75-19	14069-14073	zero	_	
75-20	14073-14074	.	_	

#Text=For three participants, a lower occurrence of explosions precluded unique estimation of basic event regressors and parametric modulators for 'Explode' events; this was additionally the case for one participant for 'Win' events.
76-1	14075-14078	For	_	
76-2	14079-14084	three	_	
76-3	14085-14097	participants	_	
76-4	14097-14098	,	_	
76-5	14099-14100	a	_	
76-6	14101-14106	lower	_	
76-7	14107-14117	occurrence	_	
76-8	14118-14120	of	_	
76-9	14121-14131	explosions	_	
76-10	14132-14141	precluded	_	
76-11	14142-14148	unique	_	
76-12	14149-14159	estimation	_	
76-13	14160-14162	of	_	
76-14	14163-14168	basic	_	
76-15	14169-14174	event	_	
76-16	14175-14185	regressors	_	
76-17	14186-14189	and	_	
76-18	14190-14200	parametric	_	
76-19	14201-14211	modulators	_	
76-20	14212-14215	for	_	
76-21	14216-14217	'	_	
76-22	14217-14224	Explode	_	
76-23	14224-14225	'	_	
76-24	14226-14232	events	_	
76-25	14232-14233	;	_	
76-26	14234-14238	this	_	
76-27	14239-14242	was	_	
76-28	14243-14255	additionally	_	
76-29	14256-14259	the	_	
76-30	14260-14264	case	_	
76-31	14265-14268	for	_	
76-32	14269-14272	one	_	
76-33	14273-14284	participant	_	
76-34	14285-14288	for	_	
76-35	14289-14290	'	_	
76-36	14290-14293	Win	_	
76-37	14293-14294	'	_	
76-38	14295-14301	events	_	
76-39	14301-14302	.	_	

#Text=These participants were accordingly excluded from parametric modulator contrasts of each corresponding type.
77-1	14303-14308	These	_	
77-2	14309-14321	participants	_	
77-3	14322-14326	were	_	
77-4	14327-14338	accordingly	_	
77-5	14339-14347	excluded	_	
77-6	14348-14352	from	_	
77-7	14353-14363	parametric	_	
77-8	14364-14373	modulator	_	
77-9	14374-14383	contrasts	_	
77-10	14384-14386	of	_	
77-11	14387-14391	each	_	
77-12	14392-14405	corresponding	_	
77-13	14406-14410	type	_	
77-14	14410-14411	.	_	

#Text=Given our hypotheses, only the five parametric modulators representing explosion probability (designated by '*p(Explode)') were considered in second-level analyses.
78-1	14412-14417	Given	_	
78-2	14418-14421	our	_	
78-3	14422-14432	hypotheses	_	
78-4	14432-14433	,	_	
78-5	14434-14438	only	_	
78-6	14439-14442	the	_	
78-7	14443-14447	five	_	
78-8	14448-14458	parametric	_	
78-9	14459-14469	modulators	_	
78-10	14470-14482	representing	_	
78-11	14483-14492	explosion	_	
78-12	14493-14504	probability	_	
78-13	14505-14506	(	_	
78-14	14506-14516	designated	_	
78-15	14517-14519	by	_	
78-16	14520-14521	'	_	
78-17	14521-14522	*	_	
78-18	14522-14523	p	_	
78-19	14523-14524	(	_	
78-20	14524-14531	Explode	_	
78-21	14531-14532	)	_	
78-22	14532-14533	'	_	
78-23	14533-14534	)	_	
78-24	14535-14539	were	_	
78-25	14540-14550	considered	_	
78-26	14551-14553	in	_	
78-27	14554-14566	second-level	_	
78-28	14567-14575	analyses	_	
78-29	14575-14576	.	_	

#Text=We specifically explored longitudinal change in parametric modulators by computing longitudinal contrasts (i.e., 3-month follow-up – baseline, hereafter FU-BL) and evaluating these contrasts using one-sample t-tests to assess main effects and correlation analyses to assess longitudinal change related to substance use outcomes (represented by the SUM).
79-1	14577-14579	We	_	
79-2	14580-14592	specifically	_	
79-3	14593-14601	explored	_	
79-4	14602-14614	longitudinal	_	
79-5	14615-14621	change	_	
79-6	14622-14624	in	_	
79-7	14625-14635	parametric	_	
79-8	14636-14646	modulators	_	
79-9	14647-14649	by	_	
79-10	14650-14659	computing	_	
79-11	14660-14672	longitudinal	_	
79-12	14673-14682	contrasts	_	
79-13	14683-14684	(	_	
79-14	14684-14687	i.e	_	
79-15	14687-14688	.	_	
79-16	14688-14689	,	_	
79-17	14690-14691	3	_	
79-18	14691-14692	-	_	
79-19	14692-14697	month	_	
79-20	14698-14707	follow-up	_	
79-21	14708-14709	–	_	
79-22	14710-14718	baseline	_	
79-23	14718-14719	,	_	
79-24	14720-14729	hereafter	_	
79-25	14730-14735	FU-BL	_	
79-26	14735-14736	)	_	
79-27	14737-14740	and	_	
79-28	14741-14751	evaluating	_	
79-29	14752-14757	these	_	
79-30	14758-14767	contrasts	_	
79-31	14768-14773	using	_	
79-32	14774-14784	one-sample	_	
79-33	14785-14792	t-tests	_	
79-34	14793-14795	to	_	
79-35	14796-14802	assess	_	
79-36	14803-14807	main	_	
79-37	14808-14815	effects	_	
79-38	14816-14819	and	_	
79-39	14820-14831	correlation	_	
79-40	14832-14840	analyses	_	
79-41	14841-14843	to	_	
79-42	14844-14850	assess	_	
79-43	14851-14863	longitudinal	_	
79-44	14864-14870	change	_	
79-45	14871-14878	related	_	
79-46	14879-14881	to	_	
79-47	14882-14891	substance	_	
79-48	14892-14895	use	_	
79-49	14896-14904	outcomes	_	
79-50	14905-14906	(	_	
79-51	14906-14917	represented	_	
79-52	14918-14920	by	_	
79-53	14921-14924	the	_	
79-54	14925-14928	SUM	_	
79-55	14928-14929	)	_	
79-56	14929-14930	.	_	

#Text=Longitudinal contrasts were specified at the first-level and tested at the second-level with random effects to model between-subjects variance.
80-1	14931-14943	Longitudinal	_	
80-2	14944-14953	contrasts	_	
80-3	14954-14958	were	_	
80-4	14959-14968	specified	_	
80-5	14969-14971	at	_	
80-6	14972-14975	the	_	
80-7	14976-14987	first-level	_	
80-8	14988-14991	and	_	
80-9	14992-14998	tested	_	
80-10	14999-15001	at	_	
80-11	15002-15005	the	_	
80-12	15006-15018	second-level	_	
80-13	15019-15023	with	_	
80-14	15024-15030	random	_	
80-15	15031-15038	effects	_	
80-16	15039-15041	to	_	
80-17	15042-15047	model	_	
80-18	15048-15064	between-subjects	_	
80-19	15065-15073	variance	_	
80-20	15073-15074	.	_	

#Text=To exclude effects related to behavior change between sessions, the difference in mean BART inflation number between acquisition sessions (FU-BL) was included as a nuisance covariate at the second-level.
81-1	15075-15077	To	_	
81-2	15078-15085	exclude	_	
81-3	15086-15093	effects	_	
81-4	15094-15101	related	_	
81-5	15102-15104	to	_	
81-6	15105-15113	behavior	_	
81-7	15114-15120	change	_	
81-8	15121-15128	between	_	
81-9	15129-15137	sessions	_	
81-10	15137-15138	,	_	
81-11	15139-15142	the	_	
81-12	15143-15153	difference	_	
81-13	15154-15156	in	_	
81-14	15157-15161	mean	_	
81-15	15162-15166	BART	_	
81-16	15167-15176	inflation	_	
81-17	15177-15183	number	_	
81-18	15184-15191	between	_	
81-19	15192-15203	acquisition	_	
81-20	15204-15212	sessions	_	
81-21	15213-15214	(	_	
81-22	15214-15219	FU-BL	_	
81-23	15219-15220	)	_	
81-24	15221-15224	was	_	
81-25	15225-15233	included	_	
81-26	15234-15236	as	_	
81-27	15237-15238	a	_	
81-28	15239-15247	nuisance	_	
81-29	15248-15257	covariate	_	
81-30	15258-15260	at	_	
81-31	15261-15264	the	_	
81-32	15265-15277	second-level	_	
81-33	15277-15278	.	_	

#Text=Reported p-values for second-level analyses reflect one-tailed tests of significance.
82-1	15279-15287	Reported	_	
82-2	15288-15296	p-values	_	
82-3	15297-15300	for	_	
82-4	15301-15313	second-level	_	
82-5	15314-15322	analyses	_	
82-6	15323-15330	reflect	_	
82-7	15331-15341	one-tailed	_	
82-8	15342-15347	tests	_	
82-9	15348-15350	of	_	
82-10	15351-15363	significance	_	
82-11	15363-15364	.	_	

#Text=In order to test predictions from the Inflate*p(Explode) FU-BL contrast was specified to identify regions wherein longitudinal signal increased with escalating risk/reward during decision-making and the Success*p(Explode) FU-BL contrast was specified to identify regions with less signal to high-risk reward over time.
83-1	15365-15367	In	_	
83-2	15368-15373	order	_	
83-3	15374-15376	to	_	
83-4	15377-15381	test	_	
83-5	15382-15393	predictions	_	
83-6	15394-15398	from	_	
83-7	15399-15402	the	_	
83-8	15403-15410	Inflate	_	
83-9	15410-15411	*	_	
83-10	15411-15412	p	_	
83-11	15412-15413	(	_	
83-12	15413-15420	Explode	_	
83-13	15420-15421	)	_	
83-14	15422-15427	FU-BL	_	
83-15	15428-15436	contrast	_	
83-16	15437-15440	was	_	
83-17	15441-15450	specified	_	
83-18	15451-15453	to	_	
83-19	15454-15462	identify	_	
83-20	15463-15470	regions	_	
83-21	15471-15478	wherein	_	
83-22	15479-15491	longitudinal	_	
83-23	15492-15498	signal	_	
83-24	15499-15508	increased	_	
83-25	15509-15513	with	_	
83-26	15514-15524	escalating	_	
83-27	15525-15529	risk	_	
83-28	15529-15530	/	_	
83-29	15530-15536	reward	_	
83-30	15537-15543	during	_	
83-31	15544-15559	decision-making	_	
83-32	15560-15563	and	_	
83-33	15564-15567	the	_	
83-34	15568-15575	Success	_	
83-35	15575-15576	*	_	
83-36	15576-15577	p	_	
83-37	15577-15578	(	_	
83-38	15578-15585	Explode	_	
83-39	15585-15586	)	_	
83-40	15587-15592	FU-BL	_	
83-41	15593-15601	contrast	_	
83-42	15602-15605	was	_	
83-43	15606-15615	specified	_	
83-44	15616-15618	to	_	
83-45	15619-15627	identify	_	
83-46	15628-15635	regions	_	
83-47	15636-15640	with	_	
83-48	15641-15645	less	_	
83-49	15646-15652	signal	_	
83-50	15653-15655	to	_	
83-51	15656-15665	high-risk	_	
83-52	15666-15672	reward	_	
83-53	15673-15677	over	_	
83-54	15678-15682	time	_	
83-55	15682-15683	.	_	

#Text=Longitudinal contrasts were similarly specified for Explode*p(Explode), Win*p(Explode), and Redeem*p(Explode) parametric modulators.
84-1	15684-15696	Longitudinal	_	
84-2	15697-15706	contrasts	_	
84-3	15707-15711	were	_	
84-4	15712-15721	similarly	_	
84-5	15722-15731	specified	_	
84-6	15732-15735	for	_	
84-7	15736-15743	Explode	_	
84-8	15743-15744	*	_	
84-9	15744-15745	p	_	
84-10	15745-15746	(	_	
84-11	15746-15753	Explode	_	
84-12	15753-15754	)	_	
84-13	15754-15755	,	_	
84-14	15756-15759	Win	_	
84-15	15759-15760	*	_	
84-16	15760-15761	p	_	
84-17	15761-15762	(	_	
84-18	15762-15769	Explode	_	
84-19	15769-15770	)	_	
84-20	15770-15771	,	_	
84-21	15772-15775	and	_	
84-22	15776-15782	Redeem	_	
84-23	15782-15783	*	_	
84-24	15783-15784	p	_	
84-25	15784-15785	(	_	
84-26	15785-15792	Explode	_	
84-27	15792-15793	)	_	
84-28	15794-15804	parametric	_	
84-29	15805-15815	modulators	_	
84-30	15815-15816	.	_	

#Text=Between-subject, whole-brain correlational analyses were conducted for longitudinal contrasts to identify regions wherein changes in task-related signal related to substance use outcomes (i.e., SUM).
85-1	15817-15832	Between-subject	_	
85-2	15832-15833	,	_	
85-3	15834-15845	whole-brain	_	
85-4	15846-15859	correlational	_	
85-5	15860-15868	analyses	_	
85-6	15869-15873	were	_	
85-7	15874-15883	conducted	_	
85-8	15884-15887	for	_	
85-9	15888-15900	longitudinal	_	
85-10	15901-15910	contrasts	_	
85-11	15911-15913	to	_	
85-12	15914-15922	identify	_	
85-13	15923-15930	regions	_	
85-14	15931-15938	wherein	_	
85-15	15939-15946	changes	_	
85-16	15947-15949	in	_	
85-17	15950-15962	task-related	_	
85-18	15963-15969	signal	_	
85-19	15970-15977	related	_	
85-20	15978-15980	to	_	
85-21	15981-15990	substance	_	
85-22	15991-15994	use	_	
85-23	15995-16003	outcomes	_	
85-24	16004-16005	(	_	
85-25	16005-16008	i.e	_	
85-26	16008-16009	.	_	
85-27	16009-16010	,	_	
85-28	16011-16014	SUM	_	
85-29	16014-16015	)	_	
85-30	16015-16016	.	_	

#Text=Negative correlations represent less use with increased parametrically-modulated event-related activation at follow-up, relative to baseline.
86-1	16017-16025	Negative	_	
86-2	16026-16038	correlations	_	
86-3	16039-16048	represent	_	
86-4	16049-16053	less	_	
86-5	16054-16057	use	_	
86-6	16058-16062	with	_	
86-7	16063-16072	increased	_	
86-8	16073-16097	parametrically-modulated	_	
86-9	16098-16111	event-related	_	
86-10	16112-16122	activation	_	
86-11	16123-16125	at	_	
86-12	16126-16135	follow-up	_	
86-13	16135-16136	,	_	
86-14	16137-16145	relative	_	
86-15	16146-16148	to	_	
86-16	16149-16157	baseline	_	
86-17	16157-16158	.	_	

#Text=Positive correlations indicate that increased parametrically-modulated signal at follow-up corresponded with more use.
87-1	16159-16167	Positive	_	
87-2	16168-16180	correlations	_	
87-3	16181-16189	indicate	_	
87-4	16190-16194	that	_	
87-5	16195-16204	increased	_	
87-6	16205-16229	parametrically-modulated	_	
87-7	16230-16236	signal	_	
87-8	16237-16239	at	_	
87-9	16240-16249	follow-up	_	
87-10	16250-16262	corresponded	_	
87-11	16263-16267	with	_	
87-12	16268-16272	more	_	
87-13	16273-16276	use	_	
87-14	16276-16277	.	_	

#Text=We employed a whole brain search space to improve hypothesis-generating potential; however, our hypotheses specifically concerned mPFC/ACC, justifying small volume correction for that region.
88-1	16278-16280	We	_	
88-2	16281-16289	employed	_	
88-3	16290-16291	a	_	
88-4	16292-16297	whole	_	
88-5	16298-16303	brain	_	
88-6	16304-16310	search	_	
88-7	16311-16316	space	_	
88-8	16317-16319	to	_	
88-9	16320-16327	improve	_	
88-10	16328-16349	hypothesis-generating	_	
88-11	16350-16359	potential	_	
88-12	16359-16360	;	_	
88-13	16361-16368	however	_	
88-14	16368-16369	,	_	
88-15	16370-16373	our	_	
88-16	16374-16384	hypotheses	_	
88-17	16385-16397	specifically	_	
88-18	16398-16407	concerned	_	
88-19	16408-16412	mPFC	_	
88-20	16412-16413	/	_	
88-21	16413-16416	ACC	_	
88-22	16416-16417	,	_	
88-23	16418-16428	justifying	_	
88-24	16429-16434	small	_	
88-25	16435-16441	volume	_	
88-26	16442-16452	correction	_	
88-27	16453-16456	for	_	
88-28	16457-16461	that	_	
88-29	16462-16468	region	_	
88-30	16468-16469	.	_	

#Text=Clusters of 30 or more contiguous voxels, passing cluster-level correction at the 0.05 α-level (initial cluster-forming threshold of 0.001; cluster extent estimated using AFNI's 3dClustSim to achieve a type I error rate of 0.5%), were identified as regions of interest.
89-1	16470-16478	Clusters	_	
89-2	16479-16481	of	_	
89-3	16482-16484	30	_	
89-4	16485-16487	or	_	
89-5	16488-16492	more	_	
89-6	16493-16503	contiguous	_	
89-7	16504-16510	voxels	_	
89-8	16510-16511	,	_	
89-9	16512-16519	passing	_	
89-10	16520-16533	cluster-level	_	
89-11	16534-16544	correction	_	
89-12	16545-16547	at	_	
89-13	16548-16551	the	_	
89-14	16552-16556	0.05	_	
89-15	16557-16564	α-level	_	
89-16	16565-16566	(	_	
89-17	16566-16573	initial	_	
89-18	16574-16589	cluster-forming	_	
89-19	16590-16599	threshold	_	
89-20	16600-16602	of	_	
89-21	16603-16608	0.001	_	
89-22	16608-16609	;	_	
89-23	16610-16617	cluster	_	
89-24	16618-16624	extent	_	
89-25	16625-16634	estimated	_	
89-26	16635-16640	using	_	
89-27	16641-16647	AFNI's	_	
89-28	16648-16658	3dClustSim	_	
89-29	16659-16661	to	_	
89-30	16662-16669	achieve	_	
89-31	16670-16671	a	_	
89-32	16672-16676	type	_	
89-33	16677-16678	I	_	
89-34	16679-16684	error	_	
89-35	16685-16689	rate	_	
89-36	16690-16692	of	_	
89-37	16693-16697	0.5%	_	
89-38	16697-16698	)	_	
89-39	16698-16699	,	_	
89-40	16700-16704	were	_	
89-41	16705-16715	identified	_	
89-42	16716-16718	as	_	
89-43	16719-16726	regions	_	
89-44	16727-16729	of	_	
89-45	16730-16738	interest	_	
89-46	16738-16739	.	_	

#Text=Bonferroni correction was additionally applied for 10 whole brain correlations (5 positive and 5 negative longitudinal contrast correlations), lowering the cluster-corrected p-value to 0.005 for these comparisons.
90-1	16740-16750	Bonferroni	_	
90-2	16751-16761	correction	_	
90-3	16762-16765	was	_	
90-4	16766-16778	additionally	_	
90-5	16779-16786	applied	_	
90-6	16787-16790	for	_	
90-7	16791-16793	10	_	
90-8	16794-16799	whole	_	
90-9	16800-16805	brain	_	
90-10	16806-16818	correlations	_	
90-11	16819-16820	(	_	
90-12	16820-16821	5	_	
90-13	16822-16830	positive	_	
90-14	16831-16834	and	_	
90-15	16835-16836	5	_	
90-16	16837-16845	negative	_	
90-17	16846-16858	longitudinal	_	
90-18	16859-16867	contrast	_	
90-19	16868-16880	correlations	_	
90-20	16880-16881	)	_	
90-21	16881-16882	,	_	
90-22	16883-16891	lowering	_	
90-23	16892-16895	the	_	
90-24	16896-16913	cluster-corrected	_	
90-25	16914-16921	p-value	_	
90-26	16922-16924	to	_	
90-27	16925-16930	0.005	_	
90-28	16931-16934	for	_	
90-29	16935-16940	these	_	
90-30	16941-16952	comparisons	_	
90-31	16952-16953	.	_	

#Text=Correlation analyses were repeated following exclusion of participants with SUM scores exceeding 2 standard deviations of the mean to assess the influence of extreme values.
#Text=2.4.
91-1	16954-16965	Correlation	_	
91-2	16966-16974	analyses	_	
91-3	16975-16979	were	_	
91-4	16980-16988	repeated	_	
91-5	16989-16998	following	_	
91-6	16999-17008	exclusion	_	
91-7	17009-17011	of	_	
91-8	17012-17024	participants	_	
91-9	17025-17029	with	_	
91-10	17030-17033	SUM	_	
91-11	17034-17040	scores	_	
91-12	17041-17050	exceeding	_	
91-13	17051-17052	2	_	
91-14	17053-17061	standard	_	
91-15	17062-17072	deviations	_	
91-16	17073-17075	of	_	
91-17	17076-17079	the	_	
91-18	17080-17084	mean	_	
91-19	17085-17087	to	_	
91-20	17088-17094	assess	_	
91-21	17095-17098	the	_	
91-22	17099-17108	influence	_	
91-23	17109-17111	of	_	
91-24	17112-17119	extreme	_	
91-25	17120-17126	values	_	
91-26	17126-17127	.	_	
91-27	17128-17131	2.4	_	
91-28	17131-17132	.	_	

#Text=Cognitive-behavioral and self-report data
#Text=Repeated-measures analysis of variance (ANOVA) was used to assess longitudinal change in BART performance, as well as self-report and cognitive-behavioral measures (see Supplementary materials).
92-1	17133-17153	Cognitive-behavioral	_	
92-2	17154-17157	and	_	
92-3	17158-17169	self-report	_	
92-4	17170-17174	data	_	
92-5	17175-17192	Repeated-measures	_	
92-6	17193-17201	analysis	_	
92-7	17202-17204	of	_	
92-8	17205-17213	variance	_	
92-9	17214-17215	(	_	
92-10	17215-17220	ANOVA	_	
92-11	17220-17221	)	_	
92-12	17222-17225	was	_	
92-13	17226-17230	used	_	
92-14	17231-17233	to	_	
92-15	17234-17240	assess	_	
92-16	17241-17253	longitudinal	_	
92-17	17254-17260	change	_	
92-18	17261-17263	in	_	
92-19	17264-17268	BART	_	
92-20	17269-17280	performance	_	
92-21	17280-17281	,	_	
92-22	17282-17284	as	_	
92-23	17285-17289	well	_	
92-24	17290-17292	as	_	
92-25	17293-17304	self-report	_	
92-26	17305-17308	and	_	
92-27	17309-17329	cognitive-behavioral	_	
92-28	17330-17338	measures	_	
92-29	17339-17340	(	_	
92-30	17340-17343	see	_	
92-31	17344-17357	Supplementary	_	
92-32	17358-17367	materials	_	
92-33	17367-17368	)	_	
92-34	17368-17369	.	_	

#Text=Pearson correlations between SUM values and longitudinal change in these variables were also calculated.
93-1	17370-17377	Pearson	_	
93-2	17378-17390	correlations	_	
93-3	17391-17398	between	_	
93-4	17399-17402	SUM	_	
93-5	17403-17409	values	_	
93-6	17410-17413	and	_	
93-7	17414-17426	longitudinal	_	
93-8	17427-17433	change	_	
93-9	17434-17436	in	_	
93-10	17437-17442	these	_	
93-11	17443-17452	variables	_	
93-12	17453-17457	were	_	
93-13	17458-17462	also	_	
93-14	17463-17473	calculated	_	
93-15	17473-17474	.	_	

#Text=Post hoc paired t-tests were utilized for comparison of specific conditions.
94-1	17475-17479	Post	_	
94-2	17480-17483	hoc	_	
94-3	17484-17490	paired	_	
94-4	17491-17498	t-tests	_	
94-5	17499-17503	were	_	
94-6	17504-17512	utilized	_	
94-7	17513-17516	for	_	
94-8	17517-17527	comparison	_	
94-9	17528-17530	of	_	
94-10	17531-17539	specific	_	
94-11	17540-17550	conditions	_	
94-12	17550-17551	.	_	

#Text=Reported p-values reflect a two-tailed test of significance.
#Text=3.
95-1	17552-17560	Reported	_	
95-2	17561-17569	p-values	_	
95-3	17570-17577	reflect	_	
95-4	17578-17579	a	_	
95-5	17580-17590	two-tailed	_	
95-6	17591-17595	test	_	
95-7	17596-17598	of	_	
95-8	17599-17611	significance	_	
95-9	17611-17612	.	_	
95-10	17613-17614	3	_	
95-11	17614-17615	.	_	

#Text=Results
#Text=3.1.
96-1	17616-17623	Results	_	
96-2	17624-17627	3.1	_	
96-3	17627-17628	.	_	

#Text=BART behavior and substance use measures
#Text=BART performance and substance use outcome data are summarized in Table 3.
97-1	17629-17633	BART	_	
97-2	17634-17642	behavior	_	
97-3	17643-17646	and	_	
97-4	17647-17656	substance	_	
97-5	17657-17660	use	_	
97-6	17661-17669	measures	_	
97-7	17670-17674	BART	_	
97-8	17675-17686	performance	_	
97-9	17687-17690	and	_	
97-10	17691-17700	substance	_	
97-11	17701-17704	use	_	
97-12	17705-17712	outcome	_	
97-13	17713-17717	data	_	
97-14	17718-17721	are	_	
97-15	17722-17732	summarized	_	
97-16	17733-17735	in	_	
97-17	17736-17741	Table	_	
97-18	17742-17743	3	_	
97-19	17743-17744	.	_	

#Text=A 2 (timepoint) × 2 (block) repeated-measures ANOVA revealed no significant effects for total balloons, exploded balloons, won balloons, average 'Redeem' inflation number, or average 'Explode' inflation number.
98-1	17745-17746	A	_	
98-2	17747-17748	2	_	
98-3	17749-17750	(	_	
98-4	17750-17759	timepoint	_	
98-5	17759-17760	)	_	
98-6	17761-17762	×	_	
98-7	17763-17764	2	_	
98-8	17765-17766	(	_	
98-9	17766-17771	block	_	
98-10	17771-17772	)	_	
98-11	17773-17790	repeated-measures	_	
98-12	17791-17796	ANOVA	_	
98-13	17797-17805	revealed	_	
98-14	17806-17808	no	_	
98-15	17809-17820	significant	_	
98-16	17821-17828	effects	_	
98-17	17829-17832	for	_	
98-18	17833-17838	total	_	
98-19	17839-17847	balloons	_	
98-20	17847-17848	,	_	
98-21	17849-17857	exploded	_	
98-22	17858-17866	balloons	_	
98-23	17866-17867	,	_	
98-24	17868-17871	won	_	
98-25	17872-17880	balloons	_	
98-26	17880-17881	,	_	
98-27	17882-17889	average	_	
98-28	17890-17891	'	_	
98-29	17891-17897	Redeem	_	
98-30	17897-17898	'	_	
98-31	17899-17908	inflation	_	
98-32	17909-17915	number	_	
98-33	17915-17916	,	_	
98-34	17917-17919	or	_	
98-35	17920-17927	average	_	
98-36	17928-17929	'	_	
98-37	17929-17936	Explode	_	
98-38	17936-17937	'	_	
98-39	17938-17947	inflation	_	
98-40	17948-17954	number	_	
98-41	17954-17955	.	_	

#Text='Explode' events were less frequent than 'Win' at both baseline (t(20) = 4.57, p < 0.001) and follow-up (t(20) = 5.09, p < 0.001).
99-1	17956-17957	'	_	
99-2	17957-17964	Explode	_	
99-3	17964-17965	'	_	
99-4	17966-17972	events	_	
99-5	17973-17977	were	_	
99-6	17978-17982	less	_	
99-7	17983-17991	frequent	_	
99-8	17992-17996	than	_	
99-9	17997-17998	'	_	
99-10	17998-18001	Win	_	
99-11	18001-18002	'	_	
99-12	18003-18005	at	_	
99-13	18006-18010	both	_	
99-14	18011-18019	baseline	_	
99-15	18020-18021	(	_	
99-16	18021-18022	t	_	
99-17	18022-18023	(	_	
99-18	18023-18025	20	_	
99-19	18025-18026	)	_	
99-20	18027-18028	=	_	
99-21	18029-18033	4.57	_	
99-22	18033-18034	,	_	
99-23	18035-18036	p	_	
99-24	18037-18038	<	_	
99-25	18039-18044	0.001	_	
99-26	18044-18045	)	_	
99-27	18046-18049	and	_	
99-28	18050-18059	follow-up	_	
99-29	18060-18061	(	_	
99-30	18061-18062	t	_	
99-31	18062-18063	(	_	
99-32	18063-18065	20	_	
99-33	18065-18066	)	_	
99-34	18067-18068	=	_	
99-35	18069-18073	5.09	_	
99-36	18073-18074	,	_	
99-37	18075-18076	p	_	
99-38	18077-18078	<	_	
99-39	18079-18084	0.001	_	
99-40	18084-18085	)	_	
99-41	18085-18086	.	_	

#Text=With respect to RT, a 2 (timepoint) × 2 (block) × 2 (decision type) repeated-measures ANOVA identified a significant main effect of timepoint, with evidence of faster overall RTs at follow-up relative to baseline (t(20) = 1.72, p = 0.052).
100-1	18087-18091	With	_	
100-2	18092-18099	respect	_	
100-3	18100-18102	to	_	
100-4	18103-18105	RT	_	
100-5	18105-18106	,	_	
100-6	18107-18108	a	_	
100-7	18109-18110	2	_	
100-8	18111-18112	(	_	
100-9	18112-18121	timepoint	_	
100-10	18121-18122	)	_	
100-11	18123-18124	×	_	
100-12	18125-18126	2	_	
100-13	18127-18128	(	_	
100-14	18128-18133	block	_	
100-15	18133-18134	)	_	
100-16	18135-18136	×	_	
100-17	18137-18138	2	_	
100-18	18139-18140	(	_	
100-19	18140-18148	decision	_	
100-20	18149-18153	type	_	
100-21	18153-18154	)	_	
100-22	18155-18172	repeated-measures	_	
100-23	18173-18178	ANOVA	_	
100-24	18179-18189	identified	_	
100-25	18190-18191	a	_	
100-26	18192-18203	significant	_	
100-27	18204-18208	main	_	
100-28	18209-18215	effect	_	
100-29	18216-18218	of	_	
100-30	18219-18228	timepoint	_	
100-31	18228-18229	,	_	
100-32	18230-18234	with	_	
100-33	18235-18243	evidence	_	
100-34	18244-18246	of	_	
100-35	18247-18253	faster	_	
100-36	18254-18261	overall	_	
100-37	18262-18265	RTs	_	
100-38	18266-18268	at	_	
100-39	18269-18278	follow-up	_	
100-40	18279-18287	relative	_	
100-41	18288-18290	to	_	
100-42	18291-18299	baseline	_	
100-43	18300-18301	(	_	
100-44	18301-18302	t	_	
100-45	18302-18303	(	_	
100-46	18303-18305	20	_	
100-47	18305-18306	)	_	
100-48	18307-18308	=	_	
100-49	18309-18313	1.72	_	
100-50	18313-18314	,	_	
100-51	18315-18316	p	_	
100-52	18317-18318	=	_	
100-53	18319-18324	0.052	_	
100-54	18324-18325	)	_	
100-55	18325-18326	.	_	

#Text=This finding supports inclusion of RT-based parametric modulators in first-level GLMs.
101-1	18327-18331	This	_	
101-2	18332-18339	finding	_	
101-3	18340-18348	supports	_	
101-4	18349-18358	inclusion	_	
101-5	18359-18361	of	_	
101-6	18362-18370	RT-based	_	
101-7	18371-18381	parametric	_	
101-8	18382-18392	modulators	_	
101-9	18393-18395	in	_	
101-10	18396-18407	first-level	_	
101-11	18408-18412	GLMs	_	
101-12	18412-18413	.	_	

#Text=No other significant effects were identified.
102-1	18414-18416	No	_	
102-2	18417-18422	other	_	
102-3	18423-18434	significant	_	
102-4	18435-18442	effects	_	
102-5	18443-18447	were	_	
102-6	18448-18458	identified	_	
102-7	18458-18459	.	_	

#Text=Less substance use during the study interval was associated with a greater reduction in RT from baseline to follow-up on 'Inflate' trials (r(21) = 0.586; p = 0.005) but not on 'Redeem' trials (r(21) = 0.065; p = 0.780).
103-1	18460-18464	Less	_	
103-2	18465-18474	substance	_	
103-3	18475-18478	use	_	
103-4	18479-18485	during	_	
103-5	18486-18489	the	_	
103-6	18490-18495	study	_	
103-7	18496-18504	interval	_	
103-8	18505-18508	was	_	
103-9	18509-18519	associated	_	
103-10	18520-18524	with	_	
103-11	18525-18526	a	_	
103-12	18527-18534	greater	_	
103-13	18535-18544	reduction	_	
103-14	18545-18547	in	_	
103-15	18548-18550	RT	_	
103-16	18551-18555	from	_	
103-17	18556-18564	baseline	_	
103-18	18565-18567	to	_	
103-19	18568-18577	follow-up	_	
103-20	18578-18580	on	_	
103-21	18581-18582	'	_	
103-22	18582-18589	Inflate	_	
103-23	18589-18590	'	_	
103-24	18591-18597	trials	_	
103-25	18598-18599	(	_	
103-26	18599-18600	r	_	
103-27	18600-18601	(	_	
103-28	18601-18603	21	_	
103-29	18603-18604	)	_	
103-30	18605-18606	=	_	
103-31	18607-18612	0.586	_	
103-32	18612-18613	;	_	
103-33	18614-18615	p	_	
103-34	18616-18617	=	_	
103-35	18618-18623	0.005	_	
103-36	18623-18624	)	_	
103-37	18625-18628	but	_	
103-38	18629-18632	not	_	
103-39	18633-18635	on	_	
103-40	18636-18637	'	_	
103-41	18637-18643	Redeem	_	
103-42	18643-18644	'	_	
103-43	18645-18651	trials	_	
103-44	18652-18653	(	_	
103-45	18653-18654	r	_	
103-46	18654-18655	(	_	
103-47	18655-18657	21	_	
103-48	18657-18658	)	_	
103-49	18659-18660	=	_	
103-50	18661-18666	0.065	_	
103-51	18666-18667	;	_	
103-52	18668-18669	p	_	
103-53	18670-18671	=	_	
103-54	18672-18677	0.780	_	
103-55	18677-18678	)	_	
103-56	18678-18679	.	_	

#Text=Longitudinal change in mean stop inflation number did not significantly correlate with SUM (r(21) = 0.245; p = 0.284).
104-1	18680-18692	Longitudinal	_	
104-2	18693-18699	change	_	
104-3	18700-18702	in	_	
104-4	18703-18707	mean	_	
104-5	18708-18712	stop	_	
104-6	18713-18722	inflation	_	
104-7	18723-18729	number	_	
104-8	18730-18733	did	_	
104-9	18734-18737	not	_	
104-10	18738-18751	significantly	_	
104-11	18752-18761	correlate	_	
104-12	18762-18766	with	_	
104-13	18767-18770	SUM	_	
104-14	18771-18772	(	_	
104-15	18772-18773	r	_	
104-16	18773-18774	(	_	
104-17	18774-18776	21	_	
104-18	18776-18777	)	_	
104-19	18778-18779	=	_	
104-20	18780-18785	0.245	_	
104-21	18785-18786	;	_	
104-22	18787-18788	p	_	
104-23	18789-18790	=	_	
104-24	18791-18796	0.284	_	
104-25	18796-18797	)	_	
104-26	18797-18798	.	_	

#Text=Additional self-report and cognitive-behavioral measures are summarized in Supplementary Table 1.
#Text=3.2.
105-1	18799-18809	Additional	_	
105-2	18810-18821	self-report	_	
105-3	18822-18825	and	_	
105-4	18826-18846	cognitive-behavioral	_	
105-5	18847-18855	measures	_	
105-6	18856-18859	are	_	
105-7	18860-18870	summarized	_	
105-8	18871-18873	in	_	
105-9	18874-18887	Supplementary	_	
105-10	18888-18893	Table	_	
105-11	18894-18895	1	_	
105-12	18895-18896	.	_	
105-13	18897-18900	3.2	_	
105-14	18900-18901	.	_	

#Text=Longitudinal change in parametrically-modulated brain signals
#Text=Longitudinal contrast results are summarized in Table 4.
106-1	18902-18914	Longitudinal	_	
106-2	18915-18921	change	_	
106-3	18922-18924	in	_	
106-4	18925-18949	parametrically-modulated	_	
106-5	18950-18955	brain	_	
106-6	18956-18963	signals	_	
106-7	18964-18976	Longitudinal	_	
106-8	18977-18985	contrast	_	
106-9	18986-18993	results	_	
106-10	18994-18997	are	_	
106-11	18998-19008	summarized	_	
106-12	19009-19011	in	_	
106-13	19012-19017	Table	_	
106-14	19018-19019	4	_	
106-15	19019-19020	.	_	

#Text=FU-BL main effect contrasts for decision events revealed greater increasing parametrically-modulated risk/reward signal during 'Redeem' events (i.e., 'Redeem*p(Explode)') at follow-up in left dorsal premotor cortex (BA 6).
107-1	19021-19026	FU-BL	_	
107-2	19027-19031	main	_	
107-3	19032-19038	effect	_	
107-4	19039-19048	contrasts	_	
107-5	19049-19052	for	_	
107-6	19053-19061	decision	_	
107-7	19062-19068	events	_	
107-8	19069-19077	revealed	_	
107-9	19078-19085	greater	_	
107-10	19086-19096	increasing	_	
107-11	19097-19121	parametrically-modulated	_	
107-12	19122-19126	risk	_	
107-13	19126-19127	/	_	
107-14	19127-19133	reward	_	
107-15	19134-19140	signal	_	
107-16	19141-19147	during	_	
107-17	19148-19149	'	_	
107-18	19149-19155	Redeem	_	
107-19	19155-19156	'	_	
107-20	19157-19163	events	_	
107-21	19164-19165	(	_	
107-22	19165-19168	i.e	_	
107-23	19168-19169	.	_	
107-24	19169-19170	,	_	
107-25	19171-19172	'	_	
107-26	19172-19178	Redeem	_	
107-27	19178-19179	*	_	
107-28	19179-19180	p	_	
107-29	19180-19181	(	_	
107-30	19181-19188	Explode	_	
107-31	19188-19189	)	_	
107-32	19189-19190	'	_	
107-33	19190-19191	)	_	
107-34	19192-19194	at	_	
107-35	19195-19204	follow-up	_	
107-36	19205-19207	in	_	
107-37	19208-19212	left	_	
107-38	19213-19219	dorsal	_	
107-39	19220-19228	premotor	_	
107-40	19229-19235	cortex	_	
107-41	19236-19237	(	_	
107-42	19237-19239	BA	_	
107-43	19240-19241	6	_	
107-44	19241-19242	)	_	
107-45	19242-19243	.	_	

#Text=No significant areas of decreased 'Redeem*p(Explode)' signal were identified and the 'Inflate*p(Explode)' FU-BL contrast yielded no significant effect in either direction.
108-1	19244-19246	No	_	
108-2	19247-19258	significant	_	
108-3	19259-19264	areas	_	
108-4	19265-19267	of	_	
108-5	19268-19277	decreased	_	
108-6	19278-19279	'	_	
108-7	19279-19285	Redeem	_	
108-8	19285-19286	*	_	
108-9	19286-19287	p	_	
108-10	19287-19288	(	_	
108-11	19288-19295	Explode	_	
108-12	19295-19296	)	_	
108-13	19296-19297	'	_	
108-14	19298-19304	signal	_	
108-15	19305-19309	were	_	
108-16	19310-19320	identified	_	
108-17	19321-19324	and	_	
108-18	19325-19328	the	_	
108-19	19329-19330	'	_	
108-20	19330-19337	Inflate	_	
108-21	19337-19338	*	_	
108-22	19338-19339	p	_	
108-23	19339-19340	(	_	
108-24	19340-19347	Explode	_	
108-25	19347-19348	)	_	
108-26	19348-19349	'	_	
108-27	19350-19355	FU-BL	_	
108-28	19356-19364	contrast	_	
108-29	19365-19372	yielded	_	
108-30	19373-19375	no	_	
108-31	19376-19387	significant	_	
108-32	19388-19394	effect	_	
108-33	19395-19397	in	_	
108-34	19398-19404	either	_	
108-35	19405-19414	direction	_	
108-36	19414-19415	.	_	

#Text=For outcome events, greater increasing activity with increasing risk/reward for 'Success' feedback (i.e., 'Success*p(Explode)') at follow-up was identified between right caudal ACC and PCC (BA 24).
109-1	19416-19419	For	_	
109-2	19420-19427	outcome	_	
109-3	19428-19434	events	_	
109-4	19434-19435	,	_	
109-5	19436-19443	greater	_	
109-6	19444-19454	increasing	_	
109-7	19455-19463	activity	_	
109-8	19464-19468	with	_	
109-9	19469-19479	increasing	_	
109-10	19480-19484	risk	_	
109-11	19484-19485	/	_	
109-12	19485-19491	reward	_	
109-13	19492-19495	for	_	
109-14	19496-19497	'	_	
109-15	19497-19504	Success	_	
109-16	19504-19505	'	_	
109-17	19506-19514	feedback	_	
109-18	19515-19516	(	_	
109-19	19516-19519	i.e	_	
109-20	19519-19520	.	_	
109-21	19520-19521	,	_	
109-22	19522-19523	'	_	
109-23	19523-19530	Success	_	
109-24	19530-19531	*	_	
109-25	19531-19532	p	_	
109-26	19532-19533	(	_	
109-27	19533-19540	Explode	_	
109-28	19540-19541	)	_	
109-29	19541-19542	'	_	
109-30	19542-19543	)	_	
109-31	19544-19546	at	_	
109-32	19547-19556	follow-up	_	
109-33	19557-19560	was	_	
109-34	19561-19571	identified	_	
109-35	19572-19579	between	_	
109-36	19580-19585	right	_	
109-37	19586-19592	caudal	_	
109-38	19593-19596	ACC	_	
109-39	19597-19600	and	_	
109-40	19601-19604	PCC	_	
109-41	19605-19606	(	_	
109-42	19606-19608	BA	_	
109-43	19609-19611	24	_	
109-44	19611-19612	)	_	
109-45	19612-19613	.	_	

#Text=In addition, decreasing parametrically-modulated activity from baseline to follow-up was identified for the 'Explode*p(Explode)' contrast in right IFG (BA 47) and left caudal ACC (BA 24), extending into the cingulum.
110-1	19614-19616	In	_	
110-2	19617-19625	addition	_	
110-3	19625-19626	,	_	
110-4	19627-19637	decreasing	_	
110-5	19638-19662	parametrically-modulated	_	
110-6	19663-19671	activity	_	
110-7	19672-19676	from	_	
110-8	19677-19685	baseline	_	
110-9	19686-19688	to	_	
110-10	19689-19698	follow-up	_	
110-11	19699-19702	was	_	
110-12	19703-19713	identified	_	
110-13	19714-19717	for	_	
110-14	19718-19721	the	_	
110-15	19722-19723	'	_	
110-16	19723-19730	Explode	_	
110-17	19730-19731	*	_	
110-18	19731-19732	p	_	
110-19	19732-19733	(	_	
110-20	19733-19740	Explode	_	
110-21	19740-19741	)	_	
110-22	19741-19742	'	_	
110-23	19743-19751	contrast	_	
110-24	19752-19754	in	_	
110-25	19755-19760	right	_	
110-26	19761-19764	IFG	_	
110-27	19765-19766	(	_	
110-28	19766-19768	BA	_	
110-29	19769-19771	47	_	
110-30	19771-19772	)	_	
110-31	19773-19776	and	_	
110-32	19777-19781	left	_	
110-33	19782-19788	caudal	_	
110-34	19789-19792	ACC	_	
110-35	19793-19794	(	_	
110-36	19794-19796	BA	_	
110-37	19797-19799	24	_	
110-38	19799-19800	)	_	
110-39	19800-19801	,	_	
110-40	19802-19811	extending	_	
110-41	19812-19816	into	_	
110-42	19817-19820	the	_	
110-43	19821-19829	cingulum	_	
110-44	19829-19830	.	_	

#Text=Significant longitudinal change in 'Win*p(Explode)' was not identified.
111-1	19831-19842	Significant	_	
111-2	19843-19855	longitudinal	_	
111-3	19856-19862	change	_	
111-4	19863-19865	in	_	
111-5	19866-19867	'	_	
111-6	19867-19870	Win	_	
111-7	19870-19871	*	_	
111-8	19871-19872	p	_	
111-9	19872-19873	(	_	
111-10	19873-19880	Explode	_	
111-11	19880-19881	)	_	
111-12	19881-19882	'	_	
111-13	19883-19886	was	_	
111-14	19887-19890	not	_	
111-15	19891-19901	identified	_	
111-16	19901-19902	.	_	

#Text=Outcome-related clusters are depicted in Fig. 2.
112-1	19903-19918	Outcome-related	_	
112-2	19919-19927	clusters	_	
112-3	19928-19931	are	_	
112-4	19932-19940	depicted	_	
112-5	19941-19943	in	_	
112-6	19944-19947	Fig	_	
112-7	19947-19948	.	_	
112-8	19949-19950	2	_	
112-9	19950-19951	.	_	

#Text=Collectively, outcome-related effects suggest increased sensitivity to surprising events or prediction error.
#Text=3.3.
113-1	19952-19964	Collectively	_	
113-2	19964-19965	,	_	
113-3	19966-19981	outcome-related	_	
113-4	19982-19989	effects	_	
113-5	19990-19997	suggest	_	
113-6	19998-20007	increased	_	
113-7	20008-20019	sensitivity	_	
113-8	20020-20022	to	_	
113-9	20023-20033	surprising	_	
113-10	20034-20040	events	_	
113-11	20041-20043	or	_	
113-12	20044-20054	prediction	_	
113-13	20055-20060	error	_	
113-14	20060-20061	.	_	
113-15	20062-20065	3.3	_	
113-16	20065-20066	.	_	

#Text=Whole brain correlations between FU-BL contrasts and substance use outcomes
#Text=Several regions demonstrated a significant correlation between longitudinal change in parametrically-modulated signals and substance use outcomes (i.e., greater signal modulation by risk/reward at follow-up associated with more or less use during the study interval).
114-1	20067-20072	Whole	_	
114-2	20073-20078	brain	_	
114-3	20079-20091	correlations	_	
114-4	20092-20099	between	_	
114-5	20100-20105	FU-BL	_	
114-6	20106-20115	contrasts	_	
114-7	20116-20119	and	_	
114-8	20120-20129	substance	_	
114-9	20130-20133	use	_	
114-10	20134-20142	outcomes	_	
114-11	20143-20150	Several	_	
114-12	20151-20158	regions	_	
114-13	20159-20171	demonstrated	_	
114-14	20172-20173	a	_	
114-15	20174-20185	significant	_	
114-16	20186-20197	correlation	_	
114-17	20198-20205	between	_	
114-18	20206-20218	longitudinal	_	
114-19	20219-20225	change	_	
114-20	20226-20228	in	_	
114-21	20229-20253	parametrically-modulated	_	
114-22	20254-20261	signals	_	
114-23	20262-20265	and	_	
114-24	20266-20275	substance	_	
114-25	20276-20279	use	_	
114-26	20280-20288	outcomes	_	
114-27	20289-20290	(	_	
114-28	20290-20293	i.e	_	
114-29	20293-20294	.	_	
114-30	20294-20295	,	_	
114-31	20296-20303	greater	_	
114-32	20304-20310	signal	_	
114-33	20311-20321	modulation	_	
114-34	20322-20324	by	_	
114-35	20325-20329	risk	_	
114-36	20329-20330	/	_	
114-37	20330-20336	reward	_	
114-38	20337-20339	at	_	
114-39	20340-20349	follow-up	_	
114-40	20350-20360	associated	_	
114-41	20361-20365	with	_	
114-42	20366-20370	more	_	
114-43	20371-20373	or	_	
114-44	20374-20378	less	_	
114-45	20379-20382	use	_	
114-46	20383-20389	during	_	
114-47	20390-20393	the	_	
114-48	20394-20399	study	_	
114-49	20400-20408	interval	_	
114-50	20408-20409	)	_	
114-51	20409-20410	.	_	

#Text=These are summarized in Table 4.
115-1	20411-20416	These	_	
115-2	20417-20420	are	_	
115-3	20421-20431	summarized	_	
115-4	20432-20434	in	_	
115-5	20435-20440	Table	_	
115-6	20441-20442	4	_	
115-7	20442-20443	.	_	

#Text=While no arcsine-transformed SUM scores exceeded 3.25 standard deviations of the mean, we sought to test if results were robust to exclusion of extreme SUM values (exceeding 2 standard deviations of the mean).
116-1	20444-20449	While	_	
116-2	20450-20452	no	_	
116-3	20453-20472	arcsine-transformed	_	
116-4	20473-20476	SUM	_	
116-5	20477-20483	scores	_	
116-6	20484-20492	exceeded	_	
116-7	20493-20497	3.25	_	
116-8	20498-20506	standard	_	
116-9	20507-20517	deviations	_	
116-10	20518-20520	of	_	
116-11	20521-20524	the	_	
116-12	20525-20529	mean	_	
116-13	20529-20530	,	_	
116-14	20531-20533	we	_	
116-15	20534-20540	sought	_	
116-16	20541-20543	to	_	
116-17	20544-20548	test	_	
116-18	20549-20551	if	_	
116-19	20552-20559	results	_	
116-20	20560-20564	were	_	
116-21	20565-20571	robust	_	
116-22	20572-20574	to	_	
116-23	20575-20584	exclusion	_	
116-24	20585-20587	of	_	
116-25	20588-20595	extreme	_	
116-26	20596-20599	SUM	_	
116-27	20600-20606	values	_	
116-28	20607-20608	(	_	
116-29	20608-20617	exceeding	_	
116-30	20618-20619	2	_	
116-31	20620-20628	standard	_	
116-32	20629-20639	deviations	_	
116-33	20640-20642	of	_	
116-34	20643-20646	the	_	
116-35	20647-20651	mean	_	
116-36	20651-20652	)	_	
116-37	20652-20653	.	_	

#Text=Therefore, we re-ran correlational analyses following exclusion of 2 participants with the heaviest reported use during the study interval.
117-1	20654-20663	Therefore	_	
117-2	20663-20664	,	_	
117-3	20665-20667	we	_	
117-4	20668-20674	re-ran	_	
117-5	20675-20688	correlational	_	
117-6	20689-20697	analyses	_	
117-7	20698-20707	following	_	
117-8	20708-20717	exclusion	_	
117-9	20718-20720	of	_	
117-10	20721-20722	2	_	
117-11	20723-20735	participants	_	
117-12	20736-20740	with	_	
117-13	20741-20744	the	_	
117-14	20745-20753	heaviest	_	
117-15	20754-20762	reported	_	
117-16	20763-20766	use	_	
117-17	20767-20773	during	_	
117-18	20774-20777	the	_	
117-19	20778-20783	study	_	
117-20	20784-20792	interval	_	
117-21	20792-20793	.	_	

#Text=A single cluster between left dorsal ACC (dACC; BA 32) and ventromedial PFC (vmPFC), demonstrating a positive correlation for the Inflate*p(Explode) FU-BL contrast in the full sample, survived cluster extent thresholding when excluding the heaviest users (cluster size: 30 voxels, peak voxel: −6, 36, 10, z-score = 4.27) but did not pass cluster-level correction for the whole brain search volume (cluster-corrected p-value = 0.337, uncorrected p-value = 0.008).
118-1	20794-20795	A	_	
118-2	20796-20802	single	_	
118-3	20803-20810	cluster	_	
118-4	20811-20818	between	_	
118-5	20819-20823	left	_	
118-6	20824-20830	dorsal	_	
118-7	20831-20834	ACC	_	
118-8	20835-20836	(	_	
118-9	20836-20840	dACC	_	
118-10	20840-20841	;	_	
118-11	20842-20844	BA	_	
118-12	20845-20847	32	_	
118-13	20847-20848	)	_	
118-14	20849-20852	and	_	
118-15	20853-20865	ventromedial	_	
118-16	20866-20869	PFC	_	
118-17	20870-20871	(	_	
118-18	20871-20876	vmPFC	_	
118-19	20876-20877	)	_	
118-20	20877-20878	,	_	
118-21	20879-20892	demonstrating	_	
118-22	20893-20894	a	_	
118-23	20895-20903	positive	_	
118-24	20904-20915	correlation	_	
118-25	20916-20919	for	_	
118-26	20920-20923	the	_	
118-27	20924-20931	Inflate	_	
118-28	20931-20932	*	_	
118-29	20932-20933	p	_	
118-30	20933-20934	(	_	
118-31	20934-20941	Explode	_	
118-32	20941-20942	)	_	
118-33	20943-20948	FU-BL	_	
118-34	20949-20957	contrast	_	
118-35	20958-20960	in	_	
118-36	20961-20964	the	_	
118-37	20965-20969	full	_	
118-38	20970-20976	sample	_	
118-39	20976-20977	,	_	
118-40	20978-20986	survived	_	
118-41	20987-20994	cluster	_	
118-42	20995-21001	extent	_	
118-43	21002-21014	thresholding	_	
118-44	21015-21019	when	_	
118-45	21020-21029	excluding	_	
118-46	21030-21033	the	_	
118-47	21034-21042	heaviest	_	
118-48	21043-21048	users	_	
118-49	21049-21050	(	_	
118-50	21050-21057	cluster	_	
118-51	21058-21062	size	_	
118-52	21062-21063	:	_	
118-53	21064-21066	30	_	
118-54	21067-21073	voxels	_	
118-55	21073-21074	,	_	
118-56	21075-21079	peak	_	
118-57	21080-21085	voxel	_	
118-58	21085-21086	:	_	
118-59	21087-21088	−	_	
118-60	21088-21089	6	_	
118-61	21089-21090	,	_	
118-62	21091-21093	36	_	
118-63	21093-21094	,	_	
118-64	21095-21097	10	_	
118-65	21097-21098	,	_	
118-66	21099-21106	z-score	_	
118-67	21107-21108	=	_	
118-68	21109-21113	4.27	_	
118-69	21113-21114	)	_	
118-70	21115-21118	but	_	
118-71	21119-21122	did	_	
118-72	21123-21126	not	_	
118-73	21127-21131	pass	_	
118-74	21132-21145	cluster-level	_	
118-75	21146-21156	correction	_	
118-76	21157-21160	for	_	
118-77	21161-21164	the	_	
118-78	21165-21170	whole	_	
118-79	21171-21176	brain	_	
118-80	21177-21183	search	_	
118-81	21184-21190	volume	_	
118-82	21191-21192	(	_	
118-83	21192-21209	cluster-corrected	_	
118-84	21210-21217	p-value	_	
118-85	21218-21219	=	_	
118-86	21220-21225	0.337	_	
118-87	21225-21226	,	_	
118-88	21227-21238	uncorrected	_	
118-89	21239-21246	p-value	_	
118-90	21247-21248	=	_	
118-91	21249-21254	0.008	_	
118-92	21254-21255	)	_	
118-93	21255-21256	.	_	

#Text=A cluster of 26 voxels passed small volume correction (p-value = 0.041) for an anatomically-defined, hypothesis-driven mask over ACC and mPFC, without Bonferroni correction for multiple comparisons.
119-1	21257-21258	A	_	
119-2	21259-21266	cluster	_	
119-3	21267-21269	of	_	
119-4	21270-21272	26	_	
119-5	21273-21279	voxels	_	
119-6	21280-21286	passed	_	
119-7	21287-21292	small	_	
119-8	21293-21299	volume	_	
119-9	21300-21310	correction	_	
119-10	21311-21312	(	_	
119-11	21312-21319	p-value	_	
119-12	21320-21321	=	_	
119-13	21322-21327	0.041	_	
119-14	21327-21328	)	_	
119-15	21329-21332	for	_	
119-16	21333-21335	an	_	
119-17	21336-21356	anatomically-defined	_	
119-18	21356-21357	,	_	
119-19	21358-21375	hypothesis-driven	_	
119-20	21376-21380	mask	_	
119-21	21381-21385	over	_	
119-22	21386-21389	ACC	_	
119-23	21390-21393	and	_	
119-24	21394-21398	mPFC	_	
119-25	21398-21399	,	_	
119-26	21400-21407	without	_	
119-27	21408-21418	Bonferroni	_	
119-28	21419-21429	correction	_	
119-29	21430-21433	for	_	
119-30	21434-21442	multiple	_	
119-31	21443-21454	comparisons	_	
119-32	21454-21455	.	_	

#Text=This cluster, as well as the larger cluster identified for the full sample, are depicted in Fig. 3, with scatterplots showing an increasing response to increasing risk/reward over time in association with greater use and a decreasing response to increasing risk/reward over time in association with reduced use.
120-1	21456-21460	This	_	
120-2	21461-21468	cluster	_	
120-3	21468-21469	,	_	
120-4	21470-21472	as	_	
120-5	21473-21477	well	_	
120-6	21478-21480	as	_	
120-7	21481-21484	the	_	
120-8	21485-21491	larger	_	
120-9	21492-21499	cluster	_	
120-10	21500-21510	identified	_	
120-11	21511-21514	for	_	
120-12	21515-21518	the	_	
120-13	21519-21523	full	_	
120-14	21524-21530	sample	_	
120-15	21530-21531	,	_	
120-16	21532-21535	are	_	
120-17	21536-21544	depicted	_	
120-18	21545-21547	in	_	
120-19	21548-21551	Fig	_	
120-20	21551-21552	.	_	
120-21	21553-21554	3	_	
120-22	21554-21555	,	_	
120-23	21556-21560	with	_	
120-24	21561-21573	scatterplots	_	
120-25	21574-21581	showing	_	
120-26	21582-21584	an	_	
120-27	21585-21595	increasing	_	
120-28	21596-21604	response	_	
120-29	21605-21607	to	_	
120-30	21608-21618	increasing	_	
120-31	21619-21623	risk	_	
120-32	21623-21624	/	_	
120-33	21624-21630	reward	_	
120-34	21631-21635	over	_	
120-35	21636-21640	time	_	
120-36	21641-21643	in	_	
120-37	21644-21655	association	_	
120-38	21656-21660	with	_	
120-39	21661-21668	greater	_	
120-40	21669-21672	use	_	
120-41	21673-21676	and	_	
120-42	21677-21678	a	_	
120-43	21679-21689	decreasing	_	
120-44	21690-21698	response	_	
120-45	21699-21701	to	_	
120-46	21702-21712	increasing	_	
120-47	21713-21717	risk	_	
120-48	21717-21718	/	_	
120-49	21718-21724	reward	_	
120-50	21725-21729	over	_	
120-51	21730-21734	time	_	
120-52	21735-21737	in	_	
120-53	21738-21749	association	_	
120-54	21750-21754	with	_	
120-55	21755-21762	reduced	_	
120-56	21763-21766	use	_	
120-57	21766-21767	.	_	

#Text=While the difference in mean BART inflation number between acquisitions was controlled for in whole brain correlation analyses, we explored the relationship between Inflate*p(Explode) FU-BL signal and BART performance at each timepoint within dACC/vmPFC clusters (see Supplementary Fig. 1), applying Bonferonni correction for 2 timepoints (α = 0.025).
121-1	21768-21773	While	_	
121-2	21774-21777	the	_	
121-3	21778-21788	difference	_	
121-4	21789-21791	in	_	
121-5	21792-21796	mean	_	
121-6	21797-21801	BART	_	
121-7	21802-21811	inflation	_	
121-8	21812-21818	number	_	
121-9	21819-21826	between	_	
121-10	21827-21839	acquisitions	_	
121-11	21840-21843	was	_	
121-12	21844-21854	controlled	_	
121-13	21855-21858	for	_	
121-14	21859-21861	in	_	
121-15	21862-21867	whole	_	
121-16	21868-21873	brain	_	
121-17	21874-21885	correlation	_	
121-18	21886-21894	analyses	_	
121-19	21894-21895	,	_	
121-20	21896-21898	we	_	
121-21	21899-21907	explored	_	
121-22	21908-21911	the	_	
121-23	21912-21924	relationship	_	
121-24	21925-21932	between	_	
121-25	21933-21940	Inflate	_	
121-26	21940-21941	*	_	
121-27	21941-21942	p	_	
121-28	21942-21943	(	_	
121-29	21943-21950	Explode	_	
121-30	21950-21951	)	_	
121-31	21952-21957	FU-BL	_	
121-32	21958-21964	signal	_	
121-33	21965-21968	and	_	
121-34	21969-21973	BART	_	
121-35	21974-21985	performance	_	
121-36	21986-21988	at	_	
121-37	21989-21993	each	_	
121-38	21994-22003	timepoint	_	
121-39	22004-22010	within	_	
121-40	22011-22015	dACC	_	
121-41	22015-22016	/	_	
121-42	22016-22021	vmPFC	_	
121-43	22022-22030	clusters	_	
121-44	22031-22032	(	_	
121-45	22032-22035	see	_	
121-46	22036-22049	Supplementary	_	
121-47	22050-22053	Fig	_	
121-48	22053-22054	.	_	
121-49	22055-22056	1	_	
121-50	22056-22057	)	_	
121-51	22057-22058	,	_	
121-52	22059-22067	applying	_	
121-53	22068-22078	Bonferonni	_	
121-54	22079-22089	correction	_	
121-55	22090-22093	for	_	
121-56	22094-22095	2	_	
121-57	22096-22106	timepoints	_	
121-58	22107-22108	(	_	
121-59	22108-22109	α	_	
121-60	22110-22111	=	_	
121-61	22112-22117	0.025	_	
121-62	22117-22118	)	_	
121-63	22118-22119	.	_	

#Text=A positive correlation between mean stop inflation number at follow-up and parameter estimates for the Inflate*p(Explode) FU-BL contrast approached uncorrected significance for the full sample (r(21) = 0.409, p = 0.066) and reached significance when excluding two participants with heaviest reported use (r(19) = 0.534, p = 0.019).
122-1	22120-22121	A	_	
122-2	22122-22130	positive	_	
122-3	22131-22142	correlation	_	
122-4	22143-22150	between	_	
122-5	22151-22155	mean	_	
122-6	22156-22160	stop	_	
122-7	22161-22170	inflation	_	
122-8	22171-22177	number	_	
122-9	22178-22180	at	_	
122-10	22181-22190	follow-up	_	
122-11	22191-22194	and	_	
122-12	22195-22204	parameter	_	
122-13	22205-22214	estimates	_	
122-14	22215-22218	for	_	
122-15	22219-22222	the	_	
122-16	22223-22230	Inflate	_	
122-17	22230-22231	*	_	
122-18	22231-22232	p	_	
122-19	22232-22233	(	_	
122-20	22233-22240	Explode	_	
122-21	22240-22241	)	_	
122-22	22242-22247	FU-BL	_	
122-23	22248-22256	contrast	_	
122-24	22257-22267	approached	_	
122-25	22268-22279	uncorrected	_	
122-26	22280-22292	significance	_	
122-27	22293-22296	for	_	
122-28	22297-22300	the	_	
122-29	22301-22305	full	_	
122-30	22306-22312	sample	_	
122-31	22313-22314	(	_	
122-32	22314-22315	r	_	
122-33	22315-22316	(	_	
122-34	22316-22318	21	_	
122-35	22318-22319	)	_	
122-36	22320-22321	=	_	
122-37	22322-22327	0.409	_	
122-38	22327-22328	,	_	
122-39	22329-22330	p	_	
122-40	22331-22332	=	_	
122-41	22333-22338	0.066	_	
122-42	22338-22339	)	_	
122-43	22340-22343	and	_	
122-44	22344-22351	reached	_	
122-45	22352-22364	significance	_	
122-46	22365-22369	when	_	
122-47	22370-22379	excluding	_	
122-48	22380-22383	two	_	
122-49	22384-22396	participants	_	
122-50	22397-22401	with	_	
122-51	22402-22410	heaviest	_	
122-52	22411-22419	reported	_	
122-53	22420-22423	use	_	
122-54	22424-22425	(	_	
122-55	22425-22426	r	_	
122-56	22426-22427	(	_	
122-57	22427-22429	19	_	
122-58	22429-22430	)	_	
122-59	22431-22432	=	_	
122-60	22433-22438	0.534	_	
122-61	22438-22439	,	_	
122-62	22440-22441	p	_	
122-63	22442-22443	=	_	
122-64	22444-22449	0.019	_	
122-65	22449-22450	)	_	
122-66	22450-22451	.	_	

#Text=Correlations between parameter estimates and mean stop inflation number at baseline were not significant (see Supplementary Fig. 1).
123-1	22452-22464	Correlations	_	
123-2	22465-22472	between	_	
123-3	22473-22482	parameter	_	
123-4	22483-22492	estimates	_	
123-5	22493-22496	and	_	
123-6	22497-22501	mean	_	
123-7	22502-22506	stop	_	
123-8	22507-22516	inflation	_	
123-9	22517-22523	number	_	
123-10	22524-22526	at	_	
123-11	22527-22535	baseline	_	
123-12	22536-22540	were	_	
123-13	22541-22544	not	_	
123-14	22545-22556	significant	_	
123-15	22557-22558	(	_	
123-16	22558-22561	see	_	
123-17	22562-22575	Supplementary	_	
123-18	22576-22579	Fig	_	
123-19	22579-22580	.	_	
123-20	22581-22582	1	_	
123-21	22582-22583	)	_	
123-22	22583-22584	.	_	

#Text=Taken together, our findings suggest longitudinal attenuation of a risky reward-seeking signal in dACC/vmPFC in association with both decreased substance use and risk-taking in the BART at follow-up.
#Text=4.
124-1	22585-22590	Taken	_	
124-2	22591-22599	together	_	
124-3	22599-22600	,	_	
124-4	22601-22604	our	_	
124-5	22605-22613	findings	_	
124-6	22614-22621	suggest	_	
124-7	22622-22634	longitudinal	_	
124-8	22635-22646	attenuation	_	
124-9	22647-22649	of	_	
124-10	22650-22651	a	_	
124-11	22652-22657	risky	_	
124-12	22658-22672	reward-seeking	_	
124-13	22673-22679	signal	_	
124-14	22680-22682	in	_	
124-15	22683-22687	dACC	_	
124-16	22687-22688	/	_	
124-17	22688-22693	vmPFC	_	
124-18	22694-22696	in	_	
124-19	22697-22708	association	_	
124-20	22709-22713	with	_	
124-21	22714-22718	both	_	
124-22	22719-22728	decreased	_	
124-23	22729-22738	substance	_	
124-24	22739-22742	use	_	
124-25	22743-22746	and	_	
124-26	22747-22758	risk-taking	_	
124-27	22759-22761	in	_	
124-28	22762-22765	the	_	
124-29	22766-22770	BART	_	
124-30	22771-22773	at	_	
124-31	22774-22783	follow-up	_	
124-32	22783-22784	.	_	
124-33	22785-22786	4	_	
124-34	22786-22787	.	_	

#Text=Discussion
#Text=The current study explored change in risk/reward-related modulation of the BOLD response to decision-making and outcome evaluation during early recovery from SUDs.
125-1	22788-22798	Discussion	_	
125-2	22799-22802	The	_	
125-3	22803-22810	current	_	
125-4	22811-22816	study	_	
125-5	22817-22825	explored	_	
125-6	22826-22832	change	_	
125-7	22833-22835	in	_	
125-8	22836-22840	risk	_	
125-9	22840-22841	/	_	
125-10	22841-22855	reward-related	_	
125-11	22856-22866	modulation	_	
125-12	22867-22869	of	_	
125-13	22870-22873	the	_	
125-14	22874-22878	BOLD	_	
125-15	22879-22887	response	_	
125-16	22888-22890	to	_	
125-17	22891-22906	decision-making	_	
125-18	22907-22910	and	_	
125-19	22911-22918	outcome	_	
125-20	22919-22929	evaluation	_	
125-21	22930-22936	during	_	
125-22	22937-22942	early	_	
125-23	22943-22951	recovery	_	
125-24	22952-22956	from	_	
125-25	22957-22961	SUDs	_	
125-26	22961-22962	.	_	

#Text=While it was hypothesized that improved substance use outcomes would be observed in conjunction with increased parametrically-modulated risk/reward signals during inflations and decreased parametrically-modulated risk/reward signals to positive feedback in ACC/mPFC, successful recovery was instead associated with reduction in a vmPFC-based reward-seeking signal.
126-1	22963-22968	While	_	
126-2	22969-22971	it	_	
126-3	22972-22975	was	_	
126-4	22976-22988	hypothesized	_	
126-5	22989-22993	that	_	
126-6	22994-23002	improved	_	
126-7	23003-23012	substance	_	
126-8	23013-23016	use	_	
126-9	23017-23025	outcomes	_	
126-10	23026-23031	would	_	
126-11	23032-23034	be	_	
126-12	23035-23043	observed	_	
126-13	23044-23046	in	_	
126-14	23047-23058	conjunction	_	
126-15	23059-23063	with	_	
126-16	23064-23073	increased	_	
126-17	23074-23098	parametrically-modulated	_	
126-18	23099-23103	risk	_	
126-19	23103-23104	/	_	
126-20	23104-23110	reward	_	
126-21	23111-23118	signals	_	
126-22	23119-23125	during	_	
126-23	23126-23136	inflations	_	
126-24	23137-23140	and	_	
126-25	23141-23150	decreased	_	
126-26	23151-23175	parametrically-modulated	_	
126-27	23176-23180	risk	_	
126-28	23180-23181	/	_	
126-29	23181-23187	reward	_	
126-30	23188-23195	signals	_	
126-31	23196-23198	to	_	
126-32	23199-23207	positive	_	
126-33	23208-23216	feedback	_	
126-34	23217-23219	in	_	
126-35	23220-23223	ACC	_	
126-36	23223-23224	/	_	
126-37	23224-23228	mPFC	_	
126-38	23228-23229	,	_	
126-39	23230-23240	successful	_	
126-40	23241-23249	recovery	_	
126-41	23250-23253	was	_	
126-42	23254-23261	instead	_	
126-43	23262-23272	associated	_	
126-44	23273-23277	with	_	
126-45	23278-23287	reduction	_	
126-46	23288-23290	in	_	
126-47	23291-23292	a	_	
126-48	23293-23304	vmPFC-based	_	
126-49	23305-23319	reward-seeking	_	
126-50	23320-23326	signal	_	
126-51	23326-23327	.	_	

#Text=There was also evidence of overall increased signaling to high risk/reward 'Success' outcomes in caudal ACC and increased signaling to low risk/reward 'Explode' outcomes in IFG and caudal ACC from baseline to follow-up.
127-1	23328-23333	There	_	
127-2	23334-23337	was	_	
127-3	23338-23342	also	_	
127-4	23343-23351	evidence	_	
127-5	23352-23354	of	_	
127-6	23355-23362	overall	_	
127-7	23363-23372	increased	_	
127-8	23373-23382	signaling	_	
127-9	23383-23385	to	_	
127-10	23386-23390	high	_	
127-11	23391-23395	risk	_	
127-12	23395-23396	/	_	
127-13	23396-23402	reward	_	
127-14	23403-23404	'	_	
127-15	23404-23411	Success	_	
127-16	23411-23412	'	_	
127-17	23413-23421	outcomes	_	
127-18	23422-23424	in	_	
127-19	23425-23431	caudal	_	
127-20	23432-23435	ACC	_	
127-21	23436-23439	and	_	
127-22	23440-23449	increased	_	
127-23	23450-23459	signaling	_	
127-24	23460-23462	to	_	
127-25	23463-23466	low	_	
127-26	23467-23471	risk	_	
127-27	23471-23472	/	_	
127-28	23472-23478	reward	_	
127-29	23479-23480	'	_	
127-30	23480-23487	Explode	_	
127-31	23487-23488	'	_	
127-32	23489-23497	outcomes	_	
127-33	23498-23500	in	_	
127-34	23501-23504	IFG	_	
127-35	23505-23508	and	_	
127-36	23509-23515	caudal	_	
127-37	23516-23519	ACC	_	
127-38	23520-23524	from	_	
127-39	23525-23533	baseline	_	
127-40	23534-23536	to	_	
127-41	23537-23546	follow-up	_	
127-42	23546-23547	.	_	

#Text=These results may be consistent with an increased surprise signal to unexpected outcomes (i.e., high risk successes and low risk explosions) in recovery which may, in turn, reflect formation of stronger expectancies based on previous outcomes.
128-1	23548-23553	These	_	
128-2	23554-23561	results	_	
128-3	23562-23565	may	_	
128-4	23566-23568	be	_	
128-5	23569-23579	consistent	_	
128-6	23580-23584	with	_	
128-7	23585-23587	an	_	
128-8	23588-23597	increased	_	
128-9	23598-23606	surprise	_	
128-10	23607-23613	signal	_	
128-11	23614-23616	to	_	
128-12	23617-23627	unexpected	_	
128-13	23628-23636	outcomes	_	
128-14	23637-23638	(	_	
128-15	23638-23641	i.e	_	
128-16	23641-23642	.	_	
128-17	23642-23643	,	_	
128-18	23644-23648	high	_	
128-19	23649-23653	risk	_	
128-20	23654-23663	successes	_	
128-21	23664-23667	and	_	
128-22	23668-23671	low	_	
128-23	23672-23676	risk	_	
128-24	23677-23687	explosions	_	
128-25	23687-23688	)	_	
128-26	23689-23691	in	_	
128-27	23692-23700	recovery	_	
128-28	23701-23706	which	_	
128-29	23707-23710	may	_	
128-30	23710-23711	,	_	
128-31	23712-23714	in	_	
128-32	23715-23719	turn	_	
128-33	23719-23720	,	_	
128-34	23721-23728	reflect	_	
128-35	23729-23738	formation	_	
128-36	23739-23741	of	_	
128-37	23742-23750	stronger	_	
128-38	23751-23763	expectancies	_	
128-39	23764-23769	based	_	
128-40	23770-23772	on	_	
128-41	23773-23781	previous	_	
128-42	23782-23790	outcomes	_	
128-43	23790-23791	.	_	

#Text=However, we cannot exclude the possibility that this is a learning effect, unrelated to substance use recovery.
129-1	23792-23799	However	_	
129-2	23799-23800	,	_	
129-3	23801-23803	we	_	
129-4	23804-23810	cannot	_	
129-5	23811-23818	exclude	_	
129-6	23819-23822	the	_	
129-7	23823-23834	possibility	_	
129-8	23835-23839	that	_	
129-9	23840-23844	this	_	
129-10	23845-23847	is	_	
129-11	23848-23849	a	_	
129-12	23850-23858	learning	_	
129-13	23859-23865	effect	_	
129-14	23865-23866	,	_	
129-15	23867-23876	unrelated	_	
129-16	23877-23879	to	_	
129-17	23880-23889	substance	_	
129-18	23890-23893	use	_	
129-19	23894-23902	recovery	_	
129-20	23902-23903	.	_	

#Text=A longitudinal increase in the Redeem*p(Explode) parametric modulator was also noted in dorsal premotor cortex, consistent with greater internally-guided motor planning during safe responses in association with elevated risk/reward.
130-1	23904-23905	A	_	
130-2	23906-23918	longitudinal	_	
130-3	23919-23927	increase	_	
130-4	23928-23930	in	_	
130-5	23931-23934	the	_	
130-6	23935-23941	Redeem	_	
130-7	23941-23942	*	_	
130-8	23942-23943	p	_	
130-9	23943-23944	(	_	
130-10	23944-23951	Explode	_	
130-11	23951-23952	)	_	
130-12	23953-23963	parametric	_	
130-13	23964-23973	modulator	_	
130-14	23974-23977	was	_	
130-15	23978-23982	also	_	
130-16	23983-23988	noted	_	
130-17	23989-23991	in	_	
130-18	23992-23998	dorsal	_	
130-19	23999-24007	premotor	_	
130-20	24008-24014	cortex	_	
130-21	24014-24015	,	_	
130-22	24016-24026	consistent	_	
130-23	24027-24031	with	_	
130-24	24032-24039	greater	_	
130-25	24040-24057	internally-guided	_	
130-26	24058-24063	motor	_	
130-27	24064-24072	planning	_	
130-28	24073-24079	during	_	
130-29	24080-24084	safe	_	
130-30	24085-24094	responses	_	
130-31	24095-24097	in	_	
130-32	24098-24109	association	_	
130-33	24110-24114	with	_	
130-34	24115-24123	elevated	_	
130-35	24124-24128	risk	_	
130-36	24128-24129	/	_	
130-37	24129-24135	reward	_	
130-38	24135-24136	.	_	

#Text=With respect to correlational analyses, improved substance use outcomes were associated with a decreasing dACC/vmPFC response to increasing risk/reward during inflations at follow-up relative to baseline.
131-1	24137-24141	With	_	
131-2	24142-24149	respect	_	
131-3	24150-24152	to	_	
131-4	24153-24166	correlational	_	
131-5	24167-24175	analyses	_	
131-6	24175-24176	,	_	
131-7	24177-24185	improved	_	
131-8	24186-24195	substance	_	
131-9	24196-24199	use	_	
131-10	24200-24208	outcomes	_	
131-11	24209-24213	were	_	
131-12	24214-24224	associated	_	
131-13	24225-24229	with	_	
131-14	24230-24231	a	_	
131-15	24232-24242	decreasing	_	
131-16	24243-24247	dACC	_	
131-17	24247-24248	/	_	
131-18	24248-24253	vmPFC	_	
131-19	24254-24262	response	_	
131-20	24263-24265	to	_	
131-21	24266-24276	increasing	_	
131-22	24277-24281	risk	_	
131-23	24281-24282	/	_	
131-24	24282-24288	reward	_	
131-25	24289-24295	during	_	
131-26	24296-24306	inflations	_	
131-27	24307-24309	at	_	
131-28	24310-24319	follow-up	_	
131-29	24320-24328	relative	_	
131-30	24329-24331	to	_	
131-31	24332-24340	baseline	_	
131-32	24340-24341	.	_	

#Text=While not predicted from our previous work in substance users, these results suggest recovery-related attenuation of the vmPFC “reward-seeking” signal, previously described for healthy controls.
132-1	24342-24347	While	_	
132-2	24348-24351	not	_	
132-3	24352-24361	predicted	_	
132-4	24362-24366	from	_	
132-5	24367-24370	our	_	
132-6	24371-24379	previous	_	
132-7	24380-24384	work	_	
132-8	24385-24387	in	_	
132-9	24388-24397	substance	_	
132-10	24398-24403	users	_	
132-11	24403-24404	,	_	
132-12	24405-24410	these	_	
132-13	24411-24418	results	_	
132-14	24419-24426	suggest	_	
132-15	24427-24443	recovery-related	_	
132-16	24444-24455	attenuation	_	
132-17	24456-24458	of	_	
132-18	24459-24462	the	_	
132-19	24463-24468	vmPFC	_	
132-20	24469-24470	“	_	
132-21	24470-24484	reward-seeking	_	
132-22	24484-24485	”	_	
132-23	24486-24492	signal	_	
132-24	24492-24493	,	_	
132-25	24494-24504	previously	_	
132-26	24505-24514	described	_	
132-27	24515-24518	for	_	
132-28	24519-24526	healthy	_	
132-29	24527-24535	controls	_	
132-30	24535-24536	.	_	

#Text=Specifically, individuals with less reported substance use during the study interval exhibited less increasing vmPFC activation with increasing risk/reward at follow-up, while individuals with greater use demonstrated the opposite effect.
133-1	24537-24549	Specifically	_	
133-2	24549-24550	,	_	
133-3	24551-24562	individuals	_	
133-4	24563-24567	with	_	
133-5	24568-24572	less	_	
133-6	24573-24581	reported	_	
133-7	24582-24591	substance	_	
133-8	24592-24595	use	_	
133-9	24596-24602	during	_	
133-10	24603-24606	the	_	
133-11	24607-24612	study	_	
133-12	24613-24621	interval	_	
133-13	24622-24631	exhibited	_	
133-14	24632-24636	less	_	
133-15	24637-24647	increasing	_	
133-16	24648-24653	vmPFC	_	
133-17	24654-24664	activation	_	
133-18	24665-24669	with	_	
133-19	24670-24680	increasing	_	
133-20	24681-24685	risk	_	
133-21	24685-24686	/	_	
133-22	24686-24692	reward	_	
133-23	24693-24695	at	_	
133-24	24696-24705	follow-up	_	
133-25	24705-24706	,	_	
133-26	24707-24712	while	_	
133-27	24713-24724	individuals	_	
133-28	24725-24729	with	_	
133-29	24730-24737	greater	_	
133-30	24738-24741	use	_	
133-31	24742-24754	demonstrated	_	
133-32	24755-24758	the	_	
133-33	24759-24767	opposite	_	
133-34	24768-24774	effect	_	
133-35	24774-24775	.	_	

#Text=Longitudinal change in vmPFC-based “reward-seeking” was further demonstrated to correlate with BART mean stop inflation number at follow-up such that stronger attenuation corresponded with less risk-taking in the task.
134-1	24776-24788	Longitudinal	_	
134-2	24789-24795	change	_	
134-3	24796-24798	in	_	
134-4	24799-24810	vmPFC-based	_	
134-5	24811-24812	“	_	
134-6	24812-24826	reward-seeking	_	
134-7	24826-24827	”	_	
134-8	24828-24831	was	_	
134-9	24832-24839	further	_	
134-10	24840-24852	demonstrated	_	
134-11	24853-24855	to	_	
134-12	24856-24865	correlate	_	
134-13	24866-24870	with	_	
134-14	24871-24875	BART	_	
134-15	24876-24880	mean	_	
134-16	24881-24885	stop	_	
134-17	24886-24895	inflation	_	
134-18	24896-24902	number	_	
134-19	24903-24905	at	_	
134-20	24906-24915	follow-up	_	
134-21	24916-24920	such	_	
134-22	24921-24925	that	_	
134-23	24926-24934	stronger	_	
134-24	24935-24946	attenuation	_	
134-25	24947-24959	corresponded	_	
134-26	24960-24964	with	_	
134-27	24965-24969	less	_	
134-28	24970-24981	risk-taking	_	
134-29	24982-24984	in	_	
134-30	24985-24988	the	_	
134-31	24989-24993	task	_	
134-32	24993-24994	.	_	

#Text=With respect to longitudinal effects that did not correlate with substance use outcomes, we cannot exclude that our results reflect learning or practice effects.
135-1	24995-24999	With	_	
135-2	25000-25007	respect	_	
135-3	25008-25010	to	_	
135-4	25011-25023	longitudinal	_	
135-5	25024-25031	effects	_	
135-6	25032-25036	that	_	
135-7	25037-25040	did	_	
135-8	25041-25044	not	_	
135-9	25045-25054	correlate	_	
135-10	25055-25059	with	_	
135-11	25060-25069	substance	_	
135-12	25070-25073	use	_	
135-13	25074-25082	outcomes	_	
135-14	25082-25083	,	_	
135-15	25084-25086	we	_	
135-16	25087-25093	cannot	_	
135-17	25094-25101	exclude	_	
135-18	25102-25106	that	_	
135-19	25107-25110	our	_	
135-20	25111-25118	results	_	
135-21	25119-25126	reflect	_	
135-22	25127-25135	learning	_	
135-23	25136-25138	or	_	
135-24	25139-25147	practice	_	
135-25	25148-25155	effects	_	
135-26	25155-25156	.	_	

#Text=However, consistent decision-making performance within and across timepoints may suggest against this interpretation.
136-1	25157-25164	However	_	
136-2	25164-25165	,	_	
136-3	25166-25176	consistent	_	
136-4	25177-25192	decision-making	_	
136-5	25193-25204	performance	_	
136-6	25205-25211	within	_	
136-7	25212-25215	and	_	
136-8	25216-25222	across	_	
136-9	25223-25233	timepoints	_	
136-10	25234-25237	may	_	
136-11	25238-25245	suggest	_	
136-12	25246-25253	against	_	
136-13	25254-25258	this	_	
136-14	25259-25273	interpretation	_	
136-15	25273-25274	.	_	

#Text=In addition, participants were informed that the risk of explosion increased with the number of inflations and did not need to learn this through trial-and-error.
137-1	25275-25277	In	_	
137-2	25278-25286	addition	_	
137-3	25286-25287	,	_	
137-4	25288-25300	participants	_	
137-5	25301-25305	were	_	
137-6	25306-25314	informed	_	
137-7	25315-25319	that	_	
137-8	25320-25323	the	_	
137-9	25324-25328	risk	_	
137-10	25329-25331	of	_	
137-11	25332-25341	explosion	_	
137-12	25342-25351	increased	_	
137-13	25352-25356	with	_	
137-14	25357-25360	the	_	
137-15	25361-25367	number	_	
137-16	25368-25370	of	_	
137-17	25371-25381	inflations	_	
137-18	25382-25385	and	_	
137-19	25386-25389	did	_	
137-20	25390-25393	not	_	
137-21	25394-25398	need	_	
137-22	25399-25401	to	_	
137-23	25402-25407	learn	_	
137-24	25408-25412	this	_	
137-25	25413-25420	through	_	
137-26	25421-25436	trial-and-error	_	
137-27	25436-25437	.	_	

#Text=The established test-retest reliability of the BART also suggests rapid stabilization of performance in new task-learners – although with respect to the original behavioral paradigm rather than the modified version used herein.
138-1	25438-25441	The	_	
138-2	25442-25453	established	_	
138-3	25454-25465	test-retest	_	
138-4	25466-25477	reliability	_	
138-5	25478-25480	of	_	
138-6	25481-25484	the	_	
138-7	25485-25489	BART	_	
138-8	25490-25494	also	_	
138-9	25495-25503	suggests	_	
138-10	25504-25509	rapid	_	
138-11	25510-25523	stabilization	_	
138-12	25524-25526	of	_	
138-13	25527-25538	performance	_	
138-14	25539-25541	in	_	
138-15	25542-25545	new	_	
138-16	25546-25559	task-learners	_	
138-17	25560-25561	–	_	
138-18	25562-25570	although	_	
138-19	25571-25575	with	_	
138-20	25576-25583	respect	_	
138-21	25584-25586	to	_	
138-22	25587-25590	the	_	
138-23	25591-25599	original	_	
138-24	25600-25610	behavioral	_	
138-25	25611-25619	paradigm	_	
138-26	25620-25626	rather	_	
138-27	25627-25631	than	_	
138-28	25632-25635	the	_	
138-29	25636-25644	modified	_	
138-30	25645-25652	version	_	
138-31	25653-25657	used	_	
138-32	25658-25664	herein	_	
138-33	25664-25665	.	_	

#Text=While hypotheses based on were not directly supported in the current study, the sample studied by Bogg et al. was comprised of non-treatment-seeking undergraduate students (ranging from modest alcohol users to heavy drinkers) and is appreciably different from the clinical sample of treatment-seeking SDIs reported herein.
139-1	25666-25671	While	_	
139-2	25672-25682	hypotheses	_	
139-3	25683-25688	based	_	
139-4	25689-25691	on	_	
139-5	25692-25696	were	_	
139-6	25697-25700	not	_	
139-7	25701-25709	directly	_	
139-8	25710-25719	supported	_	
139-9	25720-25722	in	_	
139-10	25723-25726	the	_	
139-11	25727-25734	current	_	
139-12	25735-25740	study	_	
139-13	25740-25741	,	_	
139-14	25742-25745	the	_	
139-15	25746-25752	sample	_	
139-16	25753-25760	studied	_	
139-17	25761-25763	by	_	
139-18	25764-25768	Bogg	_	
139-19	25769-25771	et	_	
139-20	25772-25774	al	_	
139-21	25774-25775	.	_	
139-22	25776-25779	was	_	
139-23	25780-25789	comprised	_	
139-24	25790-25792	of	_	
139-25	25793-25814	non-treatment-seeking	_	
139-26	25815-25828	undergraduate	_	
139-27	25829-25837	students	_	
139-28	25838-25839	(	_	
139-29	25839-25846	ranging	_	
139-30	25847-25851	from	_	
139-31	25852-25858	modest	_	
139-32	25859-25866	alcohol	_	
139-33	25867-25872	users	_	
139-34	25873-25875	to	_	
139-35	25876-25881	heavy	_	
139-36	25882-25890	drinkers	_	
139-37	25890-25891	)	_	
139-38	25892-25895	and	_	
139-39	25896-25898	is	_	
139-40	25899-25910	appreciably	_	
139-41	25911-25920	different	_	
139-42	25921-25925	from	_	
139-43	25926-25929	the	_	
139-44	25930-25938	clinical	_	
139-45	25939-25945	sample	_	
139-46	25946-25948	of	_	
139-47	25949-25966	treatment-seeking	_	
139-48	25967-25971	SDIs	_	
139-49	25972-25980	reported	_	
139-50	25981-25987	herein	_	
139-51	25987-25988	.	_	

#Text=Importantly, Bogg et al. reported reduced risk-seeking in the BART (lower mean stop inflation number) in association with both greater alcohol use and reduced ACC/mPFC signaling to increasing risk/reward.
140-1	25989-26000	Importantly	_	
140-2	26000-26001	,	_	
140-3	26002-26006	Bogg	_	
140-4	26007-26009	et	_	
140-5	26010-26012	al	_	
140-6	26012-26013	.	_	
140-7	26014-26022	reported	_	
140-8	26023-26030	reduced	_	
140-9	26031-26043	risk-seeking	_	
140-10	26044-26046	in	_	
140-11	26047-26050	the	_	
140-12	26051-26055	BART	_	
140-13	26056-26057	(	_	
140-14	26057-26062	lower	_	
140-15	26063-26067	mean	_	
140-16	26068-26072	stop	_	
140-17	26073-26082	inflation	_	
140-18	26083-26089	number	_	
140-19	26089-26090	)	_	
140-20	26091-26093	in	_	
140-21	26094-26105	association	_	
140-22	26106-26110	with	_	
140-23	26111-26115	both	_	
140-24	26116-26123	greater	_	
140-25	26124-26131	alcohol	_	
140-26	26132-26135	use	_	
140-27	26136-26139	and	_	
140-28	26140-26147	reduced	_	
140-29	26148-26151	ACC	_	
140-30	26151-26152	/	_	
140-31	26152-26156	mPFC	_	
140-32	26157-26166	signaling	_	
140-33	26167-26169	to	_	
140-34	26170-26180	increasing	_	
140-35	26181-26185	risk	_	
140-36	26185-26186	/	_	
140-37	26186-26192	reward	_	
140-38	26192-26193	.	_	

#Text=This paradoxical finding suggests that heavy substance using undergraduates are “loss averse reward takers” who perform more cautiously because cognitive deficits impede their exploration and use of learned task contingencies to optimize performance.
141-1	26194-26198	This	_	
141-2	26199-26210	paradoxical	_	
141-3	26211-26218	finding	_	
141-4	26219-26227	suggests	_	
141-5	26228-26232	that	_	
141-6	26233-26238	heavy	_	
141-7	26239-26248	substance	_	
141-8	26249-26254	using	_	
141-9	26255-26269	undergraduates	_	
141-10	26270-26273	are	_	
141-11	26274-26275	“	_	
141-12	26275-26279	loss	_	
141-13	26280-26286	averse	_	
141-14	26287-26293	reward	_	
141-15	26294-26300	takers	_	
141-16	26300-26301	”	_	
141-17	26302-26305	who	_	
141-18	26306-26313	perform	_	
141-19	26314-26318	more	_	
141-20	26319-26329	cautiously	_	
141-21	26330-26337	because	_	
141-22	26338-26347	cognitive	_	
141-23	26348-26356	deficits	_	
141-24	26357-26363	impede	_	
141-25	26364-26369	their	_	
141-26	26370-26381	exploration	_	
141-27	26382-26385	and	_	
141-28	26386-26389	use	_	
141-29	26390-26392	of	_	
141-30	26393-26400	learned	_	
141-31	26401-26405	task	_	
141-32	26406-26419	contingencies	_	
141-33	26420-26422	to	_	
141-34	26423-26431	optimize	_	
141-35	26432-26443	performance	_	
141-36	26443-26444	.	_	

#Text=In the present study, however, an increased vmPFC “reward-seeking” signal was associated with greater risk-taking in the BART at follow-up and greater substance use during early recovery, consistent with high risk, reward-seeking rather than “loss averse reward taking.”
142-1	26445-26447	In	_	
142-2	26448-26451	the	_	
142-3	26452-26459	present	_	
142-4	26460-26465	study	_	
142-5	26465-26466	,	_	
142-6	26467-26474	however	_	
142-7	26474-26475	,	_	
142-8	26476-26478	an	_	
142-9	26479-26488	increased	_	
142-10	26489-26494	vmPFC	_	
142-11	26495-26496	“	_	
142-12	26496-26510	reward-seeking	_	
142-13	26510-26511	”	_	
142-14	26512-26518	signal	_	
142-15	26519-26522	was	_	
142-16	26523-26533	associated	_	
142-17	26534-26538	with	_	
142-18	26539-26546	greater	_	
142-19	26547-26558	risk-taking	_	
142-20	26559-26561	in	_	
142-21	26562-26565	the	_	
142-22	26566-26570	BART	_	
142-23	26571-26573	at	_	
142-24	26574-26583	follow-up	_	
142-25	26584-26587	and	_	
142-26	26588-26595	greater	_	
142-27	26596-26605	substance	_	
142-28	26606-26609	use	_	
142-29	26610-26616	during	_	
142-30	26617-26622	early	_	
142-31	26623-26631	recovery	_	
142-32	26631-26632	,	_	
142-33	26633-26643	consistent	_	
142-34	26644-26648	with	_	
142-35	26649-26653	high	_	
142-36	26654-26658	risk	_	
142-37	26658-26659	,	_	
142-38	26660-26674	reward-seeking	_	
142-39	26675-26681	rather	_	
142-40	26682-26686	than	_	
142-41	26687-26688	“	_	
142-42	26688-26692	loss	_	
142-43	26693-26699	averse	_	
142-44	26700-26706	reward	_	
142-45	26707-26713	taking	_	
142-46	26713-26714	.	_	
142-47	26714-26715	”	_	

#Text=Unfortunately, BART brain-behavior relationships cannot be conclusively targeted herein because we lack healthy and/or non-treatment-seeking comparison groups.
143-1	26716-26729	Unfortunately	_	
143-2	26729-26730	,	_	
143-3	26731-26735	BART	_	
143-4	26736-26750	brain-behavior	_	
143-5	26751-26764	relationships	_	
143-6	26765-26771	cannot	_	
143-7	26772-26774	be	_	
143-8	26775-26787	conclusively	_	
143-9	26788-26796	targeted	_	
143-10	26797-26803	herein	_	
143-11	26804-26811	because	_	
143-12	26812-26814	we	_	
143-13	26815-26819	lack	_	
143-14	26820-26827	healthy	_	
143-15	26828-26831	and	_	
143-16	26831-26832	/	_	
143-17	26832-26834	or	_	
143-18	26835-26856	non-treatment-seeking	_	
143-19	26857-26867	comparison	_	
143-20	26868-26874	groups	_	
143-21	26874-26875	.	_	

#Text=We must also defer potentially interesting questions regarding specific SUDs due to our modest sample size and high rate of substance use comorbidity.
144-1	26876-26878	We	_	
144-2	26879-26883	must	_	
144-3	26884-26888	also	_	
144-4	26889-26894	defer	_	
144-5	26895-26906	potentially	_	
144-6	26907-26918	interesting	_	
144-7	26919-26928	questions	_	
144-8	26929-26938	regarding	_	
144-9	26939-26947	specific	_	
144-10	26948-26952	SUDs	_	
144-11	26953-26956	due	_	
144-12	26957-26959	to	_	
144-13	26960-26963	our	_	
144-14	26964-26970	modest	_	
144-15	26971-26977	sample	_	
144-16	26978-26982	size	_	
144-17	26983-26986	and	_	
144-18	26987-26991	high	_	
144-19	26992-26996	rate	_	
144-20	26997-26999	of	_	
144-21	27000-27009	substance	_	
144-22	27010-27013	use	_	
144-23	27014-27025	comorbidity	_	
144-24	27025-27026	.	_	

#Text=While a limitation of the current study, a mixed substance use sample was used in a previous study of longitudinal change in recovery.
145-1	27027-27032	While	_	
145-2	27033-27034	a	_	
145-3	27035-27045	limitation	_	
145-4	27046-27048	of	_	
145-5	27049-27052	the	_	
145-6	27053-27060	current	_	
145-7	27061-27066	study	_	
145-8	27066-27067	,	_	
145-9	27068-27069	a	_	
145-10	27070-27075	mixed	_	
145-11	27076-27085	substance	_	
145-12	27086-27089	use	_	
145-13	27090-27096	sample	_	
145-14	27097-27100	was	_	
145-15	27101-27105	used	_	
145-16	27106-27108	in	_	
145-17	27109-27110	a	_	
145-18	27111-27119	previous	_	
145-19	27120-27125	study	_	
145-20	27126-27128	of	_	
145-21	27129-27141	longitudinal	_	
145-22	27142-27148	change	_	
145-23	27149-27151	in	_	
145-24	27152-27160	recovery	_	
145-25	27160-27161	.	_	

#Text=These findings, taken together with our own, support common mechanisms of recovery across SUDs.
146-1	27162-27167	These	_	
146-2	27168-27176	findings	_	
146-3	27176-27177	,	_	
146-4	27178-27183	taken	_	
146-5	27184-27192	together	_	
146-6	27193-27197	with	_	
146-7	27198-27201	our	_	
146-8	27202-27205	own	_	
146-9	27205-27206	,	_	
146-10	27207-27214	support	_	
146-11	27215-27221	common	_	
146-12	27222-27232	mechanisms	_	
146-13	27233-27235	of	_	
146-14	27236-27244	recovery	_	
146-15	27245-27251	across	_	
146-16	27252-27256	SUDs	_	
146-17	27256-27257	.	_	

#Text=Differences in recovery-related neuroadaptation may also arise between outpatient versus residential treatment programs.
147-1	27258-27269	Differences	_	
147-2	27270-27272	in	_	
147-3	27273-27289	recovery-related	_	
147-4	27290-27305	neuroadaptation	_	
147-5	27306-27309	may	_	
147-6	27310-27314	also	_	
147-7	27315-27320	arise	_	
147-8	27321-27328	between	_	
147-9	27329-27339	outpatient	_	
147-10	27340-27346	versus	_	
147-11	27347-27358	residential	_	
147-12	27359-27368	treatment	_	
147-13	27369-27377	programs	_	
147-14	27377-27378	.	_	

#Text=Here, our small sample size and inability to reliably track treatment attendance/compliance precludes examination of this factor.
148-1	27379-27383	Here	_	
148-2	27383-27384	,	_	
148-3	27385-27388	our	_	
148-4	27389-27394	small	_	
148-5	27395-27401	sample	_	
148-6	27402-27406	size	_	
148-7	27407-27410	and	_	
148-8	27411-27420	inability	_	
148-9	27421-27423	to	_	
148-10	27424-27432	reliably	_	
148-11	27433-27438	track	_	
148-12	27439-27448	treatment	_	
148-13	27449-27459	attendance	_	
148-14	27459-27460	/	_	
148-15	27460-27470	compliance	_	
148-16	27471-27480	precludes	_	
148-17	27481-27492	examination	_	
148-18	27493-27495	of	_	
148-19	27496-27500	this	_	
148-20	27501-27507	factor	_	
148-21	27507-27508	.	_	

#Text=We also note that our utilization of self-report to track substance use is suboptimal – although participants were educated about the importance of providing accurate data and did not stand to benefit from providing a false report.
149-1	27509-27511	We	_	
149-2	27512-27516	also	_	
149-3	27517-27521	note	_	
149-4	27522-27526	that	_	
149-5	27527-27530	our	_	
149-6	27531-27542	utilization	_	
149-7	27543-27545	of	_	
149-8	27546-27557	self-report	_	
149-9	27558-27560	to	_	
149-10	27561-27566	track	_	
149-11	27567-27576	substance	_	
149-12	27577-27580	use	_	
149-13	27581-27583	is	_	
149-14	27584-27594	suboptimal	_	
149-15	27595-27596	–	_	
149-16	27597-27605	although	_	
149-17	27606-27618	participants	_	
149-18	27619-27623	were	_	
149-19	27624-27632	educated	_	
149-20	27633-27638	about	_	
149-21	27639-27642	the	_	
149-22	27643-27653	importance	_	
149-23	27654-27656	of	_	
149-24	27657-27666	providing	_	
149-25	27667-27675	accurate	_	
149-26	27676-27680	data	_	
149-27	27681-27684	and	_	
149-28	27685-27688	did	_	
149-29	27689-27692	not	_	
149-30	27693-27698	stand	_	
149-31	27699-27701	to	_	
149-32	27702-27709	benefit	_	
149-33	27710-27714	from	_	
149-34	27715-27724	providing	_	
149-35	27725-27726	a	_	
149-36	27727-27732	false	_	
149-37	27733-27739	report	_	
149-38	27739-27740	.	_	

#Text=Recent findings suggest that neural signatures present at the time of treatment engagement can predict substance use treatment outcomes.
150-1	27741-27747	Recent	_	
150-2	27748-27756	findings	_	
150-3	27757-27764	suggest	_	
150-4	27765-27769	that	_	
150-5	27770-27776	neural	_	
150-6	27777-27787	signatures	_	
150-7	27788-27795	present	_	
150-8	27796-27798	at	_	
150-9	27799-27802	the	_	
150-10	27803-27807	time	_	
150-11	27808-27810	of	_	
150-12	27811-27820	treatment	_	
150-13	27821-27831	engagement	_	
150-14	27832-27835	can	_	
150-15	27836-27843	predict	_	
150-16	27844-27853	substance	_	
150-17	27854-27857	use	_	
150-18	27858-27867	treatment	_	
150-19	27868-27876	outcomes	_	
150-20	27876-27877	.	_	

#Text=For example, brain signals associated with aberrant cue and reward processing, diminished control-related signaling and impaired decision-making have been implicated in subsequent relapse risk.
151-1	27878-27881	For	_	
151-2	27882-27889	example	_	
151-3	27889-27890	,	_	
151-4	27891-27896	brain	_	
151-5	27897-27904	signals	_	
151-6	27905-27915	associated	_	
151-7	27916-27920	with	_	
151-8	27921-27929	aberrant	_	
151-9	27930-27933	cue	_	
151-10	27934-27937	and	_	
151-11	27938-27944	reward	_	
151-12	27945-27955	processing	_	
151-13	27955-27956	,	_	
151-14	27957-27967	diminished	_	
151-15	27968-27983	control-related	_	
151-16	27984-27993	signaling	_	
151-17	27994-27997	and	_	
151-18	27998-28006	impaired	_	
151-19	28007-28022	decision-making	_	
151-20	28023-28027	have	_	
151-21	28028-28032	been	_	
151-22	28033-28043	implicated	_	
151-23	28044-28046	in	_	
151-24	28047-28057	subsequent	_	
151-25	28058-28065	relapse	_	
151-26	28066-28070	risk	_	
151-27	28070-28071	.	_	

#Text=However, there is also accumulating evidence that cognitive functioning is partially restored across multiple domains during early recovery including improved cognitive control and reduced risky decision-making.
152-1	28072-28079	However	_	
152-2	28079-28080	,	_	
152-3	28081-28086	there	_	
152-4	28087-28089	is	_	
152-5	28090-28094	also	_	
152-6	28095-28107	accumulating	_	
152-7	28108-28116	evidence	_	
152-8	28117-28121	that	_	
152-9	28122-28131	cognitive	_	
152-10	28132-28143	functioning	_	
152-11	28144-28146	is	_	
152-12	28147-28156	partially	_	
152-13	28157-28165	restored	_	
152-14	28166-28172	across	_	
152-15	28173-28181	multiple	_	
152-16	28182-28189	domains	_	
152-17	28190-28196	during	_	
152-18	28197-28202	early	_	
152-19	28203-28211	recovery	_	
152-20	28212-28221	including	_	
152-21	28222-28230	improved	_	
152-22	28231-28240	cognitive	_	
152-23	28241-28248	control	_	
152-24	28249-28252	and	_	
152-25	28253-28260	reduced	_	
152-26	28261-28266	risky	_	
152-27	28267-28282	decision-making	_	
152-28	28282-28283	.	_	

#Text=The current findings suggest that reduced reward-seeking during early recovery (which may reflect improved cognitive control) may represent a protective factor against relapse.
153-1	28284-28287	The	_	
153-2	28288-28295	current	_	
153-3	28296-28304	findings	_	
153-4	28305-28312	suggest	_	
153-5	28313-28317	that	_	
153-6	28318-28325	reduced	_	
153-7	28326-28340	reward-seeking	_	
153-8	28341-28347	during	_	
153-9	28348-28353	early	_	
153-10	28354-28362	recovery	_	
153-11	28363-28364	(	_	
153-12	28364-28369	which	_	
153-13	28370-28373	may	_	
153-14	28374-28381	reflect	_	
153-15	28382-28390	improved	_	
153-16	28391-28400	cognitive	_	
153-17	28401-28408	control	_	
153-18	28408-28409	)	_	
153-19	28410-28413	may	_	
153-20	28414-28423	represent	_	
153-21	28424-28425	a	_	
153-22	28426-28436	protective	_	
153-23	28437-28443	factor	_	
153-24	28444-28451	against	_	
153-25	28452-28459	relapse	_	
153-26	28459-28460	.	_	

#Text=While preliminary, our findings suggest that change in contextually-informed, neural representations of risk/reward during decision-making may support reduced risk-taking and continued abstinence.
154-1	28461-28466	While	_	
154-2	28467-28478	preliminary	_	
154-3	28478-28479	,	_	
154-4	28480-28483	our	_	
154-5	28484-28492	findings	_	
154-6	28493-28500	suggest	_	
154-7	28501-28505	that	_	
154-8	28506-28512	change	_	
154-9	28513-28515	in	_	
154-10	28516-28537	contextually-informed	_	
154-11	28537-28538	,	_	
154-12	28539-28545	neural	_	
154-13	28546-28561	representations	_	
154-14	28562-28564	of	_	
154-15	28565-28569	risk	_	
154-16	28569-28570	/	_	
154-17	28570-28576	reward	_	
154-18	28577-28583	during	_	
154-19	28584-28599	decision-making	_	
154-20	28600-28603	may	_	
154-21	28604-28611	support	_	
154-22	28612-28619	reduced	_	
154-23	28620-28631	risk-taking	_	
154-24	28632-28635	and	_	
154-25	28636-28645	continued	_	
154-26	28646-28656	abstinence	_	
154-27	28656-28657	.	_	

#Text=Interventions that promote such recovery may thus improve treatment outcomes in those most susceptible to relapse.
155-1	28658-28671	Interventions	_	
155-2	28672-28676	that	_	
155-3	28677-28684	promote	_	
155-4	28685-28689	such	_	
155-5	28690-28698	recovery	_	
155-6	28699-28702	may	_	
155-7	28703-28707	thus	_	
155-8	28708-28715	improve	_	
155-9	28716-28725	treatment	_	
155-10	28726-28734	outcomes	_	
155-11	28735-28737	in	_	
155-12	28738-28743	those	_	
155-13	28744-28748	most	_	
155-14	28749-28760	susceptible	_	
155-15	28761-28763	to	_	
155-16	28764-28771	relapse	_	
155-17	28771-28772	.	_	

#Text=To our knowledge, the current findings represent the first evidence of recovery in context-dependent modulations of brain activity that may inform risk appraisal and decision-making.
156-1	28773-28775	To	_	
156-2	28776-28779	our	_	
156-3	28780-28789	knowledge	_	
156-4	28789-28790	,	_	
156-5	28791-28794	the	_	
156-6	28795-28802	current	_	
156-7	28803-28811	findings	_	
156-8	28812-28821	represent	_	
156-9	28822-28825	the	_	
156-10	28826-28831	first	_	
156-11	28832-28840	evidence	_	
156-12	28841-28843	of	_	
156-13	28844-28852	recovery	_	
156-14	28853-28855	in	_	
156-15	28856-28873	context-dependent	_	
156-16	28874-28885	modulations	_	
156-17	28886-28888	of	_	
156-18	28889-28894	brain	_	
156-19	28895-28903	activity	_	
156-20	28904-28908	that	_	
156-21	28909-28912	may	_	
156-22	28913-28919	inform	_	
156-23	28920-28924	risk	_	
156-24	28925-28934	appraisal	_	
156-25	28935-28938	and	_	
156-26	28939-28954	decision-making	_	
156-27	28954-28955	.	_	

#Text=The current study adds to limited extant research into neuroadaptive processes that may benefit early recovery from SUDs.
157-1	28956-28959	The	_	
157-2	28960-28967	current	_	
157-3	28968-28973	study	_	
157-4	28974-28978	adds	_	
157-5	28979-28981	to	_	
157-6	28982-28989	limited	_	
157-7	28990-28996	extant	_	
157-8	28997-29005	research	_	
157-9	29006-29010	into	_	
157-10	29011-29024	neuroadaptive	_	
157-11	29025-29034	processes	_	
157-12	29035-29039	that	_	
157-13	29040-29043	may	_	
157-14	29044-29051	benefit	_	
157-15	29052-29057	early	_	
157-16	29058-29066	recovery	_	
157-17	29067-29071	from	_	
157-18	29072-29076	SUDs	_	
157-19	29076-29077	.	_	

#Text=Supplementary Material
#Text=Conflict of interest statement No conflict declared.
158-1	29078-29091	Supplementary	_	
158-2	29092-29100	Material	_	
158-3	29101-29109	Conflict	_	
158-4	29110-29112	of	_	
158-5	29113-29121	interest	_	
158-6	29122-29131	statement	_	
158-7	29132-29134	No	_	
158-8	29135-29143	conflict	_	
158-9	29144-29152	declared	_	
158-10	29152-29153	.	_	

#Text=Contributors PRF, JWB, and SEF were responsible for the study design and concept.
159-1	29154-29166	Contributors	_	
159-2	29167-29170	PRF	_	
159-3	29170-29171	,	_	
159-4	29172-29175	JWB	_	
159-5	29175-29176	,	_	
159-6	29177-29180	and	_	
159-7	29181-29184	SEF	_	
159-8	29185-29189	were	_	
159-9	29190-29201	responsible	_	
159-10	29202-29205	for	_	
159-11	29206-29209	the	_	
159-12	29210-29215	study	_	
159-13	29216-29222	design	_	
159-14	29223-29226	and	_	
159-15	29227-29234	concept	_	
159-16	29234-29235	.	_	

#Text=SEF performed all data preprocessing and analysis.
160-1	29236-29239	SEF	_	
160-2	29240-29249	performed	_	
160-3	29250-29253	all	_	
160-4	29254-29258	data	_	
160-5	29259-29272	preprocessing	_	
160-6	29273-29276	and	_	
160-7	29277-29285	analysis	_	
160-8	29285-29286	.	_	

#Text=SEF, JWB, and PRF contributed to the interpretation of results.
161-1	29287-29290	SEF	_	
161-2	29290-29291	,	_	
161-3	29292-29295	JWB	_	
161-4	29295-29296	,	_	
161-5	29297-29300	and	_	
161-6	29301-29304	PRF	_	
161-7	29305-29316	contributed	_	
161-8	29317-29319	to	_	
161-9	29320-29323	the	_	
161-10	29324-29338	interpretation	_	
161-11	29339-29341	of	_	
161-12	29342-29349	results	_	
161-13	29349-29350	.	_	

#Text=SEF drafted the manuscript.
162-1	29351-29354	SEF	_	
162-2	29355-29362	drafted	_	
162-3	29363-29366	the	_	
162-4	29367-29377	manuscript	_	
162-5	29377-29378	.	_	

#Text=SEF, JWB, and PRF participated in revision of the manuscript.
163-1	29379-29382	SEF	_	
163-2	29382-29383	,	_	
163-3	29384-29387	JWB	_	
163-4	29387-29388	,	_	
163-5	29389-29392	and	_	
163-6	29393-29396	PRF	_	
163-7	29397-29409	participated	_	
163-8	29410-29412	in	_	
163-9	29413-29421	revision	_	
163-10	29422-29424	of	_	
163-11	29425-29428	the	_	
163-12	29429-29439	manuscript	_	
163-13	29439-29440	.	_	

#Text=All authors critically reviewed content and approved the final version for publication.
164-1	29441-29444	All	_	
164-2	29445-29452	authors	_	
164-3	29453-29463	critically	_	
164-4	29464-29472	reviewed	_	
164-5	29473-29480	content	_	
164-6	29481-29484	and	_	
164-7	29485-29493	approved	_	
164-8	29494-29497	the	_	
164-9	29498-29503	final	_	
164-10	29504-29511	version	_	
164-11	29512-29515	for	_	
164-12	29516-29527	publication	_	
164-13	29527-29528	.	_	

#Text=SEF had full access to all the data in the study and takes responsibility for the integrity of data and the accuracy of the data analysis.
165-1	29529-29532	SEF	_	
165-2	29533-29536	had	_	
165-3	29537-29541	full	_	
165-4	29542-29548	access	_	
165-5	29549-29551	to	_	
165-6	29552-29555	all	_	
165-7	29556-29559	the	_	
165-8	29560-29564	data	_	
165-9	29565-29567	in	_	
165-10	29568-29571	the	_	
165-11	29572-29577	study	_	
165-12	29578-29581	and	_	
165-13	29582-29587	takes	_	
165-14	29588-29602	responsibility	_	
165-15	29603-29606	for	_	
165-16	29607-29610	the	_	
165-17	29611-29620	integrity	_	
165-18	29621-29623	of	_	
165-19	29624-29628	data	_	
165-20	29629-29632	and	_	
165-21	29633-29636	the	_	
165-22	29637-29645	accuracy	_	
165-23	29646-29648	of	_	
165-24	29649-29652	the	_	
165-25	29653-29657	data	_	
165-26	29658-29666	analysis	_	
165-27	29666-29667	.	_	

#Text=Appendix A.
166-1	29668-29676	Appendix	_	
166-2	29677-29678	A	_	
166-3	29678-29679	.	_	

#Text=Supplementary data Supplementary data associated with this article can be found, in the online version, at http://dx.doi.org/10.1016/j.drugalcdep.2016.08.626.
167-1	29680-29693	Supplementary	_	
167-2	29694-29698	data	_	
167-3	29699-29712	Supplementary	_	
167-4	29713-29717	data	_	
167-5	29718-29728	associated	_	
167-6	29729-29733	with	_	
167-7	29734-29738	this	_	
167-8	29739-29746	article	_	
167-9	29747-29750	can	_	
167-10	29751-29753	be	_	
167-11	29754-29759	found	_	
167-12	29759-29760	,	_	
167-13	29761-29763	in	_	
167-14	29764-29767	the	_	
167-15	29768-29774	online	_	
167-16	29775-29782	version	_	
167-17	29782-29783	,	_	
167-18	29784-29786	at	_	
167-19	29787-29791	http	_	
167-20	29791-29792	:	_	
167-21	29792-29793	/	_	
167-22	29793-29794	/	_	
167-23	29794-29804	dx.doi.org	_	
167-24	29804-29805	/	_	
167-25	29805-29812	10.1016	_	
167-26	29812-29813	/	_	
167-27	29813-29825	j.drugalcdep	_	
167-28	29825-29837	.2016.08.626	_	
167-29	29837-29838	.	_	

#Text=A substance use metric (SUM) was computed to differentially weight excessive or uncontrolled use resulting in intoxication (e.g., relapse) versus less serious use without intoxication (e.g., slip) using the following formula: [Days Alcohol Used without Intoxication + 2*(Days Alcohol Used with Intoxication) + days Drugs Used without Intoxication + 2*(Days Drugs Used with Intoxication)]/4*Total Days (See Supplementary materials for additional information.)
168-1	29839-29840	A	_	
168-2	29841-29850	substance	_	
168-3	29851-29854	use	_	
168-4	29855-29861	metric	_	
168-5	29862-29863	(	_	
168-6	29863-29866	SUM	_	
168-7	29866-29867	)	_	
168-8	29868-29871	was	_	
168-9	29872-29880	computed	_	
168-10	29881-29883	to	_	
168-11	29884-29898	differentially	_	
168-12	29899-29905	weight	_	
168-13	29906-29915	excessive	_	
168-14	29916-29918	or	_	
168-15	29919-29931	uncontrolled	_	
168-16	29932-29935	use	_	
168-17	29936-29945	resulting	_	
168-18	29946-29948	in	_	
168-19	29949-29961	intoxication	_	
168-20	29962-29963	(	_	
168-21	29963-29966	e.g	_	
168-22	29966-29967	.	_	
168-23	29967-29968	,	_	
168-24	29969-29976	relapse	_	
168-25	29976-29977	)	_	
168-26	29978-29984	versus	_	
168-27	29985-29989	less	_	
168-28	29990-29997	serious	_	
168-29	29998-30001	use	_	
168-30	30002-30009	without	_	
168-31	30010-30022	intoxication	_	
168-32	30023-30024	(	_	
168-33	30024-30027	e.g	_	
168-34	30027-30028	.	_	
168-35	30028-30029	,	_	
168-36	30030-30034	slip	_	
168-37	30034-30035	)	_	
168-38	30036-30041	using	_	
168-39	30042-30045	the	_	
168-40	30046-30055	following	_	
168-41	30056-30063	formula	_	
168-42	30063-30064	:	_	
168-43	30065-30066	[	_	
168-44	30066-30070	Days	_	
168-45	30071-30078	Alcohol	_	
168-46	30079-30083	Used	_	
168-47	30084-30091	without	_	
168-48	30092-30104	Intoxication	_	
168-49	30105-30106	+	_	
168-50	30107-30108	2	_	
168-51	30108-30109	*	_	
168-52	30109-30110	(	_	
168-53	30110-30114	Days	_	
168-54	30115-30122	Alcohol	_	
168-55	30123-30127	Used	_	
168-56	30128-30132	with	_	
168-57	30133-30145	Intoxication	_	
168-58	30145-30146	)	_	
168-59	30147-30148	+	_	
168-60	30149-30153	days	_	
168-61	30154-30159	Drugs	_	
168-62	30160-30164	Used	_	
168-63	30165-30172	without	_	
168-64	30173-30185	Intoxication	_	
168-65	30186-30187	+	_	
168-66	30188-30189	2	_	
168-67	30189-30190	*	_	
168-68	30190-30191	(	_	
168-69	30191-30195	Days	_	
168-70	30196-30201	Drugs	_	
168-71	30202-30206	Used	_	
168-72	30207-30211	with	_	
168-73	30212-30224	Intoxication	_	
168-74	30224-30225	)	_	
168-75	30225-30226	]	_	
168-76	30226-30227	/	_	
168-77	30227-30228	4	_	
168-78	30228-30229	*	_	
168-79	30229-30234	Total	_	
168-80	30235-30239	Days	_	
168-81	30240-30241	(	_	
168-82	30241-30244	See	_	
168-83	30245-30258	Supplementary	_	
168-84	30259-30268	materials	_	
168-85	30269-30272	for	_	
168-86	30273-30283	additional	_	
168-87	30284-30295	information	_	
168-88	30295-30296	.	_	
168-89	30296-30297	)	_	

#Text=References
#Text=Computational models of performance monitoring and cognitive control
#Text=Medial prefrontal cortex as an action-outcome predictor
#Text=A general role for medial prefrontal cortex in event prediction
#Text=Reward salience and risk aversion underlie differential ACC activity in substance dependence
#Text=Decoding internally and externally driven movement plans
#Text=Neurofunctional reward processing changes in cocaine dependence during recovery
#Text=The mean and the individual: integrating variable-centered and person-centered analyses of cognitive recovery in patients with substance use disorders
#Text=Effect of brain structure, brain function, and brain connectivity on relapse in alcohol-dependent patients
#Text=Cognitive control links alcohol use, trait disinhibition, and reduced cognitive capacity: evidence for medial prefrontal cortex dysregulation during reward-seeking behavior
#Text=Pretreatment brain activation during stroop task is associated with outcomes in cocaine-dependent patients
#Text=A new, semi-structured psychiatric interview for use in genetic linkage studies: a report on the reliability of the SSAGA
#Text=The neurobiology of cognitive control in successful cocaine abstinence
#Text=Risky decision-making but not delay discounting improves during inpatient treatment of polysubstance dependent alcoholics
#Text=A preliminary study of the neural effects of behavioral therapy for substance use disorders
#Text=Risk-taking but not response inhibition or delay discounting predict alcohol consumption in social drinkers
#Text=Decision making in the Balloon Analogue Risk Task (BART): anterior cingulate cortex signals loss aversion but not the infrequency of risky choices
#Text=Decisions during negatively-framed messages yield smaller risk-aversion-related brain activation in substance-dependent individuals
#Text=Drug addiction and its underlying neurobiological basis: neuroimaging evidence for the involvement of the frontal cortex
#Text=Dysfunction of the prefrontal cortex in addiction: neuroimaging findings and clinical implications
#Text=Attenuated insular processing during risk predicts relapse in early abstinent methamphetamine-dependent individuals
#Text=Cue-induced activation of the striatum and medial prefrontal cortex is associated with subsequent relapse in abstinent alcoholics
#Text=Neural activation during risky decision-making in youth at high risk for substance use disorders
#Text=An initial study of neural responses to monetary incentives as related to treatment outcome in cocaine dependence
#Text=Overlapping responses for the expectation of juice and money rewards in human ventromedial prefrontal cortex
#Text=Cannabis abstinence during treatment and one-year follow-up: relationship to neural activity in men
#Text=Common and distinct neural targets of treatment: changing brain function in substance addiction
#Text=Anterior insula activity predicts the influence of positively framed messages on decision making
#Text=Impaired error-likelihood prediction in medial prefrontal cortex in schizophrenia
#Text=Relapse prevention: an overview of Marlatt's cognitive-behavioral model
#Text=Evaluation of a behavioral measure of risk taking: the Balloon Analogue Risk Task (BART)
#Text=Error processing and gender-shared and -specific neural predictors of relapse in cocaine dependence
#Text=Rapid recovery from cognitive deficits in abstinent alcoholics: a controlled test-retest study
#Text=Individual differences in anterior cingulate activation associated with attentional bias predict cocaine use after treatment
#Text=Error-related brain activity predicts cocaine use after treatment at 3-month follow-up
#Text=Enhanced midbrain response at 6-month follow-up in cocaine addiction, association with reduced drug-related choice
#Text=Neural activation patterns of methamphetamine-dependent subjects during decision making predict relapse
#Text=Neural correlates of voluntary and involuntary risk taking in the human brain: an fMRI Study of the Balloon Analog Risk Task (BART)
#Text=A unified framework for addiction: vulnerabilities in the decision process
#Text=Predicting treatment outcome in stimulant dependence
#Text=Reliability of a timeline method: assessing normal drinkers' reports of recent drinking and a comparative evaluation across several populations
#Text=Widespread and sustained cognitive deficits in alcoholism: a meta-analysis
#Text=Cocaine dependent individuals with attenuated striatal activation during reinforcement learning are more susceptible to relapse
#Text=Striatum and insula dysfunction during reinforcement learning differentiates abstinent and relapsed methamphetamine-dependent individuals
#Text=Test-retest reliability of behavioral measures of impulsive choice, impulsive action, and inattention
#Text=Test-retest characteristics of the Balloon Analogue Risk Task (BART)
#Text=Schematic representation of the Balloon Analogue Risk Task (BART).
169-1	30298-30308	References	_	
169-2	30309-30322	Computational	_	
169-3	30323-30329	models	_	
169-4	30330-30332	of	_	
169-5	30333-30344	performance	_	
169-6	30345-30355	monitoring	_	
169-7	30356-30359	and	_	
169-8	30360-30369	cognitive	_	
169-9	30370-30377	control	_	
169-10	30378-30384	Medial	_	
169-11	30385-30395	prefrontal	_	
169-12	30396-30402	cortex	_	
169-13	30403-30405	as	_	
169-14	30406-30408	an	_	
169-15	30409-30423	action-outcome	_	
169-16	30424-30433	predictor	_	
169-17	30434-30435	A	_	
169-18	30436-30443	general	_	
169-19	30444-30448	role	_	
169-20	30449-30452	for	_	
169-21	30453-30459	medial	_	
169-22	30460-30470	prefrontal	_	
169-23	30471-30477	cortex	_	
169-24	30478-30480	in	_	
169-25	30481-30486	event	_	
169-26	30487-30497	prediction	_	
169-27	30498-30504	Reward	_	
169-28	30505-30513	salience	_	
169-29	30514-30517	and	_	
169-30	30518-30522	risk	_	
169-31	30523-30531	aversion	_	
169-32	30532-30540	underlie	_	
169-33	30541-30553	differential	_	
169-34	30554-30557	ACC	_	
169-35	30558-30566	activity	_	
169-36	30567-30569	in	_	
169-37	30570-30579	substance	_	
169-38	30580-30590	dependence	_	
169-39	30591-30599	Decoding	_	
169-40	30600-30610	internally	_	
169-41	30611-30614	and	_	
169-42	30615-30625	externally	_	
169-43	30626-30632	driven	_	
169-44	30633-30641	movement	_	
169-45	30642-30647	plans	_	
169-46	30648-30663	Neurofunctional	_	
169-47	30664-30670	reward	_	
169-48	30671-30681	processing	_	
169-49	30682-30689	changes	_	
169-50	30690-30692	in	_	
169-51	30693-30700	cocaine	_	
169-52	30701-30711	dependence	_	
169-53	30712-30718	during	_	
169-54	30719-30727	recovery	_	
169-55	30728-30731	The	_	
169-56	30732-30736	mean	_	
169-57	30737-30740	and	_	
169-58	30741-30744	the	_	
169-59	30745-30755	individual	_	
169-60	30755-30756	:	_	
169-61	30757-30768	integrating	_	
169-62	30769-30786	variable-centered	_	
169-63	30787-30790	and	_	
169-64	30791-30806	person-centered	_	
169-65	30807-30815	analyses	_	
169-66	30816-30818	of	_	
169-67	30819-30828	cognitive	_	
169-68	30829-30837	recovery	_	
169-69	30838-30840	in	_	
169-70	30841-30849	patients	_	
169-71	30850-30854	with	_	
169-72	30855-30864	substance	_	
169-73	30865-30868	use	_	
169-74	30869-30878	disorders	_	
169-75	30879-30885	Effect	_	
169-76	30886-30888	of	_	
169-77	30889-30894	brain	_	
169-78	30895-30904	structure	_	
169-79	30904-30905	,	_	
169-80	30906-30911	brain	_	
169-81	30912-30920	function	_	
169-82	30920-30921	,	_	
169-83	30922-30925	and	_	
169-84	30926-30931	brain	_	
169-85	30932-30944	connectivity	_	
169-86	30945-30947	on	_	
169-87	30948-30955	relapse	_	
169-88	30956-30958	in	_	
169-89	30959-30976	alcohol-dependent	_	
169-90	30977-30985	patients	_	
169-91	30986-30995	Cognitive	_	
169-92	30996-31003	control	_	
169-93	31004-31009	links	_	
169-94	31010-31017	alcohol	_	
169-95	31018-31021	use	_	
169-96	31021-31022	,	_	
169-97	31023-31028	trait	_	
169-98	31029-31042	disinhibition	_	
169-99	31042-31043	,	_	
169-100	31044-31047	and	_	
169-101	31048-31055	reduced	_	
169-102	31056-31065	cognitive	_	
169-103	31066-31074	capacity	_	
169-104	31074-31075	:	_	
169-105	31076-31084	evidence	_	
169-106	31085-31088	for	_	
169-107	31089-31095	medial	_	
169-108	31096-31106	prefrontal	_	
169-109	31107-31113	cortex	_	
169-110	31114-31127	dysregulation	_	
169-111	31128-31134	during	_	
169-112	31135-31149	reward-seeking	_	
169-113	31150-31158	behavior	_	
169-114	31159-31171	Pretreatment	_	
169-115	31172-31177	brain	_	
169-116	31178-31188	activation	_	
169-117	31189-31195	during	_	
169-118	31196-31202	stroop	_	
169-119	31203-31207	task	_	
169-120	31208-31210	is	_	
169-121	31211-31221	associated	_	
169-122	31222-31226	with	_	
169-123	31227-31235	outcomes	_	
169-124	31236-31238	in	_	
169-125	31239-31256	cocaine-dependent	_	
169-126	31257-31265	patients	_	
169-127	31266-31267	A	_	
169-128	31268-31271	new	_	
169-129	31271-31272	,	_	
169-130	31273-31288	semi-structured	_	
169-131	31289-31300	psychiatric	_	
169-132	31301-31310	interview	_	
169-133	31311-31314	for	_	
169-134	31315-31318	use	_	
169-135	31319-31321	in	_	
169-136	31322-31329	genetic	_	
169-137	31330-31337	linkage	_	
169-138	31338-31345	studies	_	
169-139	31345-31346	:	_	
169-140	31347-31348	a	_	
169-141	31349-31355	report	_	
169-142	31356-31358	on	_	
169-143	31359-31362	the	_	
169-144	31363-31374	reliability	_	
169-145	31375-31377	of	_	
169-146	31378-31381	the	_	
169-147	31382-31387	SSAGA	_	
169-148	31388-31391	The	_	
169-149	31392-31404	neurobiology	_	
169-150	31405-31407	of	_	
169-151	31408-31417	cognitive	_	
169-152	31418-31425	control	_	
169-153	31426-31428	in	_	
169-154	31429-31439	successful	_	
169-155	31440-31447	cocaine	_	
169-156	31448-31458	abstinence	_	
169-157	31459-31464	Risky	_	
169-158	31465-31480	decision-making	_	
169-159	31481-31484	but	_	
169-160	31485-31488	not	_	
169-161	31489-31494	delay	_	
169-162	31495-31506	discounting	_	
169-163	31507-31515	improves	_	
169-164	31516-31522	during	_	
169-165	31523-31532	inpatient	_	
169-166	31533-31542	treatment	_	
169-167	31543-31545	of	_	
169-168	31546-31559	polysubstance	_	
169-169	31560-31569	dependent	_	
169-170	31570-31580	alcoholics	_	
169-171	31581-31582	A	_	
169-172	31583-31594	preliminary	_	
169-173	31595-31600	study	_	
169-174	31601-31603	of	_	
169-175	31604-31607	the	_	
169-176	31608-31614	neural	_	
169-177	31615-31622	effects	_	
169-178	31623-31625	of	_	
169-179	31626-31636	behavioral	_	
169-180	31637-31644	therapy	_	
169-181	31645-31648	for	_	
169-182	31649-31658	substance	_	
169-183	31659-31662	use	_	
169-184	31663-31672	disorders	_	
169-185	31673-31684	Risk-taking	_	
169-186	31685-31688	but	_	
169-187	31689-31692	not	_	
169-188	31693-31701	response	_	
169-189	31702-31712	inhibition	_	
169-190	31713-31715	or	_	
169-191	31716-31721	delay	_	
169-192	31722-31733	discounting	_	
169-193	31734-31741	predict	_	
169-194	31742-31749	alcohol	_	
169-195	31750-31761	consumption	_	
169-196	31762-31764	in	_	
169-197	31765-31771	social	_	
169-198	31772-31780	drinkers	_	
169-199	31781-31789	Decision	_	
169-200	31790-31796	making	_	
169-201	31797-31799	in	_	
169-202	31800-31803	the	_	
169-203	31804-31811	Balloon	_	
169-204	31812-31820	Analogue	_	
169-205	31821-31825	Risk	_	
169-206	31826-31830	Task	_	
169-207	31831-31832	(	_	
169-208	31832-31836	BART	_	
169-209	31836-31837	)	_	
169-210	31837-31838	:	_	
169-211	31839-31847	anterior	_	
169-212	31848-31857	cingulate	_	
169-213	31858-31864	cortex	_	
169-214	31865-31872	signals	_	
169-215	31873-31877	loss	_	
169-216	31878-31886	aversion	_	
169-217	31887-31890	but	_	
169-218	31891-31894	not	_	
169-219	31895-31898	the	_	
169-220	31899-31910	infrequency	_	
169-221	31911-31913	of	_	
169-222	31914-31919	risky	_	
169-223	31920-31927	choices	_	
169-224	31928-31937	Decisions	_	
169-225	31938-31944	during	_	
169-226	31945-31962	negatively-framed	_	
169-227	31963-31971	messages	_	
169-228	31972-31977	yield	_	
169-229	31978-31985	smaller	_	
169-230	31986-32007	risk-aversion-related	_	
169-231	32008-32013	brain	_	
169-232	32014-32024	activation	_	
169-233	32025-32027	in	_	
169-234	32028-32047	substance-dependent	_	
169-235	32048-32059	individuals	_	
169-236	32060-32064	Drug	_	
169-237	32065-32074	addiction	_	
169-238	32075-32078	and	_	
169-239	32079-32082	its	_	
169-240	32083-32093	underlying	_	
169-241	32094-32109	neurobiological	_	
169-242	32110-32115	basis	_	
169-243	32115-32116	:	_	
169-244	32117-32129	neuroimaging	_	
169-245	32130-32138	evidence	_	
169-246	32139-32142	for	_	
169-247	32143-32146	the	_	
169-248	32147-32158	involvement	_	
169-249	32159-32161	of	_	
169-250	32162-32165	the	_	
169-251	32166-32173	frontal	_	
169-252	32174-32180	cortex	_	
169-253	32181-32192	Dysfunction	_	
169-254	32193-32195	of	_	
169-255	32196-32199	the	_	
169-256	32200-32210	prefrontal	_	
169-257	32211-32217	cortex	_	
169-258	32218-32220	in	_	
169-259	32221-32230	addiction	_	
169-260	32230-32231	:	_	
169-261	32232-32244	neuroimaging	_	
169-262	32245-32253	findings	_	
169-263	32254-32257	and	_	
169-264	32258-32266	clinical	_	
169-265	32267-32279	implications	_	
169-266	32280-32290	Attenuated	_	
169-267	32291-32298	insular	_	
169-268	32299-32309	processing	_	
169-269	32310-32316	during	_	
169-270	32317-32321	risk	_	
169-271	32322-32330	predicts	_	
169-272	32331-32338	relapse	_	
169-273	32339-32341	in	_	
169-274	32342-32347	early	_	
169-275	32348-32357	abstinent	_	
169-276	32358-32383	methamphetamine-dependent	_	
169-277	32384-32395	individuals	_	
169-278	32396-32407	Cue-induced	_	
169-279	32408-32418	activation	_	
169-280	32419-32421	of	_	
169-281	32422-32425	the	_	
169-282	32426-32434	striatum	_	
169-283	32435-32438	and	_	
169-284	32439-32445	medial	_	
169-285	32446-32456	prefrontal	_	
169-286	32457-32463	cortex	_	
169-287	32464-32466	is	_	
169-288	32467-32477	associated	_	
169-289	32478-32482	with	_	
169-290	32483-32493	subsequent	_	
169-291	32494-32501	relapse	_	
169-292	32502-32504	in	_	
169-293	32505-32514	abstinent	_	
169-294	32515-32525	alcoholics	_	
169-295	32526-32532	Neural	_	
169-296	32533-32543	activation	_	
169-297	32544-32550	during	_	
169-298	32551-32556	risky	_	
169-299	32557-32572	decision-making	_	
169-300	32573-32575	in	_	
169-301	32576-32581	youth	_	
169-302	32582-32584	at	_	
169-303	32585-32589	high	_	
169-304	32590-32594	risk	_	
169-305	32595-32598	for	_	
169-306	32599-32608	substance	_	
169-307	32609-32612	use	_	
169-308	32613-32622	disorders	_	
169-309	32623-32625	An	_	
169-310	32626-32633	initial	_	
169-311	32634-32639	study	_	
169-312	32640-32642	of	_	
169-313	32643-32649	neural	_	
169-314	32650-32659	responses	_	
169-315	32660-32662	to	_	
169-316	32663-32671	monetary	_	
169-317	32672-32682	incentives	_	
169-318	32683-32685	as	_	
169-319	32686-32693	related	_	
169-320	32694-32696	to	_	
169-321	32697-32706	treatment	_	
169-322	32707-32714	outcome	_	
169-323	32715-32717	in	_	
169-324	32718-32725	cocaine	_	
169-325	32726-32736	dependence	_	
169-326	32737-32748	Overlapping	_	
169-327	32749-32758	responses	_	
169-328	32759-32762	for	_	
169-329	32763-32766	the	_	
169-330	32767-32778	expectation	_	
169-331	32779-32781	of	_	
169-332	32782-32787	juice	_	
169-333	32788-32791	and	_	
169-334	32792-32797	money	_	
169-335	32798-32805	rewards	_	
169-336	32806-32808	in	_	
169-337	32809-32814	human	_	
169-338	32815-32827	ventromedial	_	
169-339	32828-32838	prefrontal	_	
169-340	32839-32845	cortex	_	
169-341	32846-32854	Cannabis	_	
169-342	32855-32865	abstinence	_	
169-343	32866-32872	during	_	
169-344	32873-32882	treatment	_	
169-345	32883-32886	and	_	
169-346	32887-32895	one-year	_	
169-347	32896-32905	follow-up	_	
169-348	32905-32906	:	_	
169-349	32907-32919	relationship	_	
169-350	32920-32922	to	_	
169-351	32923-32929	neural	_	
169-352	32930-32938	activity	_	
169-353	32939-32941	in	_	
169-354	32942-32945	men	_	
169-355	32946-32952	Common	_	
169-356	32953-32956	and	_	
169-357	32957-32965	distinct	_	
169-358	32966-32972	neural	_	
169-359	32973-32980	targets	_	
169-360	32981-32983	of	_	
169-361	32984-32993	treatment	_	
169-362	32993-32994	:	_	
169-363	32995-33003	changing	_	
169-364	33004-33009	brain	_	
169-365	33010-33018	function	_	
169-366	33019-33021	in	_	
169-367	33022-33031	substance	_	
169-368	33032-33041	addiction	_	
169-369	33042-33050	Anterior	_	
169-370	33051-33057	insula	_	
169-371	33058-33066	activity	_	
169-372	33067-33075	predicts	_	
169-373	33076-33079	the	_	
169-374	33080-33089	influence	_	
169-375	33090-33092	of	_	
169-376	33093-33103	positively	_	
169-377	33104-33110	framed	_	
169-378	33111-33119	messages	_	
169-379	33120-33122	on	_	
169-380	33123-33131	decision	_	
169-381	33132-33138	making	_	
169-382	33139-33147	Impaired	_	
169-383	33148-33164	error-likelihood	_	
169-384	33165-33175	prediction	_	
169-385	33176-33178	in	_	
169-386	33179-33185	medial	_	
169-387	33186-33196	prefrontal	_	
169-388	33197-33203	cortex	_	
169-389	33204-33206	in	_	
169-390	33207-33220	schizophrenia	_	
169-391	33221-33228	Relapse	_	
169-392	33229-33239	prevention	_	
169-393	33239-33240	:	_	
169-394	33241-33243	an	_	
169-395	33244-33252	overview	_	
169-396	33253-33255	of	_	
169-397	33256-33265	Marlatt's	_	
169-398	33266-33286	cognitive-behavioral	_	
169-399	33287-33292	model	_	
169-400	33293-33303	Evaluation	_	
169-401	33304-33306	of	_	
169-402	33307-33308	a	_	
169-403	33309-33319	behavioral	_	
169-404	33320-33327	measure	_	
169-405	33328-33330	of	_	
169-406	33331-33335	risk	_	
169-407	33336-33342	taking	_	
169-408	33342-33343	:	_	
169-409	33344-33347	the	_	
169-410	33348-33355	Balloon	_	
169-411	33356-33364	Analogue	_	
169-412	33365-33369	Risk	_	
169-413	33370-33374	Task	_	
169-414	33375-33376	(	_	
169-415	33376-33380	BART	_	
169-416	33380-33381	)	_	
169-417	33382-33387	Error	_	
169-418	33388-33398	processing	_	
169-419	33399-33402	and	_	
169-420	33403-33416	gender-shared	_	
169-421	33417-33420	and	_	
169-422	33421-33422	-	_	
169-423	33422-33430	specific	_	
169-424	33431-33437	neural	_	
169-425	33438-33448	predictors	_	
169-426	33449-33451	of	_	
169-427	33452-33459	relapse	_	
169-428	33460-33462	in	_	
169-429	33463-33470	cocaine	_	
169-430	33471-33481	dependence	_	
169-431	33482-33487	Rapid	_	
169-432	33488-33496	recovery	_	
169-433	33497-33501	from	_	
169-434	33502-33511	cognitive	_	
169-435	33512-33520	deficits	_	
169-436	33521-33523	in	_	
169-437	33524-33533	abstinent	_	
169-438	33534-33544	alcoholics	_	
169-439	33544-33545	:	_	
169-440	33546-33547	a	_	
169-441	33548-33558	controlled	_	
169-442	33559-33570	test-retest	_	
169-443	33571-33576	study	_	
169-444	33577-33587	Individual	_	
169-445	33588-33599	differences	_	
169-446	33600-33602	in	_	
169-447	33603-33611	anterior	_	
169-448	33612-33621	cingulate	_	
169-449	33622-33632	activation	_	
169-450	33633-33643	associated	_	
169-451	33644-33648	with	_	
169-452	33649-33660	attentional	_	
169-453	33661-33665	bias	_	
169-454	33666-33673	predict	_	
169-455	33674-33681	cocaine	_	
169-456	33682-33685	use	_	
169-457	33686-33691	after	_	
169-458	33692-33701	treatment	_	
169-459	33702-33715	Error-related	_	
169-460	33716-33721	brain	_	
169-461	33722-33730	activity	_	
169-462	33731-33739	predicts	_	
169-463	33740-33747	cocaine	_	
169-464	33748-33751	use	_	
169-465	33752-33757	after	_	
169-466	33758-33767	treatment	_	
169-467	33768-33770	at	_	
169-468	33771-33772	3	_	
169-469	33772-33773	-	_	
169-470	33773-33778	month	_	
169-471	33779-33788	follow-up	_	
169-472	33789-33797	Enhanced	_	
169-473	33798-33806	midbrain	_	
169-474	33807-33815	response	_	
169-475	33816-33818	at	_	
169-476	33819-33820	6	_	
169-477	33820-33821	-	_	
169-478	33821-33826	month	_	
169-479	33827-33836	follow-up	_	
169-480	33837-33839	in	_	
169-481	33840-33847	cocaine	_	
169-482	33848-33857	addiction	_	
169-483	33857-33858	,	_	
169-484	33859-33870	association	_	
169-485	33871-33875	with	_	
169-486	33876-33883	reduced	_	
169-487	33884-33896	drug-related	_	
169-488	33897-33903	choice	_	
169-489	33904-33910	Neural	_	
169-490	33911-33921	activation	_	
169-491	33922-33930	patterns	_	
169-492	33931-33933	of	_	
169-493	33934-33959	methamphetamine-dependent	_	
169-494	33960-33968	subjects	_	
169-495	33969-33975	during	_	
169-496	33976-33984	decision	_	
169-497	33985-33991	making	_	
169-498	33992-33999	predict	_	
169-499	34000-34007	relapse	_	
169-500	34008-34014	Neural	_	
169-501	34015-34025	correlates	_	
169-502	34026-34028	of	_	
169-503	34029-34038	voluntary	_	
169-504	34039-34042	and	_	
169-505	34043-34054	involuntary	_	
169-506	34055-34059	risk	_	
169-507	34060-34066	taking	_	
169-508	34067-34069	in	_	
169-509	34070-34073	the	_	
169-510	34074-34079	human	_	
169-511	34080-34085	brain	_	
169-512	34085-34086	:	_	
169-513	34087-34089	an	_	
169-514	34090-34094	fMRI	_	
169-515	34095-34100	Study	_	
169-516	34101-34103	of	_	
169-517	34104-34107	the	_	
169-518	34108-34115	Balloon	_	
169-519	34116-34122	Analog	_	
169-520	34123-34127	Risk	_	
169-521	34128-34132	Task	_	
169-522	34133-34134	(	_	
169-523	34134-34138	BART	_	
169-524	34138-34139	)	_	
169-525	34140-34141	A	_	
169-526	34142-34149	unified	_	
169-527	34150-34159	framework	_	
169-528	34160-34163	for	_	
169-529	34164-34173	addiction	_	
169-530	34173-34174	:	_	
169-531	34175-34190	vulnerabilities	_	
169-532	34191-34193	in	_	
169-533	34194-34197	the	_	
169-534	34198-34206	decision	_	
169-535	34207-34214	process	_	
169-536	34215-34225	Predicting	_	
169-537	34226-34235	treatment	_	
169-538	34236-34243	outcome	_	
169-539	34244-34246	in	_	
169-540	34247-34256	stimulant	_	
169-541	34257-34267	dependence	_	
169-542	34268-34279	Reliability	_	
169-543	34280-34282	of	_	
169-544	34283-34284	a	_	
169-545	34285-34293	timeline	_	
169-546	34294-34300	method	_	
169-547	34300-34301	:	_	
169-548	34302-34311	assessing	_	
169-549	34312-34318	normal	_	
169-550	34319-34327	drinkers	_	
169-551	34327-34328	'	_	
169-552	34329-34336	reports	_	
169-553	34337-34339	of	_	
169-554	34340-34346	recent	_	
169-555	34347-34355	drinking	_	
169-556	34356-34359	and	_	
169-557	34360-34361	a	_	
169-558	34362-34373	comparative	_	
169-559	34374-34384	evaluation	_	
169-560	34385-34391	across	_	
169-561	34392-34399	several	_	
169-562	34400-34411	populations	_	
169-563	34412-34422	Widespread	_	
169-564	34423-34426	and	_	
169-565	34427-34436	sustained	_	
169-566	34437-34446	cognitive	_	
169-567	34447-34455	deficits	_	
169-568	34456-34458	in	_	
169-569	34459-34469	alcoholism	_	
169-570	34469-34470	:	_	
169-571	34471-34472	a	_	
169-572	34473-34486	meta-analysis	_	
169-573	34487-34494	Cocaine	_	
169-574	34495-34504	dependent	_	
169-575	34505-34516	individuals	_	
169-576	34517-34521	with	_	
169-577	34522-34532	attenuated	_	
169-578	34533-34541	striatal	_	
169-579	34542-34552	activation	_	
169-580	34553-34559	during	_	
169-581	34560-34573	reinforcement	_	
169-582	34574-34582	learning	_	
169-583	34583-34586	are	_	
169-584	34587-34591	more	_	
169-585	34592-34603	susceptible	_	
169-586	34604-34606	to	_	
169-587	34607-34614	relapse	_	
169-588	34615-34623	Striatum	_	
169-589	34624-34627	and	_	
169-590	34628-34634	insula	_	
169-591	34635-34646	dysfunction	_	
169-592	34647-34653	during	_	
169-593	34654-34667	reinforcement	_	
169-594	34668-34676	learning	_	
169-595	34677-34691	differentiates	_	
169-596	34692-34701	abstinent	_	
169-597	34702-34705	and	_	
169-598	34706-34714	relapsed	_	
169-599	34715-34740	methamphetamine-dependent	_	
169-600	34741-34752	individuals	_	
169-601	34753-34764	Test-retest	_	
169-602	34765-34776	reliability	_	
169-603	34777-34779	of	_	
169-604	34780-34790	behavioral	_	
169-605	34791-34799	measures	_	
169-606	34800-34802	of	_	
169-607	34803-34812	impulsive	_	
169-608	34813-34819	choice	_	
169-609	34819-34820	,	_	
169-610	34821-34830	impulsive	_	
169-611	34831-34837	action	_	
169-612	34837-34838	,	_	
169-613	34839-34842	and	_	
169-614	34843-34854	inattention	_	
169-615	34855-34866	Test-retest	_	
169-616	34867-34882	characteristics	_	
169-617	34883-34885	of	_	
169-618	34886-34889	the	_	
169-619	34890-34897	Balloon	_	
169-620	34898-34906	Analogue	_	
169-621	34907-34911	Risk	_	
169-622	34912-34916	Task	_	
169-623	34917-34918	(	_	
169-624	34918-34922	BART	_	
169-625	34922-34923	)	_	
169-626	34924-34933	Schematic	_	
169-627	34934-34948	representation	_	
169-628	34949-34951	of	_	
169-629	34952-34955	the	_	
169-630	34956-34963	Balloon	_	
169-631	34964-34972	Analogue	_	
169-632	34973-34977	Risk	_	
169-633	34978-34982	Task	_	
169-634	34983-34984	(	_	
169-635	34984-34988	BART	_	
169-636	34988-34989	)	_	
169-637	34989-34990	.	_	

#Text=Adapted, with permission, from.
170-1	34991-34998	Adapted	_	
170-2	34998-34999	,	_	
170-3	35000-35004	with	_	
170-4	35005-35015	permission	_	
170-5	35015-35016	,	_	
170-6	35017-35021	from	_	
170-7	35021-35022	.	_	

#Text=Regions demonstrating longitudinal recovery of prediction error effects, as a change in signaling to positive and negative BART outcomes.
171-1	35023-35030	Regions	_	
171-2	35031-35044	demonstrating	_	
171-3	35045-35057	longitudinal	_	
171-4	35058-35066	recovery	_	
171-5	35067-35069	of	_	
171-6	35070-35080	prediction	_	
171-7	35081-35086	error	_	
171-8	35087-35094	effects	_	
171-9	35094-35095	,	_	
171-10	35096-35098	as	_	
171-11	35099-35100	a	_	
171-12	35101-35107	change	_	
171-13	35108-35110	in	_	
171-14	35111-35120	signaling	_	
171-15	35121-35123	to	_	
171-16	35124-35132	positive	_	
171-17	35133-35136	and	_	
171-18	35137-35145	negative	_	
171-19	35146-35150	BART	_	
171-20	35151-35159	outcomes	_	
171-21	35159-35160	.	_	

#Text=A greater increasing activation to successful inflation feedback with increasing explosion probability (i.e., 'Success*p(Explode)') was identified at follow-up in right caudal ACC (peak voxel: 8, 4, 34) and a greater decreasing signal to explosion feedback with increasing explosion probability ('Explode*p(Explode)') was identified at follow-up in right IFG (peak voxel: 32, 20, −14) and left caudal ACC/cingulum (peak voxel: −18, 12, 32).
172-1	35161-35162	A	_	
172-2	35163-35170	greater	_	
172-3	35171-35181	increasing	_	
172-4	35182-35192	activation	_	
172-5	35193-35195	to	_	
172-6	35196-35206	successful	_	
172-7	35207-35216	inflation	_	
172-8	35217-35225	feedback	_	
172-9	35226-35230	with	_	
172-10	35231-35241	increasing	_	
172-11	35242-35251	explosion	_	
172-12	35252-35263	probability	_	
172-13	35264-35265	(	_	
172-14	35265-35268	i.e	_	
172-15	35268-35269	.	_	
172-16	35269-35270	,	_	
172-17	35271-35272	'	_	
172-18	35272-35279	Success	_	
172-19	35279-35280	*	_	
172-20	35280-35281	p	_	
172-21	35281-35282	(	_	
172-22	35282-35289	Explode	_	
172-23	35289-35290	)	_	
172-24	35290-35291	'	_	
172-25	35291-35292	)	_	
172-26	35293-35296	was	_	
172-27	35297-35307	identified	_	
172-28	35308-35310	at	_	
172-29	35311-35320	follow-up	_	
172-30	35321-35323	in	_	
172-31	35324-35329	right	_	
172-32	35330-35336	caudal	_	
172-33	35337-35340	ACC	_	
172-34	35341-35342	(	_	
172-35	35342-35346	peak	_	
172-36	35347-35352	voxel	_	
172-37	35352-35353	:	_	
172-38	35354-35355	8	_	
172-39	35355-35356	,	_	
172-40	35357-35358	4	_	
172-41	35358-35359	,	_	
172-42	35360-35362	34	_	
172-43	35362-35363	)	_	
172-44	35364-35367	and	_	
172-45	35368-35369	a	_	
172-46	35370-35377	greater	_	
172-47	35378-35388	decreasing	_	
172-48	35389-35395	signal	_	
172-49	35396-35398	to	_	
172-50	35399-35408	explosion	_	
172-51	35409-35417	feedback	_	
172-52	35418-35422	with	_	
172-53	35423-35433	increasing	_	
172-54	35434-35443	explosion	_	
172-55	35444-35455	probability	_	
172-56	35456-35457	(	_	
172-57	35457-35458	'	_	
172-58	35458-35465	Explode	_	
172-59	35465-35466	*	_	
172-60	35466-35467	p	_	
172-61	35467-35468	(	_	
172-62	35468-35475	Explode	_	
172-63	35475-35476	)	_	
172-64	35476-35477	'	_	
172-65	35477-35478	)	_	
172-66	35479-35482	was	_	
172-67	35483-35493	identified	_	
172-68	35494-35496	at	_	
172-69	35497-35506	follow-up	_	
172-70	35507-35509	in	_	
172-71	35510-35515	right	_	
172-72	35516-35519	IFG	_	
172-73	35520-35521	(	_	
172-74	35521-35525	peak	_	
172-75	35526-35531	voxel	_	
172-76	35531-35532	:	_	
172-77	35533-35535	32	_	
172-78	35535-35536	,	_	
172-79	35537-35539	20	_	
172-80	35539-35540	,	_	
172-81	35541-35542	−	_	
172-82	35542-35544	14	_	
172-83	35544-35545	)	_	
172-84	35546-35549	and	_	
172-85	35550-35554	left	_	
172-86	35555-35561	caudal	_	
172-87	35562-35565	ACC	_	
172-88	35565-35566	/	_	
172-89	35566-35574	cingulum	_	
172-90	35575-35576	(	_	
172-91	35576-35580	peak	_	
172-92	35581-35586	voxel	_	
172-93	35586-35587	:	_	
172-94	35588-35589	−	_	
172-95	35589-35591	18	_	
172-96	35591-35592	,	_	
172-97	35593-35595	12	_	
172-98	35595-35596	,	_	
172-99	35597-35599	32	_	
172-100	35599-35600	)	_	
172-101	35600-35601	.	_	

#Text=Results suggest more robust signaling of unexpected (low likelihood) outcomes at follow-up which is consistent with stronger formation of risk-informed outcome expectations.
173-1	35602-35609	Results	_	
173-2	35610-35617	suggest	_	
173-3	35618-35622	more	_	
173-4	35623-35629	robust	_	
173-5	35630-35639	signaling	_	
173-6	35640-35642	of	_	
173-7	35643-35653	unexpected	_	
173-8	35654-35655	(	_	
173-9	35655-35658	low	_	
173-10	35659-35669	likelihood	_	
173-11	35669-35670	)	_	
173-12	35671-35679	outcomes	_	
173-13	35680-35682	at	_	
173-14	35683-35692	follow-up	_	
173-15	35693-35698	which	_	
173-16	35699-35701	is	_	
173-17	35702-35712	consistent	_	
173-18	35713-35717	with	_	
173-19	35718-35726	stronger	_	
173-20	35727-35736	formation	_	
173-21	35737-35739	of	_	
173-22	35740-35753	risk-informed	_	
173-23	35754-35761	outcome	_	
173-24	35762-35774	expectations	_	
173-25	35774-35775	.	_	

#Text=Line plots at the right side of the figure are included to conceptually illustrate longitudinal parametric modulator contrasts.
174-1	35776-35780	Line	_	
174-2	35781-35786	plots	_	
174-3	35787-35789	at	_	
174-4	35790-35793	the	_	
174-5	35794-35799	right	_	
174-6	35800-35804	side	_	
174-7	35805-35807	of	_	
174-8	35808-35811	the	_	
174-9	35812-35818	figure	_	
174-10	35819-35822	are	_	
174-11	35823-35831	included	_	
174-12	35832-35834	to	_	
174-13	35835-35847	conceptually	_	
174-14	35848-35858	illustrate	_	
174-15	35859-35871	longitudinal	_	
174-16	35872-35882	parametric	_	
174-17	35883-35892	modulator	_	
174-18	35893-35902	contrasts	_	
174-19	35902-35903	.	_	

#Text=For the Success*p(Explode) contrast (green), there was a greater positive relationship between trial-to-trial variation in p(Explode) and the magnetic resonance (MR) signal at follow-up (i.e., stronger signal with a higher probability of an explosion (or magnitude of reward) at follow-up.
175-1	35904-35907	For	_	
175-2	35908-35911	the	_	
175-3	35912-35919	Success	_	
175-4	35919-35920	*	_	
175-5	35920-35921	p	_	
175-6	35921-35922	(	_	
175-7	35922-35929	Explode	_	
175-8	35929-35930	)	_	
175-9	35931-35939	contrast	_	
175-10	35940-35941	(	_	
175-11	35941-35946	green	_	
175-12	35946-35947	)	_	
175-13	35947-35948	,	_	
175-14	35949-35954	there	_	
175-15	35955-35958	was	_	
175-16	35959-35960	a	_	
175-17	35961-35968	greater	_	
175-18	35969-35977	positive	_	
175-19	35978-35990	relationship	_	
175-20	35991-35998	between	_	
175-21	35999-36013	trial-to-trial	_	
175-22	36014-36023	variation	_	
175-23	36024-36026	in	_	
175-24	36027-36028	p	_	
175-25	36028-36029	(	_	
175-26	36029-36036	Explode	_	
175-27	36036-36037	)	_	
175-28	36038-36041	and	_	
175-29	36042-36045	the	_	
175-30	36046-36054	magnetic	_	
175-31	36055-36064	resonance	_	
175-32	36065-36066	(	_	
175-33	36066-36068	MR	_	
175-34	36068-36069	)	_	
175-35	36070-36076	signal	_	
175-36	36077-36079	at	_	
175-37	36080-36089	follow-up	_	
175-38	36090-36091	(	_	
175-39	36091-36094	i.e	_	
175-40	36094-36095	.	_	
175-41	36095-36096	,	_	
175-42	36097-36105	stronger	_	
175-43	36106-36112	signal	_	
175-44	36113-36117	with	_	
175-45	36118-36119	a	_	
175-46	36120-36126	higher	_	
175-47	36127-36138	probability	_	
175-48	36139-36141	of	_	
175-49	36142-36144	an	_	
175-50	36145-36154	explosion	_	
175-51	36155-36156	(	_	
175-52	36156-36158	or	_	
175-53	36159-36168	magnitude	_	
175-54	36169-36171	of	_	
175-55	36172-36178	reward	_	
175-56	36178-36179	)	_	
175-57	36180-36182	at	_	
175-58	36183-36192	follow-up	_	
175-59	36192-36193	.	_	

#Text=For the Explode*p(Explode) contrast (red), there was a greater negative relationship between trial-to-trial variation in p(Explode) and the magnetic resonance (MR) signal at follow-up (i.e., stronger signal with a lower probability of an explosion (or magnitude of reward) at follow-up.
176-1	36194-36197	For	_	
176-2	36198-36201	the	_	
176-3	36202-36209	Explode	_	
176-4	36209-36210	*	_	
176-5	36210-36211	p	_	
176-6	36211-36212	(	_	
176-7	36212-36219	Explode	_	
176-8	36219-36220	)	_	
176-9	36221-36229	contrast	_	
176-10	36230-36231	(	_	
176-11	36231-36234	red	_	
176-12	36234-36235	)	_	
176-13	36235-36236	,	_	
176-14	36237-36242	there	_	
176-15	36243-36246	was	_	
176-16	36247-36248	a	_	
176-17	36249-36256	greater	_	
176-18	36257-36265	negative	_	
176-19	36266-36278	relationship	_	
176-20	36279-36286	between	_	
176-21	36287-36301	trial-to-trial	_	
176-22	36302-36311	variation	_	
176-23	36312-36314	in	_	
176-24	36315-36316	p	_	
176-25	36316-36317	(	_	
176-26	36317-36324	Explode	_	
176-27	36324-36325	)	_	
176-28	36326-36329	and	_	
176-29	36330-36333	the	_	
176-30	36334-36342	magnetic	_	
176-31	36343-36352	resonance	_	
176-32	36353-36354	(	_	
176-33	36354-36356	MR	_	
176-34	36356-36357	)	_	
176-35	36358-36364	signal	_	
176-36	36365-36367	at	_	
176-37	36368-36377	follow-up	_	
176-38	36378-36379	(	_	
176-39	36379-36382	i.e	_	
176-40	36382-36383	.	_	
176-41	36383-36384	,	_	
176-42	36385-36393	stronger	_	
176-43	36394-36400	signal	_	
176-44	36401-36405	with	_	
176-45	36406-36407	a	_	
176-46	36408-36413	lower	_	
176-47	36414-36425	probability	_	
176-48	36426-36428	of	_	
176-49	36429-36431	an	_	
176-50	36432-36441	explosion	_	
176-51	36442-36443	(	_	
176-52	36443-36445	or	_	
176-53	36446-36455	magnitude	_	
176-54	36456-36458	of	_	
176-55	36459-36465	reward	_	
176-56	36465-36466	)	_	
176-57	36467-36469	at	_	
176-58	36470-36479	follow-up	_	
176-59	36479-36480	.	_	

#Text=(For interpretation of the references to color in this figure legend, the reader is referred to the web version of this article.)
177-1	36481-36482	(	_	
177-2	36482-36485	For	_	
177-3	36486-36500	interpretation	_	
177-4	36501-36503	of	_	
177-5	36504-36507	the	_	
177-6	36508-36518	references	_	
177-7	36519-36521	to	_	
177-8	36522-36527	color	_	
177-9	36528-36530	in	_	
177-10	36531-36535	this	_	
177-11	36536-36542	figure	_	
177-12	36543-36549	legend	_	
177-13	36549-36550	,	_	
177-14	36551-36554	the	_	
177-15	36555-36561	reader	_	
177-16	36562-36564	is	_	
177-17	36565-36573	referred	_	
177-18	36574-36576	to	_	
177-19	36577-36580	the	_	
177-20	36581-36584	web	_	
177-21	36585-36592	version	_	
177-22	36593-36595	of	_	
177-23	36596-36600	this	_	
177-24	36601-36608	article	_	
177-25	36608-36609	.	_	
177-26	36609-36610	)	_	

#Text=Longitudinal attenuation of the “risk-seeking” signal in dACC/vmPFC during 'Inflate' decisions corresponded with decreased substance use during the study interval.
178-1	36611-36623	Longitudinal	_	
178-2	36624-36635	attenuation	_	
178-3	36636-36638	of	_	
178-4	36639-36642	the	_	
178-5	36643-36644	“	_	
178-6	36644-36656	risk-seeking	_	
178-7	36656-36657	”	_	
178-8	36658-36664	signal	_	
178-9	36665-36667	in	_	
178-10	36668-36672	dACC	_	
178-11	36672-36673	/	_	
178-12	36673-36678	vmPFC	_	
178-13	36679-36685	during	_	
178-14	36686-36687	'	_	
178-15	36687-36694	Inflate	_	
178-16	36694-36695	'	_	
178-17	36696-36705	decisions	_	
178-18	36706-36718	corresponded	_	
178-19	36719-36723	with	_	
178-20	36724-36733	decreased	_	
178-21	36734-36743	substance	_	
178-22	36744-36747	use	_	
178-23	36748-36754	during	_	
178-24	36755-36758	the	_	
178-25	36759-36764	study	_	
178-26	36765-36773	interval	_	
178-27	36773-36774	.	_	

#Text=Overlapping clusters were identified with (peak voxel: −2, 44, 10) and without (peak voxel: −6, 36, 10) inclusion of two participants with the heaviest reported substance use, indicating the effect was robust to the exclusion of potential outliers.
179-1	36775-36786	Overlapping	_	
179-2	36787-36795	clusters	_	
179-3	36796-36800	were	_	
179-4	36801-36811	identified	_	
179-5	36812-36816	with	_	
179-6	36817-36818	(	_	
179-7	36818-36822	peak	_	
179-8	36823-36828	voxel	_	
179-9	36828-36829	:	_	
179-10	36830-36831	−	_	
179-11	36831-36832	2	_	
179-12	36832-36833	,	_	
179-13	36834-36836	44	_	
179-14	36836-36837	,	_	
179-15	36838-36840	10	_	
179-16	36840-36841	)	_	
179-17	36842-36845	and	_	
179-18	36846-36853	without	_	
179-19	36854-36855	(	_	
179-20	36855-36859	peak	_	
179-21	36860-36865	voxel	_	
179-22	36865-36866	:	_	
179-23	36867-36868	−	_	
179-24	36868-36869	6	_	
179-25	36869-36870	,	_	
179-26	36871-36873	36	_	
179-27	36873-36874	,	_	
179-28	36875-36877	10	_	
179-29	36877-36878	)	_	
179-30	36879-36888	inclusion	_	
179-31	36889-36891	of	_	
179-32	36892-36895	two	_	
179-33	36896-36908	participants	_	
179-34	36909-36913	with	_	
179-35	36914-36917	the	_	
179-36	36918-36926	heaviest	_	
179-37	36927-36935	reported	_	
179-38	36936-36945	substance	_	
179-39	36946-36949	use	_	
179-40	36949-36950	,	_	
179-41	36951-36961	indicating	_	
179-42	36962-36965	the	_	
179-43	36966-36972	effect	_	
179-44	36973-36976	was	_	
179-45	36977-36983	robust	_	
179-46	36984-36986	to	_	
179-47	36987-36990	the	_	
179-48	36991-37000	exclusion	_	
179-49	37001-37003	of	_	
179-50	37004-37013	potential	_	
179-51	37014-37022	outliers	_	
179-52	37022-37023	.	_	

#Text=A positive longitudinal contrast, indicating increased signal with increasing reward at follow-up, was associated with increased substance use.
180-1	37024-37025	A	_	
180-2	37026-37034	positive	_	
180-3	37035-37047	longitudinal	_	
180-4	37048-37056	contrast	_	
180-5	37056-37057	,	_	
180-6	37058-37068	indicating	_	
180-7	37069-37078	increased	_	
180-8	37079-37085	signal	_	
180-9	37086-37090	with	_	
180-10	37091-37101	increasing	_	
180-11	37102-37108	reward	_	
180-12	37109-37111	at	_	
180-13	37112-37121	follow-up	_	
180-14	37121-37122	,	_	
180-15	37123-37126	was	_	
180-16	37127-37137	associated	_	
180-17	37138-37142	with	_	
180-18	37143-37152	increased	_	
180-19	37153-37162	substance	_	
180-20	37163-37166	use	_	
180-21	37166-37167	.	_	

#Text=A negative longitudinal contrast, indicating decreased signal with increasing reward at follow-up, was associated with less substance use.
181-1	37168-37169	A	_	
181-2	37170-37178	negative	_	
181-3	37179-37191	longitudinal	_	
181-4	37192-37200	contrast	_	
181-5	37200-37201	,	_	
181-6	37202-37212	indicating	_	
181-7	37213-37222	decreased	_	
181-8	37223-37229	signal	_	
181-9	37230-37234	with	_	
181-10	37235-37245	increasing	_	
181-11	37246-37252	reward	_	
181-12	37253-37255	at	_	
181-13	37256-37265	follow-up	_	
181-14	37265-37266	,	_	
181-15	37267-37270	was	_	
181-16	37271-37281	associated	_	
181-17	37282-37286	with	_	
181-18	37287-37291	less	_	
181-19	37292-37301	substance	_	
181-20	37302-37305	use	_	
181-21	37305-37306	.	_	

#Text=A vmPFC-based reward-seeking signal was previously described in association with BART inflation events in healthy participants.
182-1	37307-37308	A	_	
182-2	37309-37320	vmPFC-based	_	
182-3	37321-37335	reward-seeking	_	
182-4	37336-37342	signal	_	
182-5	37343-37346	was	_	
182-6	37347-37357	previously	_	
182-7	37358-37367	described	_	
182-8	37368-37370	in	_	
182-9	37371-37382	association	_	
182-10	37383-37387	with	_	
182-11	37388-37392	BART	_	
182-12	37393-37402	inflation	_	
182-13	37403-37409	events	_	
182-14	37410-37412	in	_	
182-15	37413-37420	healthy	_	
182-16	37421-37433	participants	_	
182-17	37433-37434	.	_	

#Text=Longitudinal attenuation of this signal in successful early recovery may reflect improved inhibition of reward-seeking and may, in turn, be mediated by restoration of control-related functioning in other prefrontal regions.
183-1	37435-37447	Longitudinal	_	
183-2	37448-37459	attenuation	_	
183-3	37460-37462	of	_	
183-4	37463-37467	this	_	
183-5	37468-37474	signal	_	
183-6	37475-37477	in	_	
183-7	37478-37488	successful	_	
183-8	37489-37494	early	_	
183-9	37495-37503	recovery	_	
183-10	37504-37507	may	_	
183-11	37508-37515	reflect	_	
183-12	37516-37524	improved	_	
183-13	37525-37535	inhibition	_	
183-14	37536-37538	of	_	
183-15	37539-37553	reward-seeking	_	
183-16	37554-37557	and	_	
183-17	37558-37561	may	_	
183-18	37561-37562	,	_	
183-19	37563-37565	in	_	
183-20	37566-37570	turn	_	
183-21	37570-37571	,	_	
183-22	37572-37574	be	_	
183-23	37575-37583	mediated	_	
183-24	37584-37586	by	_	
183-25	37587-37598	restoration	_	
183-26	37599-37601	of	_	
183-27	37602-37617	control-related	_	
183-28	37618-37629	functioning	_	
183-29	37630-37632	in	_	
183-30	37633-37638	other	_	
183-31	37639-37649	prefrontal	_	
183-32	37650-37657	regions	_	
183-33	37657-37658	.	_	

#Text=Wager amount and probability of explosion by inflation number.
184-1	37659-37664	Wager	_	
184-2	37665-37671	amount	_	
184-3	37672-37675	and	_	
184-4	37676-37687	probability	_	
184-5	37688-37690	of	_	
184-6	37691-37700	explosion	_	
184-7	37701-37703	by	_	
184-8	37704-37713	inflation	_	
184-9	37714-37720	number	_	
184-10	37720-37721	.	_	

#Text=Inflation#\tWager Amount\tp(Explode)\t \t0\t$0.00\t0.0%\t \t1\t$0.05\t2.1%\t \t2\t$0.15\t4.2%\t \t3\t$0.25\t6.3%\t \t4\t$0.55\t14.6%\t \t5\t$0.95\t23.9%\t \t6\t$1.45\t31.3%\t \t7\t$2.05\t43.8%\t \t8\t$2.75\t56.3%\t \t9\t$3.45\t68.8%\t \t10\t$4.25\t79.2%\t \t11\t$5.15\t89.6%\t \t
#Text=*Correlation between wager amount and probability of explosion is r = 0.995
#Text=Sample demographic and recruitment data (n = 21).
185-1	37722-37731	Inflation	_	
185-2	37731-37732	#	_	
185-3	37733-37738	Wager	_	
185-4	37739-37745	Amount	_	
185-5	37746-37747	p	_	
185-6	37747-37748	(	_	
185-7	37748-37755	Explode	_	
185-8	37755-37756	)	_	
185-9	37759-37760	0	_	
185-10	37761-37766	$0.00	_	
185-11	37767-37771	0.0%	_	
185-12	37774-37775	1	_	
185-13	37776-37781	$0.05	_	
185-14	37782-37786	2.1%	_	
185-15	37789-37790	2	_	
185-16	37791-37796	$0.15	_	
185-17	37797-37801	4.2%	_	
185-18	37804-37805	3	_	
185-19	37806-37811	$0.25	_	
185-20	37812-37816	6.3%	_	
185-21	37819-37820	4	_	
185-22	37821-37826	$0.55	_	
185-23	37827-37832	14.6%	_	
185-24	37835-37836	5	_	
185-25	37837-37842	$0.95	_	
185-26	37843-37848	23.9%	_	
185-27	37851-37852	6	_	
185-28	37853-37858	$1.45	_	
185-29	37859-37864	31.3%	_	
185-30	37867-37868	7	_	
185-31	37869-37874	$2.05	_	
185-32	37875-37880	43.8%	_	
185-33	37883-37884	8	_	
185-34	37885-37890	$2.75	_	
185-35	37891-37896	56.3%	_	
185-36	37899-37900	9	_	
185-37	37901-37906	$3.45	_	
185-38	37907-37912	68.8%	_	
185-39	37915-37917	10	_	
185-40	37918-37923	$4.25	_	
185-41	37924-37929	79.2%	_	
185-42	37932-37934	11	_	
185-43	37935-37940	$5.15	_	
185-44	37941-37946	89.6%	_	
185-45	37950-37951	*	_	
185-46	37951-37962	Correlation	_	
185-47	37963-37970	between	_	
185-48	37971-37976	wager	_	
185-49	37977-37983	amount	_	
185-50	37984-37987	and	_	
185-51	37988-37999	probability	_	
185-52	38000-38002	of	_	
185-53	38003-38012	explosion	_	
185-54	38013-38015	is	_	
185-55	38016-38017	r	_	
185-56	38018-38019	=	_	
185-57	38020-38025	0.995	_	
185-58	38026-38032	Sample	_	
185-59	38033-38044	demographic	_	
185-60	38045-38048	and	_	
185-61	38049-38060	recruitment	_	
185-62	38061-38065	data	_	
185-63	38066-38067	(	_	
185-64	38067-38068	n	_	
185-65	38069-38070	=	_	
185-66	38071-38073	21	_	
185-67	38073-38074	)	_	
185-68	38074-38075	.	_	

#Text=Demographic Variables\t\t\t\t\t \tAge\t\t\t27 (6.8)\t\t \tMale\t\t\t15\t\t \tTotal Years of Education\t\t\t13 (1.9)\t\t \tEmployment Status\t\t\tBaseline\t3 Mo.
186-1	38076-38087	Demographic	_	
186-2	38088-38097	Variables	_	
186-3	38104-38107	Age	_	
186-4	38110-38112	27	_	
186-5	38113-38114	(	_	
186-6	38114-38117	6.8	_	
186-7	38117-38118	)	_	
186-8	38122-38126	Male	_	
186-9	38129-38131	15	_	
186-10	38135-38140	Total	_	
186-11	38141-38146	Years	_	
186-12	38147-38149	of	_	
186-13	38150-38159	Education	_	
186-14	38162-38164	13	_	
186-15	38165-38166	(	_	
186-16	38166-38169	1.9	_	
186-17	38169-38170	)	_	
186-18	38174-38184	Employment	_	
186-19	38185-38191	Status	_	
186-20	38194-38202	Baseline	_	
186-21	38203-38204	3	_	
186-22	38205-38207	Mo	_	
186-23	38207-38208	.	_	

#Text=Employed Full Time\t5\t8\t\t \t\tEmployed Part Time\t5\t4\t\t \t\tUnemployed\t9\t8\t\t \t\tStudent\t2\t1\t\t \tRecruitment Information\t\t\t\t\t \tTreatment Setting\t\tOutpatient\t12\t\t \t\tResidential\t9\t\t\t \tReferral Source\t\tSelf\t13\t\t \t\tDrug Court\t5\t\t\t \t\tProbation\t3\t\t\t \tClinical Variables\t\t\t\t\t \tNumber of Times in Previous Treatment\t\t\t2 (2.5)\t\t \tSSAGA Symptom Count\t\t\t6.5 (0.7)\t\t \tPrimary DSM-IV Diagnosis\tAlcohol dependence\t\t\t12\t \t\tSedative, Hypnotic, or Anxiolytic dependence\t\t\t1\t \t\tCannabis dependence\t\t\t1\t \t\tAmphetamine dependence\t\t\t1\t \t\tOpioid dependence\t\t\t2\t \t\tPolysubstance dependence\t\t\t4\t \tAdditional Psychiatric Diagnoses\tMajor Depressive Disorder\t\t\t4\t \t\tGeneralized Anxiety Disorder\t\t\t4\t \t\tPosttraumatic Stress Disorder\t\t\t1\t \t\tAnxiety Disorder NOS\t\t\t2\t \t\tAntisocial Personality Disorder\t\t\t1\t \t\tNone\t\t\t7\t \t
#Text=Summary of BART behavioral performance measures and substance use outcomes.
187-1	38212-38220	Employed	_	
187-2	38221-38225	Full	_	
187-3	38226-38230	Time	_	
187-4	38231-38232	5	_	
187-5	38233-38234	8	_	
187-6	38239-38247	Employed	_	
187-7	38248-38252	Part	_	
187-8	38253-38257	Time	_	
187-9	38258-38259	5	_	
187-10	38260-38261	4	_	
187-11	38266-38276	Unemployed	_	
187-12	38277-38278	9	_	
187-13	38279-38280	8	_	
187-14	38285-38292	Student	_	
187-15	38293-38294	2	_	
187-16	38295-38296	1	_	
187-17	38300-38311	Recruitment	_	
187-18	38312-38323	Information	_	
187-19	38330-38339	Treatment	_	
187-20	38340-38347	Setting	_	
187-21	38349-38359	Outpatient	_	
187-22	38360-38362	12	_	
187-23	38367-38378	Residential	_	
187-24	38379-38380	9	_	
187-25	38385-38393	Referral	_	
187-26	38394-38400	Source	_	
187-27	38402-38406	Self	_	
187-28	38407-38409	13	_	
187-29	38414-38418	Drug	_	
187-30	38419-38424	Court	_	
187-31	38425-38426	5	_	
187-32	38432-38441	Probation	_	
187-33	38442-38443	3	_	
187-34	38448-38456	Clinical	_	
187-35	38457-38466	Variables	_	
187-36	38473-38479	Number	_	
187-37	38480-38482	of	_	
187-38	38483-38488	Times	_	
187-39	38489-38491	in	_	
187-40	38492-38500	Previous	_	
187-41	38501-38510	Treatment	_	
187-42	38513-38514	2	_	
187-43	38515-38516	(	_	
187-44	38516-38519	2.5	_	
187-45	38519-38520	)	_	
187-46	38524-38529	SSAGA	_	
187-47	38530-38537	Symptom	_	
187-48	38538-38543	Count	_	
187-49	38546-38549	6.5	_	
187-50	38550-38551	(	_	
187-51	38551-38554	0.7	_	
187-52	38554-38555	)	_	
187-53	38559-38566	Primary	_	
187-54	38567-38573	DSM-IV	_	
187-55	38574-38583	Diagnosis	_	
187-56	38584-38591	Alcohol	_	
187-57	38592-38602	dependence	_	
187-58	38605-38607	12	_	
187-59	38611-38619	Sedative	_	
187-60	38619-38620	,	_	
187-61	38621-38629	Hypnotic	_	
187-62	38629-38630	,	_	
187-63	38631-38633	or	_	
187-64	38634-38644	Anxiolytic	_	
187-65	38645-38655	dependence	_	
187-66	38658-38659	1	_	
187-67	38663-38671	Cannabis	_	
187-68	38672-38682	dependence	_	
187-69	38685-38686	1	_	
187-70	38690-38701	Amphetamine	_	
187-71	38702-38712	dependence	_	
187-72	38715-38716	1	_	
187-73	38720-38726	Opioid	_	
187-74	38727-38737	dependence	_	
187-75	38740-38741	2	_	
187-76	38745-38758	Polysubstance	_	
187-77	38759-38769	dependence	_	
187-78	38772-38773	4	_	
187-79	38776-38786	Additional	_	
187-80	38787-38798	Psychiatric	_	
187-81	38799-38808	Diagnoses	_	
187-82	38809-38814	Major	_	
187-83	38815-38825	Depressive	_	
187-84	38826-38834	Disorder	_	
187-85	38837-38838	4	_	
187-86	38842-38853	Generalized	_	
187-87	38854-38861	Anxiety	_	
187-88	38862-38870	Disorder	_	
187-89	38873-38874	4	_	
187-90	38878-38891	Posttraumatic	_	
187-91	38892-38898	Stress	_	
187-92	38899-38907	Disorder	_	
187-93	38910-38911	1	_	
187-94	38915-38922	Anxiety	_	
187-95	38923-38931	Disorder	_	
187-96	38932-38935	NOS	_	
187-97	38938-38939	2	_	
187-98	38943-38953	Antisocial	_	
187-99	38954-38965	Personality	_	
187-100	38966-38974	Disorder	_	
187-101	38977-38978	1	_	
187-102	38982-38986	None	_	
187-103	38989-38990	7	_	
187-104	38994-39001	Summary	_	
187-105	39002-39004	of	_	
187-106	39005-39009	BART	_	
187-107	39010-39020	behavioral	_	
187-108	39021-39032	performance	_	
187-109	39033-39041	measures	_	
187-110	39042-39045	and	_	
187-111	39046-39055	substance	_	
187-112	39056-39059	use	_	
187-113	39060-39068	outcomes	_	
187-114	39068-39069	.	_	

#Text=BART Behavioral Performance\t \tDependent Variable\tMean (SD)\tF-statistic (p-value)\t \tBaseline\tFollow-up\tMain Effect: Timepoint\tMain Effect: Block\tInteraction\t \tBlock 1\tBlock 2\tBlock 1\tBlock 2\t \tTotal # of Balloons\t16.5 (1.6)\t16.3 (1.9)\t17.0 (2.5)\t17.1 (2.8)\t2.81 (0.109)\t0.08 (0.785)\t0.35 (0.559)\t \t# of Balloons Exploded\t5.9 (2.5)\t5.9 (2.2)\t6.0 (2.2)\t5.8 (2.1)\t0.00 (1.00)\t0.09 (0.766)\t0.01 (0.906)\t \t# of Balloons Won\t10.6 (3.1)\t10.4 (3.0)\t11.1 (3.4)\t11.3 (3.7)\t1.22 (0.283)\t0.00 (0.946)\t0.26 (0.617)\t \tAverage Stop Inflation #\t6.29 (0.87)\t6.34 (0.68)\t6.25 (0.75)\t6.22 (0.67)\t0.22 (0.642)\t0.01 (0.918)\t0.19 (0.672)\t \tAverage Explode Inflation #\t4.96 (0.82)\t5.04 (1.34)\t4.92 (0.86)\t4.89 (0.94)\t0.35 (0.559)\t0.01 (0.919)\t0.09 (0.769)\t \tChoose Inflate Trial RT\t1081 (458)\t1036 (488)\t952 (432)\t952 (512)\t3.24 (0.087)\t0.41 (0.527)\t0.78 (0.387)\t \tChoose Win Trial RT\t1115 (743)\t1003 (819)\t875 (494)\t811 (420)\t4.45 (0.048)\t1.63 (0.217)\t0.16 (0.690)\t \tRT (All Trials)\t1098 (583)\t1019 (621)\t914 (392)\t882 (436)\t6.46 (0.019)**\t1.49 (0.237)\t0.42 (0.522)\t \t
#Text=Substance Use Outcomes\t\t\t\t\t\t \t\t \t\t\t1 Mo.\t2 Mo.\t3 Mo.
188-1	39070-39074	BART	_	
188-2	39075-39085	Behavioral	_	
188-3	39086-39097	Performance	_	
188-4	39100-39109	Dependent	_	
188-5	39110-39118	Variable	_	
188-6	39119-39123	Mean	_	
188-7	39124-39125	(	_	
188-8	39125-39127	SD	_	
188-9	39127-39128	)	_	
188-10	39129-39140	F-statistic	_	
188-11	39141-39142	(	_	
188-12	39142-39149	p-value	_	
188-13	39149-39150	)	_	
188-14	39153-39161	Baseline	_	
188-15	39162-39171	Follow-up	_	
188-16	39172-39176	Main	_	
188-17	39177-39183	Effect	_	
188-18	39183-39184	:	_	
188-19	39185-39194	Timepoint	_	
188-20	39195-39199	Main	_	
188-21	39200-39206	Effect	_	
188-22	39206-39207	:	_	
188-23	39208-39213	Block	_	
188-24	39214-39225	Interaction	_	
188-25	39228-39233	Block	_	
188-26	39234-39235	1	_	
188-27	39236-39241	Block	_	
188-28	39242-39243	2	_	
188-29	39244-39249	Block	_	
188-30	39250-39251	1	_	
188-31	39252-39257	Block	_	
188-32	39258-39259	2	_	
188-33	39262-39267	Total	_	
188-34	39268-39269	#	_	
188-35	39270-39272	of	_	
188-36	39273-39281	Balloons	_	
188-37	39282-39286	16.5	_	
188-38	39287-39288	(	_	
188-39	39288-39291	1.6	_	
188-40	39291-39292	)	_	
188-41	39293-39297	16.3	_	
188-42	39298-39299	(	_	
188-43	39299-39302	1.9	_	
188-44	39302-39303	)	_	
188-45	39304-39308	17.0	_	
188-46	39309-39310	(	_	
188-47	39310-39313	2.5	_	
188-48	39313-39314	)	_	
188-49	39315-39319	17.1	_	
188-50	39320-39321	(	_	
188-51	39321-39324	2.8	_	
188-52	39324-39325	)	_	
188-53	39326-39330	2.81	_	
188-54	39331-39332	(	_	
188-55	39332-39337	0.109	_	
188-56	39337-39338	)	_	
188-57	39339-39343	0.08	_	
188-58	39344-39345	(	_	
188-59	39345-39350	0.785	_	
188-60	39350-39351	)	_	
188-61	39352-39356	0.35	_	
188-62	39357-39358	(	_	
188-63	39358-39363	0.559	_	
188-64	39363-39364	)	_	
188-65	39367-39368	#	_	
188-66	39369-39371	of	_	
188-67	39372-39380	Balloons	_	
188-68	39381-39389	Exploded	_	
188-69	39390-39393	5.9	_	
188-70	39394-39395	(	_	
188-71	39395-39398	2.5	_	
188-72	39398-39399	)	_	
188-73	39400-39403	5.9	_	
188-74	39404-39405	(	_	
188-75	39405-39408	2.2	_	
188-76	39408-39409	)	_	
188-77	39410-39413	6.0	_	
188-78	39414-39415	(	_	
188-79	39415-39418	2.2	_	
188-80	39418-39419	)	_	
188-81	39420-39423	5.8	_	
188-82	39424-39425	(	_	
188-83	39425-39428	2.1	_	
188-84	39428-39429	)	_	
188-85	39430-39434	0.00	_	
188-86	39435-39436	(	_	
188-87	39436-39440	1.00	_	
188-88	39440-39441	)	_	
188-89	39442-39446	0.09	_	
188-90	39447-39448	(	_	
188-91	39448-39453	0.766	_	
188-92	39453-39454	)	_	
188-93	39455-39459	0.01	_	
188-94	39460-39461	(	_	
188-95	39461-39466	0.906	_	
188-96	39466-39467	)	_	
188-97	39470-39471	#	_	
188-98	39472-39474	of	_	
188-99	39475-39483	Balloons	_	
188-100	39484-39487	Won	_	
188-101	39488-39492	10.6	_	
188-102	39493-39494	(	_	
188-103	39494-39497	3.1	_	
188-104	39497-39498	)	_	
188-105	39499-39503	10.4	_	
188-106	39504-39505	(	_	
188-107	39505-39508	3.0	_	
188-108	39508-39509	)	_	
188-109	39510-39514	11.1	_	
188-110	39515-39516	(	_	
188-111	39516-39519	3.4	_	
188-112	39519-39520	)	_	
188-113	39521-39525	11.3	_	
188-114	39526-39527	(	_	
188-115	39527-39530	3.7	_	
188-116	39530-39531	)	_	
188-117	39532-39536	1.22	_	
188-118	39537-39538	(	_	
188-119	39538-39543	0.283	_	
188-120	39543-39544	)	_	
188-121	39545-39549	0.00	_	
188-122	39550-39551	(	_	
188-123	39551-39556	0.946	_	
188-124	39556-39557	)	_	
188-125	39558-39562	0.26	_	
188-126	39563-39564	(	_	
188-127	39564-39569	0.617	_	
188-128	39569-39570	)	_	
188-129	39573-39580	Average	_	
188-130	39581-39585	Stop	_	
188-131	39586-39595	Inflation	_	
188-132	39596-39597	#	_	
188-133	39598-39602	6.29	_	
188-134	39603-39604	(	_	
188-135	39604-39608	0.87	_	
188-136	39608-39609	)	_	
188-137	39610-39614	6.34	_	
188-138	39615-39616	(	_	
188-139	39616-39620	0.68	_	
188-140	39620-39621	)	_	
188-141	39622-39626	6.25	_	
188-142	39627-39628	(	_	
188-143	39628-39632	0.75	_	
188-144	39632-39633	)	_	
188-145	39634-39638	6.22	_	
188-146	39639-39640	(	_	
188-147	39640-39644	0.67	_	
188-148	39644-39645	)	_	
188-149	39646-39650	0.22	_	
188-150	39651-39652	(	_	
188-151	39652-39657	0.642	_	
188-152	39657-39658	)	_	
188-153	39659-39663	0.01	_	
188-154	39664-39665	(	_	
188-155	39665-39670	0.918	_	
188-156	39670-39671	)	_	
188-157	39672-39676	0.19	_	
188-158	39677-39678	(	_	
188-159	39678-39683	0.672	_	
188-160	39683-39684	)	_	
188-161	39687-39694	Average	_	
188-162	39695-39702	Explode	_	
188-163	39703-39712	Inflation	_	
188-164	39713-39714	#	_	
188-165	39715-39719	4.96	_	
188-166	39720-39721	(	_	
188-167	39721-39725	0.82	_	
188-168	39725-39726	)	_	
188-169	39727-39731	5.04	_	
188-170	39732-39733	(	_	
188-171	39733-39737	1.34	_	
188-172	39737-39738	)	_	
188-173	39739-39743	4.92	_	
188-174	39744-39745	(	_	
188-175	39745-39749	0.86	_	
188-176	39749-39750	)	_	
188-177	39751-39755	4.89	_	
188-178	39756-39757	(	_	
188-179	39757-39761	0.94	_	
188-180	39761-39762	)	_	
188-181	39763-39767	0.35	_	
188-182	39768-39769	(	_	
188-183	39769-39774	0.559	_	
188-184	39774-39775	)	_	
188-185	39776-39780	0.01	_	
188-186	39781-39782	(	_	
188-187	39782-39787	0.919	_	
188-188	39787-39788	)	_	
188-189	39789-39793	0.09	_	
188-190	39794-39795	(	_	
188-191	39795-39800	0.769	_	
188-192	39800-39801	)	_	
188-193	39804-39810	Choose	_	
188-194	39811-39818	Inflate	_	
188-195	39819-39824	Trial	_	
188-196	39825-39827	RT	_	
188-197	39828-39832	1081	_	
188-198	39833-39834	(	_	
188-199	39834-39837	458	_	
188-200	39837-39838	)	_	
188-201	39839-39843	1036	_	
188-202	39844-39845	(	_	
188-203	39845-39848	488	_	
188-204	39848-39849	)	_	
188-205	39850-39853	952	_	
188-206	39854-39855	(	_	
188-207	39855-39858	432	_	
188-208	39858-39859	)	_	
188-209	39860-39863	952	_	
188-210	39864-39865	(	_	
188-211	39865-39868	512	_	
188-212	39868-39869	)	_	
188-213	39870-39874	3.24	_	
188-214	39875-39876	(	_	
188-215	39876-39881	0.087	_	
188-216	39881-39882	)	_	
188-217	39883-39887	0.41	_	
188-218	39888-39889	(	_	
188-219	39889-39894	0.527	_	
188-220	39894-39895	)	_	
188-221	39896-39900	0.78	_	
188-222	39901-39902	(	_	
188-223	39902-39907	0.387	_	
188-224	39907-39908	)	_	
188-225	39911-39917	Choose	_	
188-226	39918-39921	Win	_	
188-227	39922-39927	Trial	_	
188-228	39928-39930	RT	_	
188-229	39931-39935	1115	_	
188-230	39936-39937	(	_	
188-231	39937-39940	743	_	
188-232	39940-39941	)	_	
188-233	39942-39946	1003	_	
188-234	39947-39948	(	_	
188-235	39948-39951	819	_	
188-236	39951-39952	)	_	
188-237	39953-39956	875	_	
188-238	39957-39958	(	_	
188-239	39958-39961	494	_	
188-240	39961-39962	)	_	
188-241	39963-39966	811	_	
188-242	39967-39968	(	_	
188-243	39968-39971	420	_	
188-244	39971-39972	)	_	
188-245	39973-39977	4.45	_	
188-246	39978-39979	(	_	
188-247	39979-39984	0.048	_	
188-248	39984-39985	)	_	
188-249	39986-39990	1.63	_	
188-250	39991-39992	(	_	
188-251	39992-39997	0.217	_	
188-252	39997-39998	)	_	
188-253	39999-40003	0.16	_	
188-254	40004-40005	(	_	
188-255	40005-40010	0.690	_	
188-256	40010-40011	)	_	
188-257	40014-40016	RT	_	
188-258	40017-40018	(	_	
188-259	40018-40021	All	_	
188-260	40022-40028	Trials	_	
188-261	40028-40029	)	_	
188-262	40030-40034	1098	_	
188-263	40035-40036	(	_	
188-264	40036-40039	583	_	
188-265	40039-40040	)	_	
188-266	40041-40045	1019	_	
188-267	40046-40047	(	_	
188-268	40047-40050	621	_	
188-269	40050-40051	)	_	
188-270	40052-40055	914	_	
188-271	40056-40057	(	_	
188-272	40057-40060	392	_	
188-273	40060-40061	)	_	
188-274	40062-40065	882	_	
188-275	40066-40067	(	_	
188-276	40067-40070	436	_	
188-277	40070-40071	)	_	
188-278	40072-40076	6.46	_	
188-279	40077-40078	(	_	
188-280	40078-40083	0.019	_	
188-281	40083-40084	)	_	
188-282	40084-40085	*	_	
188-283	40085-40086	*	_	
188-284	40087-40091	1.49	_	
188-285	40092-40093	(	_	
188-286	40093-40098	0.237	_	
188-287	40098-40099	)	_	
188-288	40100-40104	0.42	_	
188-289	40105-40106	(	_	
188-290	40106-40111	0.522	_	
188-291	40111-40112	)	_	
188-292	40116-40125	Substance	_	
188-293	40126-40129	Use	_	
188-294	40130-40138	Outcomes	_	
188-295	40151-40152	1	_	
188-296	40153-40155	Mo	_	
188-297	40155-40156	.	_	
188-298	40157-40158	2	_	
188-299	40159-40161	Mo	_	
188-300	40161-40162	.	_	
188-301	40163-40164	3	_	
188-302	40165-40167	Mo	_	
188-303	40167-40168	.	_	

#Text=Total\t \tSubstance Use Metric (SUM)\tMean (SD)\t0.035 (0.082)\t0.069 (0.187)\t0.067 (0.132)\t0.057 (0.127)\t \t\tMaximum\t0.283\t0.717\t0.567\t0.519\t \t
#Text=\t\tAlcohol\tDrug\tAlcohol\tDrug\tAlcohol\tDrug\tCombined\t \tReported Days of Use\tMean (SD)\t0.3 (0.9)\t1.3 (5.9)\t0.1 (0.7)\t1.4 (6.5)\t0.1 (0.3)\t1.9 (6.3)\t5.1 (19.2)\t \tw/out Intoxication\tMaximum\t4\t27\t3\t30\t1\t26\t87\t \tReported Days of Use\tMean (SD)\t0.3 (0.7)\t1.0 (3.7)\t1.9 (6.1)\t1.5 (6.5)\t1.8 (3.8)\t1.3 (3.2)\t7.8 (14.5)\t \tw/Intoxication\tMaximum\t3\t17\t28\t30\t17\t13\t50\t \t
#Text=Regions of interest from longitudinal contrasts and whole brain correlation analysis of substance use outcomes.
189-1	40169-40174	Total	_	
189-2	40177-40186	Substance	_	
189-3	40187-40190	Use	_	
189-4	40191-40197	Metric	_	
189-5	40198-40199	(	_	
189-6	40199-40202	SUM	_	
189-7	40202-40203	)	_	
189-8	40204-40208	Mean	_	
189-9	40209-40210	(	_	
189-10	40210-40212	SD	_	
189-11	40212-40213	)	_	
189-12	40214-40219	0.035	_	
189-13	40220-40221	(	_	
189-14	40221-40226	0.082	_	
189-15	40226-40227	)	_	
189-16	40228-40233	0.069	_	
189-17	40234-40235	(	_	
189-18	40235-40240	0.187	_	
189-19	40240-40241	)	_	
189-20	40242-40247	0.067	_	
189-21	40248-40249	(	_	
189-22	40249-40254	0.132	_	
189-23	40254-40255	)	_	
189-24	40256-40261	0.057	_	
189-25	40262-40263	(	_	
189-26	40263-40268	0.127	_	
189-27	40268-40269	)	_	
189-28	40273-40280	Maximum	_	
189-29	40281-40286	0.283	_	
189-30	40287-40292	0.717	_	
189-31	40293-40298	0.567	_	
189-32	40299-40304	0.519	_	
189-33	40310-40317	Alcohol	_	
189-34	40318-40322	Drug	_	
189-35	40323-40330	Alcohol	_	
189-36	40331-40335	Drug	_	
189-37	40336-40343	Alcohol	_	
189-38	40344-40348	Drug	_	
189-39	40349-40357	Combined	_	
189-40	40360-40368	Reported	_	
189-41	40369-40373	Days	_	
189-42	40374-40376	of	_	
189-43	40377-40380	Use	_	
189-44	40381-40385	Mean	_	
189-45	40386-40387	(	_	
189-46	40387-40389	SD	_	
189-47	40389-40390	)	_	
189-48	40391-40394	0.3	_	
189-49	40395-40396	(	_	
189-50	40396-40399	0.9	_	
189-51	40399-40400	)	_	
189-52	40401-40404	1.3	_	
189-53	40405-40406	(	_	
189-54	40406-40409	5.9	_	
189-55	40409-40410	)	_	
189-56	40411-40414	0.1	_	
189-57	40415-40416	(	_	
189-58	40416-40419	0.7	_	
189-59	40419-40420	)	_	
189-60	40421-40424	1.4	_	
189-61	40425-40426	(	_	
189-62	40426-40429	6.5	_	
189-63	40429-40430	)	_	
189-64	40431-40434	0.1	_	
189-65	40435-40436	(	_	
189-66	40436-40439	0.3	_	
189-67	40439-40440	)	_	
189-68	40441-40444	1.9	_	
189-69	40445-40446	(	_	
189-70	40446-40449	6.3	_	
189-71	40449-40450	)	_	
189-72	40451-40454	5.1	_	
189-73	40455-40456	(	_	
189-74	40456-40460	19.2	_	
189-75	40460-40461	)	_	
189-76	40464-40465	w	_	
189-77	40465-40466	/	_	
189-78	40466-40469	out	_	
189-79	40470-40482	Intoxication	_	
189-80	40483-40490	Maximum	_	
189-81	40491-40492	4	_	
189-82	40493-40495	27	_	
189-83	40496-40497	3	_	
189-84	40498-40500	30	_	
189-85	40501-40502	1	_	
189-86	40503-40505	26	_	
189-87	40506-40508	87	_	
189-88	40511-40519	Reported	_	
189-89	40520-40524	Days	_	
189-90	40525-40527	of	_	
189-91	40528-40531	Use	_	
189-92	40532-40536	Mean	_	
189-93	40537-40538	(	_	
189-94	40538-40540	SD	_	
189-95	40540-40541	)	_	
189-96	40542-40545	0.3	_	
189-97	40546-40547	(	_	
189-98	40547-40550	0.7	_	
189-99	40550-40551	)	_	
189-100	40552-40555	1.0	_	
189-101	40556-40557	(	_	
189-102	40557-40560	3.7	_	
189-103	40560-40561	)	_	
189-104	40562-40565	1.9	_	
189-105	40566-40567	(	_	
189-106	40567-40570	6.1	_	
189-107	40570-40571	)	_	
189-108	40572-40575	1.5	_	
189-109	40576-40577	(	_	
189-110	40577-40580	6.5	_	
189-111	40580-40581	)	_	
189-112	40582-40585	1.8	_	
189-113	40586-40587	(	_	
189-114	40587-40590	3.8	_	
189-115	40590-40591	)	_	
189-116	40592-40595	1.3	_	
189-117	40596-40597	(	_	
189-118	40597-40600	3.2	_	
189-119	40600-40601	)	_	
189-120	40602-40605	7.8	_	
189-121	40606-40607	(	_	
189-122	40607-40611	14.5	_	
189-123	40611-40612	)	_	
189-124	40615-40616	w	_	
189-125	40616-40617	/	_	
189-126	40617-40629	Intoxication	_	
189-127	40630-40637	Maximum	_	
189-128	40638-40639	3	_	
189-129	40640-40642	17	_	
189-130	40643-40645	28	_	
189-131	40646-40648	30	_	
189-132	40649-40651	17	_	
189-133	40652-40654	13	_	
189-134	40655-40657	50	_	
189-135	40661-40668	Regions	_	
189-136	40669-40671	of	_	
189-137	40672-40680	interest	_	
189-138	40681-40685	from	_	
189-139	40686-40698	longitudinal	_	
189-140	40699-40708	contrasts	_	
189-141	40709-40712	and	_	
189-142	40713-40718	whole	_	
189-143	40719-40724	brain	_	
189-144	40725-40736	correlation	_	
189-145	40737-40745	analysis	_	
189-146	40746-40748	of	_	
189-147	40749-40758	substance	_	
189-148	40759-40762	use	_	
189-149	40763-40771	outcomes	_	
189-150	40771-40772	.	_	

#Text=Increased Parametrically-Modulated Signal at FU Relative to BL\tPeak MNI Coordinates\t\t\t \tContrast\tRegion\tCluster Size\tx\ty\tz\tz-value\tCorrected p-value\t \tFU > BL Longitudinal Contrasts (p < 0.05)\t \tInflate*p(Explode)\tn/a\t\t \t–\t \t\t\t \t–\t \t\t\t \t–\t \t\t\t \t–\t \t\t\t \t–\t \t\t\t \t–\t \t\t \tRedeem*p(Explode)\tL Dorsal Premotor Cortex (BA 6)\t55\t−48\t−4\t42\t3.94\t0.041\t \tExplode*p(Explode)\tn/a\t\t \t–\t \t\t\t \t–\t \t\t\t \t–\t \t\t\t \t–\t \t\t\t \t–\t \t\t\t \t–\t \t\t \tSuccess*p(Explode)\tR Caudal ACC/PCC (BA 24)\t77\t8\t4\t34\t4.04\t0.010\t \tWin*p(Explode)\tn/a\t\t \t–\t \t\t\t \t–\t \t\t\t \t–\t \t\t\t \t–\t \t\t\t \t–\t \t\t\t \t–\t \t\t \tFU > BL Correlates with Less Use (Negative Correlation; p < 0.005)\t \tInflate*p(Explode)\tn/a\t\t \t–\t \t\t\t \t–\t \t\t\t \t–\t \t\t\t \t–\t \t\t\t \t–\t \t\t\t \t–\t \t\t \tRedeem*p(Explode)\tn/a\t\t \t–\t \t\t\t \t–\t \t\t\t \t–\t \t\t\t \t–\t \t\t\t \t–\t \t\t\t \t–\t \t\t \tExplode*p(Explode)\tR Middle/Superior Temporal Gyrus (BA 21)\t338\t66\t−22\t2\t4.58\t<0.001\t \t\tR Lingual Gyrus (BA 19)\t184\t24\t−66\t0\t4.47\t<0.001\t \t\tR ACC (BA 24)\t119\t6\t14\t22\t4.40\t<0.001\t \t\tR Superior Temporal Gyrus (BA 22)\t196\t50\t−14\t12\t4.15\t<0.001\t \tSuccess*p(Explode)\tR Putamen/Pallidum\t156\t16\t−2\t−6\t4.51\t<0.001\t \t\tL Medial Prefrontal Cortex (BA 9)\t339\t−18\t44\t24\t4.42\t<0.001\t \t\tR Middle Temporal Gyrus (BA 21)\t143\t50\t−32\t−2\t4.36\t<0.001\t \t\tL Middle Temporal Gyrus (BA 21)\t179\t−64\t−28\t−18\t4.19\t<0.001\t \t\tR Middle Temporal Gyrus (BA 21)\t91\t58\t0\t−26\t3.98\t0.002\t \tWin*p(Explode)\tn/a\t\t \t–\t \t\t\t \t–\t \t\t\t \t–\t \t\t\t \t–\t \t\t\t \t–\t \t\t\t \t–\t \t\t \t
#Text=Decreased Parametrically-Modulated Signal at FU Relative to BL\tPeak MNI Coordinates\t\t\t \tContrast\tRegion\tCluster Size\tx\ty\tz\tz-value\tCorrected p-value\t \tFU < BL Longitudinal Contrasts (p < 0.05)\t \tInflate*p(Explode)\tn/a\t\t \t–\t \t\t\t \t–\t \t\t\t \t–\t \t\t\t \t–\t \t\t\t \t–\t \t\t\t \t–\t \t\t \tRedeem*p(Explode)\tn/a\t\t \t–\t \t\t\t \t–\t \t\t\t \t–\t \t\t\t \t–\t \t\t\t \t–\t \t\t\t \t–\t \t\t \tExplode*p(Explode)\tR Inferior Frontal Gyrus (BA 47)\t203\t32\t20\t−14\t4.84\t<0.001\t \t\tL Caudal ACC (BA 24)/Cingulum\t62\t−18\t12\t32\t4.43\t0.040\t \tSuccess*p(Explode)\tn/a\t\t \t–\t \t\t\t \t–\t \t\t\t \t–\t \t\t\t \t–\t \t\t\t \t–\t \t\t\t \t–\t \t\t \tWin*p(Explode)\tn/a\t\t \t–\t \t\t\t \t–\t \t\t\t \t–\t \t\t\t \t–\t \t\t\t \t–\t \t\t\t \t–\t \t\t \tFU < BL Correlates with Less Use (Positive Correlation; p < 0.005)\t \tInflate*p(Explode)\tL Putamen\t116\t−28\t10\t0\t4.53\t0.001\t \t\tL Middle Temporal Gyrus (BA 21)\t100\t−66\t−30\t−16\t4.09\t0.002\t \t\tL ACC (BA 32)/ventromedial PFC\t105\t−2\t44\t10\t4.08\t0.001\t \tRedeem*p(Explode)\tn/a\t\t \t–\t \t\t\t \t–\t \t\t\t \t–\t \t\t\t \t–\t \t\t\t \t–\t \t\t\t \t–\t \t\t \tExplode*p(Explode)\tn/a\t\t \t–\t \t\t\t \t–\t \t\t\t \t–\t \t\t\t \t–\t \t\t\t \t–\t \t\t\t \t–\t \t\t \tSuccess*p(Explode)\tR Cerebellum Posterior Lobe (Crus I)\t188\t30\t−84\t−22\t4.41\t<0.001\t \t\tL Paracentral Lobule (BA 6)\t83\t−4\t−16\t72\t4.05\t0.004\t \tWin*p(Explode)\tn/a\t\t \t–\t \t\t\t \t–\t \t\t\t \t–\t \t\t\t \t–\t \t\t\t \t–\t \t\t\t \t–
190-1	40773-40782	Increased	_	
190-2	40783-40807	Parametrically-Modulated	_	
190-3	40808-40814	Signal	_	
190-4	40815-40817	at	_	
190-5	40818-40820	FU	_	
190-6	40821-40829	Relative	_	
190-7	40830-40832	to	_	
190-8	40833-40835	BL	_	
190-9	40836-40840	Peak	_	
190-10	40841-40844	MNI	_	
190-11	40845-40856	Coordinates	_	
190-12	40861-40869	Contrast	_	
190-13	40870-40876	Region	_	
190-14	40877-40884	Cluster	_	
190-15	40885-40889	Size	_	
190-16	40890-40891	x	_	
190-17	40892-40893	y	_	
190-18	40894-40895	z	_	
190-19	40896-40903	z-value	_	
190-20	40904-40913	Corrected	_	
190-21	40914-40921	p-value	_	
190-22	40924-40926	FU	_	
190-23	40927-40928	>	_	
190-24	40929-40931	BL	_	
190-25	40932-40944	Longitudinal	_	
190-26	40945-40954	Contrasts	_	
190-27	40955-40956	(	_	
190-28	40956-40957	p	_	
190-29	40958-40959	<	_	
190-30	40960-40964	0.05	_	
190-31	40964-40965	)	_	
190-32	40968-40975	Inflate	_	
190-33	40975-40976	*	_	
190-34	40976-40977	p	_	
190-35	40977-40978	(	_	
190-36	40978-40985	Explode	_	
190-37	40985-40986	)	_	
190-38	40987-40988	n	_	
190-39	40988-40989	/	_	
190-40	40989-40990	a	_	
190-41	40994-40995	–	_	
190-42	41002-41003	–	_	
190-43	41010-41011	–	_	
190-44	41018-41019	–	_	
190-45	41026-41027	–	_	
190-46	41034-41035	–	_	
190-47	41041-41047	Redeem	_	
190-48	41047-41048	*	_	
190-49	41048-41049	p	_	
190-50	41049-41050	(	_	
190-51	41050-41057	Explode	_	
190-52	41057-41058	)	_	
190-53	41059-41060	L	_	
190-54	41061-41067	Dorsal	_	
190-55	41068-41076	Premotor	_	
190-56	41077-41083	Cortex	_	
190-57	41084-41085	(	_	
190-58	41085-41087	BA	_	
190-59	41088-41089	6	_	
190-60	41089-41090	)	_	
190-61	41091-41093	55	_	
190-62	41094-41095	−	_	
190-63	41095-41097	48	_	
190-64	41098-41099	−	_	
190-65	41099-41100	4	_	
190-66	41101-41103	42	_	
190-67	41104-41108	3.94	_	
190-68	41109-41114	0.041	_	
190-69	41117-41124	Explode	_	
190-70	41124-41125	*	_	
190-71	41125-41126	p	_	
190-72	41126-41127	(	_	
190-73	41127-41134	Explode	_	
190-74	41134-41135	)	_	
190-75	41136-41137	n	_	
190-76	41137-41138	/	_	
190-77	41138-41139	a	_	
190-78	41143-41144	–	_	
190-79	41151-41152	–	_	
190-80	41159-41160	–	_	
190-81	41167-41168	–	_	
190-82	41175-41176	–	_	
190-83	41183-41184	–	_	
190-84	41190-41197	Success	_	
190-85	41197-41198	*	_	
190-86	41198-41199	p	_	
190-87	41199-41200	(	_	
190-88	41200-41207	Explode	_	
190-89	41207-41208	)	_	
190-90	41209-41210	R	_	
190-91	41211-41217	Caudal	_	
190-92	41218-41221	ACC	_	
190-93	41221-41222	/	_	
190-94	41222-41225	PCC	_	
190-95	41226-41227	(	_	
190-96	41227-41229	BA	_	
190-97	41230-41232	24	_	
190-98	41232-41233	)	_	
190-99	41234-41236	77	_	
190-100	41237-41238	8	_	
190-101	41239-41240	4	_	
190-102	41241-41243	34	_	
190-103	41244-41248	4.04	_	
190-104	41249-41254	0.010	_	
190-105	41257-41260	Win	_	
190-106	41260-41261	*	_	
190-107	41261-41262	p	_	
190-108	41262-41263	(	_	
190-109	41263-41270	Explode	_	
190-110	41270-41271	)	_	
190-111	41272-41273	n	_	
190-112	41273-41274	/	_	
190-113	41274-41275	a	_	
190-114	41279-41280	–	_	
190-115	41287-41288	–	_	
190-116	41295-41296	–	_	
190-117	41303-41304	–	_	
190-118	41311-41312	–	_	
190-119	41319-41320	–	_	
190-120	41326-41328	FU	_	
190-121	41329-41330	>	_	
190-122	41331-41333	BL	_	
190-123	41334-41344	Correlates	_	
190-124	41345-41349	with	_	
190-125	41350-41354	Less	_	
190-126	41355-41358	Use	_	
190-127	41359-41360	(	_	
190-128	41360-41368	Negative	_	
190-129	41369-41380	Correlation	_	
190-130	41380-41381	;	_	
190-131	41382-41383	p	_	
190-132	41384-41385	<	_	
190-133	41386-41391	0.005	_	
190-134	41391-41392	)	_	
190-135	41395-41402	Inflate	_	
190-136	41402-41403	*	_	
190-137	41403-41404	p	_	
190-138	41404-41405	(	_	
190-139	41405-41412	Explode	_	
190-140	41412-41413	)	_	
190-141	41414-41415	n	_	
190-142	41415-41416	/	_	
190-143	41416-41417	a	_	
190-144	41421-41422	–	_	
190-145	41429-41430	–	_	
190-146	41437-41438	–	_	
190-147	41445-41446	–	_	
190-148	41453-41454	–	_	
190-149	41461-41462	–	_	
190-150	41468-41474	Redeem	_	
190-151	41474-41475	*	_	
190-152	41475-41476	p	_	
190-153	41476-41477	(	_	
190-154	41477-41484	Explode	_	
190-155	41484-41485	)	_	
190-156	41486-41487	n	_	
190-157	41487-41488	/	_	
190-158	41488-41489	a	_	
190-159	41493-41494	–	_	
190-160	41501-41502	–	_	
190-161	41509-41510	–	_	
190-162	41517-41518	–	_	
190-163	41525-41526	–	_	
190-164	41533-41534	–	_	
190-165	41540-41547	Explode	_	
190-166	41547-41548	*	_	
190-167	41548-41549	p	_	
190-168	41549-41550	(	_	
190-169	41550-41557	Explode	_	
190-170	41557-41558	)	_	
190-171	41559-41560	R	_	
190-172	41561-41567	Middle	_	
190-173	41567-41568	/	_	
190-174	41568-41576	Superior	_	
190-175	41577-41585	Temporal	_	
190-176	41586-41591	Gyrus	_	
190-177	41592-41593	(	_	
190-178	41593-41595	BA	_	
190-179	41596-41598	21	_	
190-180	41598-41599	)	_	
190-181	41600-41603	338	_	
190-182	41604-41606	66	_	
190-183	41607-41608	−	_	
190-184	41608-41610	22	_	
190-185	41611-41612	2	_	
190-186	41613-41617	4.58	_	
190-187	41618-41619	<	_	
190-188	41619-41624	0.001	_	
190-189	41628-41629	R	_	
190-190	41630-41637	Lingual	_	
190-191	41638-41643	Gyrus	_	
190-192	41644-41645	(	_	
190-193	41645-41647	BA	_	
190-194	41648-41650	19	_	
190-195	41650-41651	)	_	
190-196	41652-41655	184	_	
190-197	41656-41658	24	_	
190-198	41659-41660	−	_	
190-199	41660-41662	66	_	
190-200	41663-41664	0	_	
190-201	41665-41669	4.47	_	
190-202	41670-41671	<	_	
190-203	41671-41676	0.001	_	
190-204	41680-41681	R	_	
190-205	41682-41685	ACC	_	
190-206	41686-41687	(	_	
190-207	41687-41689	BA	_	
190-208	41690-41692	24	_	
190-209	41692-41693	)	_	
190-210	41694-41697	119	_	
190-211	41698-41699	6	_	
190-212	41700-41702	14	_	
190-213	41703-41705	22	_	
190-214	41706-41710	4.40	_	
190-215	41711-41712	<	_	
190-216	41712-41717	0.001	_	
190-217	41721-41722	R	_	
190-218	41723-41731	Superior	_	
190-219	41732-41740	Temporal	_	
190-220	41741-41746	Gyrus	_	
190-221	41747-41748	(	_	
190-222	41748-41750	BA	_	
190-223	41751-41753	22	_	
190-224	41753-41754	)	_	
190-225	41755-41758	196	_	
190-226	41759-41761	50	_	
190-227	41762-41763	−	_	
190-228	41763-41765	14	_	
190-229	41766-41768	12	_	
190-230	41769-41773	4.15	_	
190-231	41774-41775	<	_	
190-232	41775-41780	0.001	_	
190-233	41783-41790	Success	_	
190-234	41790-41791	*	_	
190-235	41791-41792	p	_	
190-236	41792-41793	(	_	
190-237	41793-41800	Explode	_	
190-238	41800-41801	)	_	
190-239	41802-41803	R	_	
190-240	41804-41811	Putamen	_	
190-241	41811-41812	/	_	
190-242	41812-41820	Pallidum	_	
190-243	41821-41824	156	_	
190-244	41825-41827	16	_	
190-245	41828-41829	−	_	
190-246	41829-41830	2	_	
190-247	41831-41832	−	_	
190-248	41832-41833	6	_	
190-249	41834-41838	4.51	_	
190-250	41839-41840	<	_	
190-251	41840-41845	0.001	_	
190-252	41849-41850	L	_	
190-253	41851-41857	Medial	_	
190-254	41858-41868	Prefrontal	_	
190-255	41869-41875	Cortex	_	
190-256	41876-41877	(	_	
190-257	41877-41879	BA	_	
190-258	41880-41881	9	_	
190-259	41881-41882	)	_	
190-260	41883-41886	339	_	
190-261	41887-41888	−	_	
190-262	41888-41890	18	_	
190-263	41891-41893	44	_	
190-264	41894-41896	24	_	
190-265	41897-41901	4.42	_	
190-266	41902-41903	<	_	
190-267	41903-41908	0.001	_	
190-268	41912-41913	R	_	
190-269	41914-41920	Middle	_	
190-270	41921-41929	Temporal	_	
190-271	41930-41935	Gyrus	_	
190-272	41936-41937	(	_	
190-273	41937-41939	BA	_	
190-274	41940-41942	21	_	
190-275	41942-41943	)	_	
190-276	41944-41947	143	_	
190-277	41948-41950	50	_	
190-278	41951-41952	−	_	
190-279	41952-41954	32	_	
190-280	41955-41956	−	_	
190-281	41956-41957	2	_	
190-282	41958-41962	4.36	_	
190-283	41963-41964	<	_	
190-284	41964-41969	0.001	_	
190-285	41973-41974	L	_	
190-286	41975-41981	Middle	_	
190-287	41982-41990	Temporal	_	
190-288	41991-41996	Gyrus	_	
190-289	41997-41998	(	_	
190-290	41998-42000	BA	_	
190-291	42001-42003	21	_	
190-292	42003-42004	)	_	
190-293	42005-42008	179	_	
190-294	42009-42010	−	_	
190-295	42010-42012	64	_	
190-296	42013-42014	−	_	
190-297	42014-42016	28	_	
190-298	42017-42018	−	_	
190-299	42018-42020	18	_	
190-300	42021-42025	4.19	_	
190-301	42026-42027	<	_	
190-302	42027-42032	0.001	_	
190-303	42036-42037	R	_	
190-304	42038-42044	Middle	_	
190-305	42045-42053	Temporal	_	
190-306	42054-42059	Gyrus	_	
190-307	42060-42061	(	_	
190-308	42061-42063	BA	_	
190-309	42064-42066	21	_	
190-310	42066-42067	)	_	
190-311	42068-42070	91	_	
190-312	42071-42073	58	_	
190-313	42074-42075	0	_	
190-314	42076-42077	−	_	
190-315	42077-42079	26	_	
190-316	42080-42084	3.98	_	
190-317	42085-42090	0.002	_	
190-318	42093-42096	Win	_	
190-319	42096-42097	*	_	
190-320	42097-42098	p	_	
190-321	42098-42099	(	_	
190-322	42099-42106	Explode	_	
190-323	42106-42107	)	_	
190-324	42108-42109	n	_	
190-325	42109-42110	/	_	
190-326	42110-42111	a	_	
190-327	42115-42116	–	_	
190-328	42123-42124	–	_	
190-329	42131-42132	–	_	
190-330	42139-42140	–	_	
190-331	42147-42148	–	_	
190-332	42155-42156	–	_	
190-333	42163-42172	Decreased	_	
190-334	42173-42197	Parametrically-Modulated	_	
190-335	42198-42204	Signal	_	
190-336	42205-42207	at	_	
190-337	42208-42210	FU	_	
190-338	42211-42219	Relative	_	
190-339	42220-42222	to	_	
190-340	42223-42225	BL	_	
190-341	42226-42230	Peak	_	
190-342	42231-42234	MNI	_	
190-343	42235-42246	Coordinates	_	
190-344	42251-42259	Contrast	_	
190-345	42260-42266	Region	_	
190-346	42267-42274	Cluster	_	
190-347	42275-42279	Size	_	
190-348	42280-42281	x	_	
190-349	42282-42283	y	_	
190-350	42284-42285	z	_	
190-351	42286-42293	z-value	_	
190-352	42294-42303	Corrected	_	
190-353	42304-42311	p-value	_	
190-354	42314-42316	FU	_	
190-355	42317-42318	<	_	
190-356	42319-42321	BL	_	
190-357	42322-42334	Longitudinal	_	
190-358	42335-42344	Contrasts	_	
190-359	42345-42346	(	_	
190-360	42346-42347	p	_	
190-361	42348-42349	<	_	
190-362	42350-42354	0.05	_	
190-363	42354-42355	)	_	
190-364	42358-42365	Inflate	_	
190-365	42365-42366	*	_	
190-366	42366-42367	p	_	
190-367	42367-42368	(	_	
190-368	42368-42375	Explode	_	
190-369	42375-42376	)	_	
190-370	42377-42378	n	_	
190-371	42378-42379	/	_	
190-372	42379-42380	a	_	
190-373	42384-42385	–	_	
190-374	42392-42393	–	_	
190-375	42400-42401	–	_	
190-376	42408-42409	–	_	
190-377	42416-42417	–	_	
190-378	42424-42425	–	_	
190-379	42431-42437	Redeem	_	
190-380	42437-42438	*	_	
190-381	42438-42439	p	_	
190-382	42439-42440	(	_	
190-383	42440-42447	Explode	_	
190-384	42447-42448	)	_	
190-385	42449-42450	n	_	
190-386	42450-42451	/	_	
190-387	42451-42452	a	_	
190-388	42456-42457	–	_	
190-389	42464-42465	–	_	
190-390	42472-42473	–	_	
190-391	42480-42481	–	_	
190-392	42488-42489	–	_	
190-393	42496-42497	–	_	
190-394	42503-42510	Explode	_	
190-395	42510-42511	*	_	
190-396	42511-42512	p	_	
190-397	42512-42513	(	_	
190-398	42513-42520	Explode	_	
190-399	42520-42521	)	_	
190-400	42522-42523	R	_	
190-401	42524-42532	Inferior	_	
190-402	42533-42540	Frontal	_	
190-403	42541-42546	Gyrus	_	
190-404	42547-42548	(	_	
190-405	42548-42550	BA	_	
190-406	42551-42553	47	_	
190-407	42553-42554	)	_	
190-408	42555-42558	203	_	
190-409	42559-42561	32	_	
190-410	42562-42564	20	_	
190-411	42565-42566	−	_	
190-412	42566-42568	14	_	
190-413	42569-42573	4.84	_	
190-414	42574-42575	<	_	
190-415	42575-42580	0.001	_	
190-416	42584-42585	L	_	
190-417	42586-42592	Caudal	_	
190-418	42593-42596	ACC	_	
190-419	42597-42598	(	_	
190-420	42598-42600	BA	_	
190-421	42601-42603	24	_	
190-422	42603-42604	)	_	
190-423	42604-42605	/	_	
190-424	42605-42613	Cingulum	_	
190-425	42614-42616	62	_	
190-426	42617-42618	−	_	
190-427	42618-42620	18	_	
190-428	42621-42623	12	_	
190-429	42624-42626	32	_	
190-430	42627-42631	4.43	_	
190-431	42632-42637	0.040	_	
190-432	42640-42647	Success	_	
190-433	42647-42648	*	_	
190-434	42648-42649	p	_	
190-435	42649-42650	(	_	
190-436	42650-42657	Explode	_	
190-437	42657-42658	)	_	
190-438	42659-42660	n	_	
190-439	42660-42661	/	_	
190-440	42661-42662	a	_	
190-441	42666-42667	–	_	
190-442	42674-42675	–	_	
190-443	42682-42683	–	_	
190-444	42690-42691	–	_	
190-445	42698-42699	–	_	
190-446	42706-42707	–	_	
190-447	42713-42716	Win	_	
190-448	42716-42717	*	_	
190-449	42717-42718	p	_	
190-450	42718-42719	(	_	
190-451	42719-42726	Explode	_	
190-452	42726-42727	)	_	
190-453	42728-42729	n	_	
190-454	42729-42730	/	_	
190-455	42730-42731	a	_	
190-456	42735-42736	–	_	
190-457	42743-42744	–	_	
190-458	42751-42752	–	_	
190-459	42759-42760	–	_	
190-460	42767-42768	–	_	
190-461	42775-42776	–	_	
190-462	42782-42784	FU	_	
190-463	42785-42786	<	_	
190-464	42787-42789	BL	_	
190-465	42790-42800	Correlates	_	
190-466	42801-42805	with	_	
190-467	42806-42810	Less	_	
190-468	42811-42814	Use	_	
190-469	42815-42816	(	_	
190-470	42816-42824	Positive	_	
190-471	42825-42836	Correlation	_	
190-472	42836-42837	;	_	
190-473	42838-42839	p	_	
190-474	42840-42841	<	_	
190-475	42842-42847	0.005	_	
190-476	42847-42848	)	_	
190-477	42851-42858	Inflate	_	
190-478	42858-42859	*	_	
190-479	42859-42860	p	_	
190-480	42860-42861	(	_	
190-481	42861-42868	Explode	_	
190-482	42868-42869	)	_	
190-483	42870-42871	L	_	
190-484	42872-42879	Putamen	_	
190-485	42880-42883	116	_	
190-486	42884-42885	−	_	
190-487	42885-42887	28	_	
190-488	42888-42890	10	_	
190-489	42891-42892	0	_	
190-490	42893-42897	4.53	_	
190-491	42898-42903	0.001	_	
190-492	42907-42908	L	_	
190-493	42909-42915	Middle	_	
190-494	42916-42924	Temporal	_	
190-495	42925-42930	Gyrus	_	
190-496	42931-42932	(	_	
190-497	42932-42934	BA	_	
190-498	42935-42937	21	_	
190-499	42937-42938	)	_	
190-500	42939-42942	100	_	
190-501	42943-42944	−	_	
190-502	42944-42946	66	_	
190-503	42947-42948	−	_	
190-504	42948-42950	30	_	
190-505	42951-42952	−	_	
190-506	42952-42954	16	_	
190-507	42955-42959	4.09	_	
190-508	42960-42965	0.002	_	
190-509	42969-42970	L	_	
190-510	42971-42974	ACC	_	
190-511	42975-42976	(	_	
190-512	42976-42978	BA	_	
190-513	42979-42981	32	_	
190-514	42981-42982	)	_	
190-515	42982-42983	/	_	
190-516	42983-42995	ventromedial	_	
190-517	42996-42999	PFC	_	
190-518	43000-43003	105	_	
190-519	43004-43005	−	_	
190-520	43005-43006	2	_	
190-521	43007-43009	44	_	
190-522	43010-43012	10	_	
190-523	43013-43017	4.08	_	
190-524	43018-43023	0.001	_	
190-525	43026-43032	Redeem	_	
190-526	43032-43033	*	_	
190-527	43033-43034	p	_	
190-528	43034-43035	(	_	
190-529	43035-43042	Explode	_	
190-530	43042-43043	)	_	
190-531	43044-43045	n	_	
190-532	43045-43046	/	_	
190-533	43046-43047	a	_	
190-534	43051-43052	–	_	
190-535	43059-43060	–	_	
190-536	43067-43068	–	_	
190-537	43075-43076	–	_	
190-538	43083-43084	–	_	
190-539	43091-43092	–	_	
190-540	43098-43105	Explode	_	
190-541	43105-43106	*	_	
190-542	43106-43107	p	_	
190-543	43107-43108	(	_	
190-544	43108-43115	Explode	_	
190-545	43115-43116	)	_	
190-546	43117-43118	n	_	
190-547	43118-43119	/	_	
190-548	43119-43120	a	_	
190-549	43124-43125	–	_	
190-550	43132-43133	–	_	
190-551	43140-43141	–	_	
190-552	43148-43149	–	_	
190-553	43156-43157	–	_	
190-554	43164-43165	–	_	
190-555	43171-43178	Success	_	
190-556	43178-43179	*	_	
190-557	43179-43180	p	_	
190-558	43180-43181	(	_	
190-559	43181-43188	Explode	_	
190-560	43188-43189	)	_	
190-561	43190-43191	R	_	
190-562	43192-43202	Cerebellum	_	
190-563	43203-43212	Posterior	_	
190-564	43213-43217	Lobe	_	
190-565	43218-43219	(	_	
190-566	43219-43223	Crus	_	
190-567	43224-43225	I	_	
190-568	43225-43226	)	_	
190-569	43227-43230	188	_	
190-570	43231-43233	30	_	
190-571	43234-43235	−	_	
190-572	43235-43237	84	_	
190-573	43238-43239	−	_	
190-574	43239-43241	22	_	
190-575	43242-43246	4.41	_	
190-576	43247-43248	<	_	
190-577	43248-43253	0.001	_	
190-578	43257-43258	L	_	
190-579	43259-43270	Paracentral	_	
190-580	43271-43277	Lobule	_	
190-581	43278-43279	(	_	
190-582	43279-43281	BA	_	
190-583	43282-43283	6	_	
190-584	43283-43284	)	_	
190-585	43285-43287	83	_	
190-586	43288-43289	−	_	
190-587	43289-43290	4	_	
190-588	43291-43292	−	_	
190-589	43292-43294	16	_	
190-590	43295-43297	72	_	
190-591	43298-43302	4.05	_	
190-592	43303-43308	0.004	_	
190-593	43311-43314	Win	_	
190-594	43314-43315	*	_	
190-595	43315-43316	p	_	
190-596	43316-43317	(	_	
190-597	43317-43324	Explode	_	
190-598	43324-43325	)	_	
190-599	43326-43327	n	_	
190-600	43327-43328	/	_	
190-601	43328-43329	a	_	
190-602	43333-43334	–	_	
190-603	43341-43342	–	_	
190-604	43349-43350	–	_	
190-605	43357-43358	–	_	
190-606	43365-43366	–	_	
190-607	43373-43374	–	_	
